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Transcriptomic analysis of pharyngeal swab samples from carriers of Neisseria 
meningitidis (Nm) may help to predict whether protein antigen meningococcal 
vaccines might impact on herd protection. Although RNA extraction and detection of 
Nm gene transcripts from in vivo mucosal samples is challenging, a probe-based gene 
expression profiling platform, the NanoString nCounter system, can detect very low 
numbers of messenger RNA (mRNA) transcripts.  
RNA extraction methods were compared. The RNeasy mini kit method was easier to 
perform, gave more reproducible results, and delivered a higher quality and quantity 
of RNA than the alternative acid:phenol:chloroform method tested.  
A panel of 47 Nm genes were selected for NanoString probe design that coded for 
proteins in current or potential vaccine candidates or that were important in 
colonisation of the pharyngeal mucosa.  
The NanoString system was first assessed in Nm culture samples. The method 
showed high sensitivity of gene detection and high reproducibility. Exposure to heat, 
cold and iron depletion resulted in a range of gene expression across the panel. This 
study showed that mRNA can be successfully detected and quantified from Nm 
cultures without the need to amplify the genes and from very small quantities of total 
RNA. 
In subsequent experiments, Nm genes were detected and counted from in vivo 
pharyngeal carriage samples for the first time. Isolates from the samples were whole 
genome sequenced to assess the gene expression results obtained by NanoString. 
Some limitations of the technique were demonstrated including cross reactivity 
between different species in samples containing multiple organisms and reduced 
specificity at low levels of gene expression. The methodologies established in this 
thesis should be important for future transcriptomic studies on Nm and other bacteria 
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Chapter 1. Introduction  
1.1  Context 
This PhD was set up within the National Institute for Health Research (NIHR) Heath 
Protection Research Unit (HPRU) at the University of Bristol (UoB) as part of a 
programme of research into carriage of Neisseria meningitidis (Nm), the 
meningococcus.  This bacterium is commonly carried harmlessly in the human 
pharynx but can cause invasive meningococcal disease (IMD), mainly presenting as 
meningitis and septicaemia. Serogroup B (MenB) was the predominant cause of 
disease in the UK, and a new MenB meningococcal vaccine containing four protein 
antigens (Bexsero) was soon to be added to the UK universal primary schedule for 
infants. It was not known whether this vaccine would impact on acquisition or 
clearance of carriage. This would probably depend upon levels of expression of the 
vaccine antigens by the bacteria during colonisation. Any effect on reducing carriage 
is important as it may lead to indirect protection of unvaccinated groups (herd 
protection).  
The HPRU was currently conducting a longitudinal study to detect and quantify 
meningococcal pharyngeal carriage in 16 to 18-year-old students. Swabs had been 
stored in ribonucleic acid (RNA) preservation medium. Direct measurement of levels 
of protein antigen expression by bacteria sampled from the pharynx is difficult even 
when relatively large numbers of bacteria are present. The intention of this PhD was 
to use novel transcriptomic techniques to study gene expression by meningococci in 
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pharyngeal carriage samples, and to gain insight into the potential impact of actual or 
potential vaccine protein antigens on the carriage of meningococci.  
1.2  Chapter overview 
Chapter 2 details the background to the thesis, including the meningococcus, 
pharyngeal carriage, meningococcal vaccines, and transcriptomics. 
The different materials and methods used to perform the assays are described in 
Chapter 3, as well as the quality control (QC) and data analysis methods used to 
assess gene expression.  
In Chapter 4, the different validation tests used to extract total RNA and assess the 
use of the NanoString nCounter gene profiling system for Nm culture samples are 
described. Two RNA extraction methods, one more modern technique (RNeasy mini 
kit) and another more traditional technique (acid:phenol:chloroform) are compared. 
Extraction of RNA using RNeasy is compared with extraction directly from lysate. RNA 
extraction using PrimeStore RNA collection, storage and extraction kits is compared 
with extraction from samples collected with RNAlater using the RNeasy minikit. The 
sensitivity, specificity and reproducibility of the NanoString nCounter technology is 
evaluated on Nm cultures, and gene profiling is assessed under hot, cold, and iron 
deficient conditions.  
The use of NanoString technology for transcript detection of gene expression of Nm 
from in vivo carriage samples is evaluated in Chapter 5, the first time that this has 
been attempted. The second part of Chapter 5 shows the validation the NanoString 
result for one gene (fhbP) using reverse transcriptase quantitative polymerase chain 
reaction (RT-qPCR).  
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In Chapter 6, the presence or absence of 47 Nm genes in the genome of Nm carriage 
isolates is assessed by whole genome sequencing (WGS). The level of expression of 
fhbP is assessed using intergenic region (IGR) identification and compared with 
expected levels from previous studies. Genetic diversity is measured in paired 
longitudinal carriage samples. 
In Chapter 7, the overall results of the thesis are discussed as well as ideas for future 
research.  
1.3  Publications and presentations  
This work has been subject to peer review and shared with the academic community 
on several occasions. Work from Chapters Three, Four and Five has been presented.  
One paper (Appendix A) based on the work described in Chapter Three was published 
in 2018: Tekletsion YK, Christensen H, Finn A. Gene detection and expression 
profiling of Neisseria meningitidis using NanoString nCounter platform. J Microbiol 
Methods. 2018; 146:100-103. (doi):10.1016/j.mimet.2018.02.003. Epub  Feb 7 (1) 
. 
Two more papers are in preparation, the first is based on the work in Chapter Five and 
the second based on the work in Chapter Six:  “Tekletsion YK, Christensen H, Cayrou 
C, Bayliss C, Reynolds R, Oliver J, Morales-Aza B, Rodrigues F, Finn A. Gene 
expression profiling of Neisseria meningitidis from pharyngeal carriage samples”, and  
“Tekletsion YK, Christensen H, Lucidarme J, Borrow R, Oliver J, Rodrigues F, 
Morales-Aza B, Finn A. Whole genome analysis of longitudinal pharyngeal samples 
shows persistence of carriage with the same meningococcal strain”. 
4 
 
As first author, I have given oral presentations of this work at international 
conferences: at the 2019 European Society for Paediatric Infectious Diseases 
Conference in Ljubljana, Slovenia; at the 2018 International Pathogenic Neisseria 
Conference in Asilomar, California; and at the 2017 European Society for Paediatric 
Infectious Diseases Conference in Madrid, Spain. 
I have presented posters on this work as first author at the 2019 European Society for 
Paediatric Infectious Diseases Conference in Ljubljana, Slovenia; at the 2017 
European Meningococcal and Haemophilus Disease Society in Prague, Czech 
Republic; and at the 2016 International Pathogenic Neisseria Conference in 
Manchester, UK.  
In 2017, I was awarded the prize for best poster for “Tekletsion YK, Christensen H, 
Finn A.  Direct multiplexed digital detection of Neisseria meningitidis genes using the 
NanoString nCounter system” at the Infection and Immunity Early Career 
Researchers’ Event and Vaccinology Symposium in Bristol, UK.  
1.4  External contributors  
The work described in this thesis was done by me, with the following exceptions: 
➢ Pharyngeal swab collection for the carriage studies was done by the University 
of Bristol, Bristol Children Vaccine Centre for the BrisMenNHC and SPIT 
studies, and by Professor Fernanda Rodrigues’ research group, Coimbra 
Children’s Hospital for the Portuguese study.  
➢ sodC quantitative polymerase chain reaction (qPCR) to identify Neisseria 
meningitidis from pharyngeal swab samples and measurement of bacterial 
carriage density was done by the University of Bristol, Finn laboratory group. 
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➢ Dr Caroline Cayrou did reverse transcriptase qPCR (RT-qPCR) for fhbP at the 
University of Leicester, I was observing.   
➢ WGS of Nm isolates was done by Public Health England (PHE) (Manchester 
and Colindale). The sequences were uploaded into pubMLST by the University 




Chapter 2. Background  
2.1  The meningococcus 
Nm, a Gram-negative diplococcus, also referred to as the meningococcus, is an 
obligate human pathogen and a normal commensal of the human pharynx. Carriage 
is a phenomenon in which bacteria asymptomatically colonise the body. Other 
important pathogens that colonise the upper respiratory tract are Streptococcus 
pneumoniae, Haemophilus influenzae and Staphylococcus aureus (2, 3). Carriage 
prevalence of Nm is age-specific in that it increases through childhood to peak in 
teenage years and then slowly declines during adulthood (4, 5). Around 10% of the 
world population are asymptomatic carriers of Nm. Exchange of respiratory droplets 
and secretions through close contact is the main route of transmission. Risk of carriage 
increases with social activity, intimate kissing and smoking (6) and in crowded 
conditions such as military barracks and pilgrimage sites e.g. the Hajj and Umrah (7-
9).   Meningococci can, on occasion, pass though the pharyngeal mucosa into the 
bloodstream to cause IMD, predominantly meningitis and septicaemia. IMD has a high 
case fatality ratio of around 10-15% (10, 11), with young children and teenagers being 
at highest risk of disease in most endemic settings (12). Other risk factors for IMD 
include close contact with a case of IMD, overcrowding, passive smoking and upper 
respiratory tract infections (13, 14). Certain medical conditions also increase the risk 
of invasive disease such as asplenia, complement deficiency and immunosuppression 
(15, 16). 10-20% of IMD survivors have serious long term sequelae such as 
neurological impairment, hearing impairment and limb amputation (17, 18).  
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The first recorded outbreak of IMD occurred in Geneva in 1805 as described by 
Vieusseux. Since then, outbreaks and epidemics have been documented around the 
world, although an area of sub-Saharan Africa stretching from Senegal in the west to 
Ethiopia in the east, known as the meningitis belt, is at particularly high risk of IMD 
every year with massive epidemics every 8-12 years (19).  The bacterium was first 
identified by Weichselbaum in 1887 and Nm is now classified into 12 capsular groups 
based on the composition of the polysaccharide capsule (20). The large majority of 
disease is caused by six serogroups (A, B, C, W, X and Y). The predominant disease-
causing serogroups vary over time and by region across the world (Figure 2.1). 
Serogroups C, W, and X are currently the main epidemic disease-causing serogroups 
in sub-Saharan Africa, with MenB being the predominant cause of endemic disease 
across the Americas, Australia and Europe including the UK  (21, 22). 
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2.2  Nm genome   
Nm strain MC58 (Genbank accession number AE002098), a pathogenic MenB strain, 
was the first neisserial strain to be gene sequenced in 2000 (23). This was also the 
first time that researchers used a genome annotation approach to identify the encoding 
genes of Nm in parallel with open reading frame (ORF) prediction. MC58 was found 
to have a genome length of 2,272,351 base pairs and about 2158 coding regions 
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(Figure 2.2) (23). Of these regions, 1158 were assigned a biological role with 85 
predicted to be located on the surface of the bacterium (23). 
 
Figure 2.2 Circular representation of the Neisseria meningitidis strain MC58 genome 
(23). 
2.3  Meningococcal vaccines  
Prevention of meningococcal disease relies mainly on vaccination. Polysaccharide 
vaccines followed by improved polysaccharide-protein conjugate vaccines have been 
successfully developed against serogroups A, C, W, and Y.   The search for an 
effective vaccine against MenB, the predominant disease-causing serogroup in 
Europe, has not been straightforward. Making  a vaccine against MenB is challenging 
because of the high variability of surface-expressed proteins and the identical 
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chemical structure of the MenB capsular polysaccharide [α(2→8)N-acetyl neuraminic 
acid or polysialic acid] to glycosylation moieties found in human neural tissue which, 
being a self-antigen, is a poor immunogen (24, 25) .  
2.4  Reverse vaccinology and MenB vaccines  
The ability to sequence the full genome of the pathogen and the subsequent use of 
modern bioinformatics tools, a series of steps dubbed “reverse vaccinology”, 
revolutionized the traditional approach to vaccine design and permitted progress in 
developing MenB vaccines (23, 26).  
Until recently the development of a vaccine followed the same techniques developed 
by Pasteur that involved isolating, purifying, inactivating or attenuating and 
administering the whole or part of the organism. Reverse vaccinology is a systematic 
search of genomic information to identify putative vaccine candidates in the protein-
coding genome of a pathogen using bioinformatics, molecular biology, and 
immunology to select and synthesise suitable antigens. The process involves the 
following steps (i) bioinformatics software to screen the genome for surface expressed 






Figure 2.3 The genomic- based  approach to vaccine development showing the steps of reverse vaccinology in the search for vaccine 




surface location (iv) animal-based immunogenicity testing, and finally (v) conventional 
vaccine trials (27) (Figure 2.3). 
Using reverse vaccinology, Nm genome sequencing led to the development of a novel 
vaccine, 4CMenB (28) now licensed as Bexsero, the first vaccine candidate to be 
developed in this way (23). Once the sequence was obtained, in-silico antigen 
prediction from computer algorithms was used to predict and interpret the genome 
functions and to select novel virulence factors among surface exposed antigens. 
Among 570 Open Reading Frames predicted to encode surface expressed proteins, 
350 were successfully expressed in Escherichia coli and used to immunise mice (23). 
Seven proteins that generated bactericidal activity were selected as potential vaccine 
candidates, tested for conservation in 22 representative MenB strains and 9 other 
neisseria species, and checked for antibody binding in the presence of capsule.  Most 
proteins were conserved, and all were surface expressed. After further refinement and 
testing against a broader range of meningococcal strains, three main antigens (fHbp, 
NadA, NHBA) were selected for inclusion in the vaccine together with an outer 
membrane vesicle derived porA NZ98/254 meningococcal strain (28).  
Bexsero was added to the UK universal primary vaccination schedule in September 
2015 (29). Another similar protein vaccine (Trumenba) containing two fHbp variants 
has been licensed in the USA (30) and Europe. Research on the effectiveness and 
duration of protection of the two licenced MenB protein vaccines is ongoing. 
Preliminary data on impact of Bexsero suggests a vaccine effectiveness of around 
80% against all MenB cases, with a 50% decline in MenB cases among those targeted 




2.5  Mucosal immunity against meningococci 
The mucosal layer is tolerant to most of the antigens encountered, including food, 
inhaled antigens, etc. and plays a major role when encountering an invading pathogen. 
Immune cells such as dendritic cells, which reside under the lamina propria, transfer 
antigens to secondary lymphoid organs that induce T cell activation (Figure 2.4). The 
T cells play a major role in regulating function by activating plasma cells and producing 
IgA antibody.  
 
Figure 2.4 Representation of mucosal immune system 
(Source:https://courses.lumenlearning.com/suny-ap2/chapter/the-immune-response-against-
pathogens/) 
Pathogens are recognised via many mechanisms such as by Pattern recognition 
molecular pattern molecules (PAMPs and toll like receptors (TLR4) that recognise, for 
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example, the Gram-negative surface lipopolysaccharide molecules  (34). 
Macrophages are also important in killing the pathogen and inducing activation of the 
adaptive immune system through the major histocompatibility (MHC) complex (34). 
Macrophages are particularly important in recognition and killing of encapsulated Nm 
since the capsule makes peptide recognition sites relatively inaccessible (35). 
Neutrophils, T cells, B cells and other cells of the adaptive immune system are 
important in the protection against IMD (36, 37).  
There is a high prevalence of meningococcal carriage compared to the incidence of 
disease. This is probably due to a number of factors such as natural mucosal immunity 
through secretory IgA and IgG antibodies (38-40), cellular immune response (41), 
innate immunity and the low virulence of many carrier strains (42). There is good 
evidence that colonisation by meningococci can elicit naturally-acquired immunity 
(43). Studies have shown that bactericidal antibody titres among meningococcal 
carriers are much higher than in non-carriers and that acquisition of Nm is followed 
within 1-2 weeks by an increase in antibody titres (44). There is also a hypothesis that 
cross-reactive immunity could be acquired through carriage of other neisserial species   
such as N. lactamica (45-47). The latest studies suggest that carriage of N. lactamica 
inhibits acquisition of meningococci but may not generate protective immunity against 
IMD (48) 
IgG antibodies are thought to be important in protection against IMD (49). It has also 
been shown that the T cell response to colonisation of meningococci is vital in 
modulating the protection by antibody class switching, affinity maturation and 
immunological memory (50). Goldschneider and colleagues demonstrated the natural 
protection induced by Nm against a specific serogroup C strain in long-term carriers 
by assessing serum bactericidal titres in those individuals (50). They also established 
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that innate immunity has an important role in protection against meningococcal 
infection. Recent research has suggested that the mucosal layer of the nasopharynx 
plays an essential part in protecting against invasion by the meningococcus and other 
commensals or pathogenic organisms due to specialised immune cells B cells which 
produce IgA. Such cells are known to reside in the lamina propria of the human 
epithelial barrier (51). There is also evidence of naturally acquired T cell-mediated 
mucosal immunity to Nm (52). 
A recent study done in Togo to assess the natural capsular natural immunity against 
serogroup X meningococci suggested that the natural antibody titres were high and 
that the SBA against serogroup X indicated  successful protection (53).  Colonisation 
is known to induce serogroup specific antibodies and raised serum bactericidal 
antibody titres (54) 
 
2.6  Effect of conjugate vaccines on carriage of Nm 
Polysaccharide vaccines and protein-polysaccharide conjugate vaccines differ in their 
effectiveness. Polysaccharide vaccines are T cell-independent antigens that produce 
a reduced immune response in infants and give direct protection to the vaccinated 
individual for a limited period, whereas conjugate vaccines by combining with a protein 
antigen become T cell-dependent that leads to both long term and indirect population-
wide protection (herd protection) (55). Differences in indirect protection between the 
vaccines can be explained by their effect on carriage. Polysaccharide vaccines 
possibly have an effect on carriage of Nm, but this is uncertain and any effect only 
lasts a few months (56). In contrast, protein-polysaccharide conjugate vaccines 
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appear highly effective at reducing carriage in the longer term (55). This means that 
carriage and transmission of organisms possessing the target polysaccharide 
antigens are greatly reduced. Vaccinating groups at high risk of carriage can therefore 
reduce the risk of disease, not only in the vaccinated but also in unvaccinated groups 
who are then less likely to be exposed to the disease-causing strains. 
Vaccination with both pneumococcal and meningococcal conjugate vaccines leads to 
a decline in disease incidence due to vaccine capsular types/groups among the 
vaccinated population (54, 57) as well as in the unvaccinated age groups, well-
illustrated by the effects of introduction of the meningococcal serogroup C conjugate 
vaccine (2, 58). Recent experience with a meningococcal serogroup A conjugate 
vaccine in the African meningitis belt has demonstrated a similar effect (59, 60). 
2.7  Effect of MenB protein vaccines on carriage 
The current recommendation is to offer Bexsero to UK children aged 2 and 4 months 
with a booster at 12 months. If Bexsero is effective in reducing prevalence of 
meningococcal carriage, then an alternative strategy for vaccine use could be 
immunisation of teenagers in the expectation of herd protection (5). One study 
suggests that Bexsero may reduce overall carriage of meningococci by around 18% 
(95%CI 3-30%) in the 3-12 month period after vaccination (61), but this estimate is 
uncertain and the duration of any such effect is unknown. Provisional results from a 
recent trial in Australia showed no evidence of a reduction in carriage of MenB strains 
after Bexsero (Marshall H, unpublished data).  
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2.8  Nm carriage density  
It is well established that understanding the dynamics of bacterial carriage is important 
in the context of vaccination. For example, for the pneumococcus, the density and 
duration of bacterial carriage could have an effect on transmission and invasion by the 
bacteria (62). There is evidence that high pneumococcal carriage density is associated 
with mucosal inflammation (63). The density of nasopharyngeal carriage  of 
Streptococcus pneumoniae in young children shows a normal distribution on a log 
scale peaking at 1,000-10,000 colony forming units/ml (Figure 2.5) (64). In contrast, 
the frequency distribution of Nm density among teenage carriers is heavily skewed to 
the left with the large majority having small numbers of detectable bacteria (Figure 2.6) 
(65). 
 
Figure 2.5 Distribution of bacterial carriage density of Streptococcus pneumoniae in 





Figure 2.6 Bacterial carriage density of Neisseria meningitidis carriage samples from 
Bristol teenagers showing the distribution of carriage (66) 
2.9  Interaction between Nm and humans  
The interaction between meningococci with humans has been studied with techniques 
such as organ culture, primary cell culture, and immortalised cell lines, as there is no 
suitable animal model to study the mechanisms of attachment of and invasion by Nm 
(67). Different stages of the bacterial life-cycle have been studied using models to map 
progress from attachment to epithelial cells to invading the blood stream, attaching to 
endothelial cells, and eventually reaching the cerebrospinal fluid leading to meningitis 
(68). One of the mechanisms of immune evasion by Nm is by modulation of the surface 
expression of genes (69, 70).  
Transcriptomic studies of Nm gene expression in pharyngeal carriage samples, its 
natural habitat, is critical to the study of the biology of the organism, including 
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establishment of colonisation, transmission and the occurrence of invasion and 
disease.  
2.10  Transcriptomics  
Transcriptomics describes the techniques used to study a complete set of transcripts 
or ribonucleic acids (RNAs) encoded in a genome of an organism. The main types of 
RNA include messenger RNA (mRNA), transfer RNA, and ribosomal RNA, which are 
involved in the transcriptional and translational processing of messages encoded in 
the genome of an organism (71).  All cells in a multicellular organism contain the same 
deoxyribonucleic acid (DNA), but different cell types express different genes 
depending on the nutrient availability, environmental variability and other internal and 
external signals. The study of transcriptomes, or transcriptomics, also referred to as 
gene expression profiling, examines the expression level of mRNA in a given cell 
population at a given time (71). 
If a gene carries information for protein synthesis, mRNA carries this information to a 
ribosome so that it can be translated into a specific protein. mRNA is the most unstable 
form of RNA with a half time of degradation in Escherichia coli of 1-3 minutes. This 
RNA degradation is important in the gene regulation process, but this instability makes 
the study of mRNA transcripts challenging.  
2.11  Transcription in bacteria  
Transcription is a multi-stage process of RNA synthesis from a DNA template involving 
the enzyme RNA polymerase (RNAP), a complex multi-subunit consisting of α2ββ’Ѡ 
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subunits originally characterised by Burgess RR in 1977 (72). In bacteria, transcription 
and translation occur simultaneously in the cytoplasm.   
Transcription occurs in three major steps after recognition of a specific transcription 
site (i) chain initiation, (ii) chain elongation and (iii) chain termination.  
(i) Initiation. RNAP triggers initiation of transcription by binding to the transcription start 
site known as the promoter region of the DNA template (73). This is where most 
regulation of gene expression occurs by accessing or blocking this site to the RNAP. 
The promoter sequences are situated 10bp and 35bp upstream of the transcription 
start site (-10 and -35 sequence respectively). In bacteria, specific target recognition 
of the promoter site is guided by the sigma (σ) factor, a protein important for specific 
recognition of the bacterial promoter site. This σ factor forms a complex with the RNAP 
to open and unwind the double helix of DNA to initiate transcription (Figure 2.7)The 
complex of the sigma factor with RNAP is collectively called a holoenzyme (74-76).  
(ii) Elongation is the second step of a transcription reaction. RNA synthesis proceeds 
from 5’ to 3’ direction catalysed by RNAP in the formation of phosphodiester bond 
between the ribonucleotides using DNA as a template (73, 75, 77-79). The RNAP links 
the nucleotides to the 3’ growing end of the mRNA molecule. Once a short RNA 
sequence starts to synthesize, the σ factor dissociates and RNAP elongates the 
growing transcript by moving from the promoter site to a full length of mRNA until the 
chain terminates.  
(iii) Termination is the last step of a transcription reaction before protein synthesis. 
Once the RNAP reaches a terminator site, the RNAP, the DNA strand and the mRNA 
transcript dissociate from each other upon receiving a termination signal (protein or 
RNA based) (74, 80), and the transcribed RNA in this form (mRNA) carries information 
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for protein synthesis. It is at this point that the amount of transcribed mRNA in a 
bacterial cell can potentially be detected and measured by gene expression profiling.     
                       
 
Figure 2.7 The three stages of bacterial DNA transcription process A) Initiation, B) 
Elongation, C) Termination Transcriptomics in the medical field (81) 
 
Transcriptomic studies have played a major role in clinical diagnosis and research 
fields in recent years (82). They generally assess and identify genes that are 
differentially expressed and regulated in different tissues and cellular conditions, for 
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example, in the diagnosis of different bacterial and systemic diseases (83-86) and in 
biomarker identification of cardiovascular diseases and cancer. By profiling gene 
expression it is possible to monitor progress of disease and to design personalised 
treatments (87). Most importantly transcriptomic profiling is used to study immune 
responses induced by vaccines (88, 89), to assess potential vaccine antigens (90), to 
study response to environmental changes (1), and to identify candidates for new drugs 
and vaccines (91).  
2.12  Nm transcriptomic studies 
Transcriptomics are important in studying the dynamics of colonisation and invasion 
of the host epithelial cell by Nm (92). Nm has evolved a mechanism to escape the host 
immune system and survive adverse host micro-environments (e.g. iron starvation, 
heat shock, oxidative stress, carbon source limitation, lack of glucose), by expressing 
different genes or up/down regulating virulence genes (93, 94). Studies of the 
transcriptional responses to the micro-environment of the host can give a detailed 
picture of how the bacteria respond to different environment and nutrient changes. 
Transcriptomic analysis of in vivo pharyngeal samples could lead to understanding 
whether the new vaccines might interfere with colonisation and may enable us to 
predict vaccine efficacy indirectly. It may also lead to discovery of novel vaccine 
candidates with a potential impact upon acquisition and clearance of Nm. Similarly, 
the potential of specific mucosal immune responses induced by vaccines to impact 
upon acquisition or clearance of carriage is likely to depend upon levels of expression 
of the vaccine antigens by the bacteria at different densities and stages of colonisation.  
Transcriptomic studies for Nm to date have used ex vivo models involving laboratory 
culture and cell lines to study the biology of the organism in the process of colonisation 
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and invasion of the host. Ex vivo studies have been done to assess the adaptation 
and survival of the bacteria in blood (95) or using cell lines to assess changes in gene 
expression when Nm attaches to epithelial or endothelial cells (92, 93) and during 
infection (93). Studies have also tried to characterise genes based on the 
transcriptomic profile of Nm using cultured isolates (96). There have been no previous 
transcriptomic studies of gene expression of Nm directly from in vivo human 
pharyngeal swab carriage samples. 
For most transcriptomic work, RNA isolation and purification are necessary. Extracting 
RNA can be challenging especially for samples collected from a non-sterile site such 
as the pharynx that harbours many different bacterial species as well as human cells 
and debris. To this end, evaluating the efficiency of different RNA isolation techniques 
will be important for analysis of Nm gene expression.  
2.13  Gene expression profiling  
Gene expression profiling is a tool used to quantify the transcription of genes by 
measuring directly, or indirectly, the quantities and distribution of mRNA transcripts 
present in a particular cell preparation or tissue under specific circumstances, in order 
to provide a global picture of this aspect of cellular function. Gene expression levels 
vary greatly depending on the response to environmental conditions and the 
physiological state of a particular cell (97, 98), although certain housekeeping genes 
are consistently expressed and are important for the basic cellular functions of 
bacteria. Expression of such genes can be a useful yardstick against which to compare 
variations in expression of other genes whose transcription rates are less immutable.  
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2.13.1 Methods of gene profiling  
Methods of gene expression profiling include sequencing techniques, relative gene 
identification or absolute transcript counting. Among the available methods, 
quantitative reverse transcriptase polymerase chain reaction (RT-qPCR), microarray 
and RNA sequencing (RNA-Seq) are the most commonly used.  
RT-qPCR 
RT-qPCR is one of the oldest transcriptomic techniques and it uses the reverse 
transcriptase enzyme to reverse transcribe RNA to complementary DNA (cDNA) to be 
amplified and detected using quantitative PCR (qPCR). This technique still is the 
method of choice of some researchers.  
Microarray 
Microarray uses short nucleotide probes that are attached to a solid substrate (a glass 
slide or silicon thin-film cell). The transcript abundance is determined by measuring 
the amount of fluorescently-labelled transcripts bound to these probes (99). The 
technique needs a prior knowledge of the genes and organism of interest to do the 
analysis, and measuring abundance using this method does not give an absolute gene 
count. The technique also needs reverse transcription of the RNA to cDNA, 
fragmentation and fluorescence labelling steps which could introduce bias.  
RNA-Seq 
RNA-Seq refers to quantification and detection of RNA (mRNA) by sequences 
generated from many short fragments of transcripts and uses computational methods 
to reconstruct the reads to a reference genome (100). RNA-Seq can identify genes 
which are active at a particular time in a particular tissue without prior knowledge of 
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the genes (100). Fragmentation of the RNA is a key step to get a reliable RNA-Seq 
result as mRNA is longer than the read length of the sequence. This technique requires 
fragmentation, library preparation, reverse transcription and alignment of the 
sequences.(101)  
NanoString nCounter technology 
NanoString nCounter technology is a recent advance in gene expression profiling 
techniques with fully automated gene expression detection and quantification methods 
(102, 103). The technology is based on digital detection and direct molecular 
barcoding of target transcripts using colour coded probe pairs.  Each probe pair 
consists of a 50 base reporter probe, which carries the signal on its 5’ end, and a 50 
pair capture probe which carries a biotin on the 3’ end. The reporter probe carries the 
signal; the capture probe allows the complex to be immobilized for data collection. The 
direct digital detection of mRNA using colour coded molecular barcoding avoids the 
need to reverse transcribe mRNA to cDNA and the need to amplify the gene. This 
method has been shown to give highly reproducible and accurate multiplexed results 
in a wide variety of samples (103). 
Among the challenges in detecting RNA transcripts is that the quantity of RNA 
available may be insufficient to construct a RNA-Seq library or to label microarray 
analysis (104). Other techniques such as RT-qPCR need reverse transcription and 
amplification of RNA which can introduce bias into the analysis. Direct transcript 
detection of mRNA from a sample is an ideal way to get the exact picture in the cellular 
sample. The NanoString nCounter system has been shown to be effective in detecting 
mRNA from a sample without the need to amplify the gene, reverse transcribe or 
prepare a library file. This technique performs a direct transcript detection of multiple 
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targets using probe pairs in a single reaction and so is well suited to analysis of 
samples with low levels of transcript. The prerequisite for the NanoString system is a 
prior knowledge of the target genes of interest.  
NanoString nCounter analysis has been shown to have a higher accuracy and 
reproducibility than techniques such as microarray and RT-qPCR and has an 
equivalent detection rate to RNA-Seq (105, 106).  RNA-Seq generates large amounts 
of data  that can be challenging for interpretation and library preparation for a small 
quantity of RNA (107). The other gene expression methods either involve conversion 
of the transcript message to cDNA or involve enzymatic reactions, which could 
introduce bias (107). 
2.14  Summary 
Transcription studies of samples from the human upper respiratory tract of genes that 
code for the meningococcal proteins in the two licensed MenB vaccines and other 
potential protein vaccine antigen candidates may provide information about their 
potential to induce protective mucosal immune responses. The NanoString system 
offers a potential method to study gene expression of Nm from in vivo pharyngeal 
samples that has not been previously used. If certain genes are expressed more in 
pharyngeal carriage, this could advance our understanding of the colonisation process 
and the potential protection from protein vaccines. 
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2.15  Aim and objectives  
2.15.1  Aim:  
To describe bacterial transcription signatures of Nm colonising the human pharynx 
(and at different densities) in order to evaluate whether gene products either in current 
vaccines, or other potential vaccine candidates, might be involved in acquisition, 
colonisation and transmission of meningococci, and thereby their potential 
effectiveness in reducing carriage.  
2.15.2  Objectives:  
➢ To establish methodology for extraction and quantification of RNA from cultured 
Nm isolates and from pharyngeal swabs obtained from meningococcal carriers.  
➢ To select a panel of meningococcal genes encoding proteins in the current 
MenB vaccines, those under consideration as vaccine candidates, and others 
that may have roles in colonisation and response to stress. 
➢ To establish mRNA transcript detection assays (NanoString) for the selected 
panel of genes 
➢ To compare the gene expression profiles of meningococci cultured under 
different environmental conditions, thus confirming the potential to detect 
changes in expression.  
➢ To establish gene expression from in vivo human pharyngeal samples and 
compare gene expression profiles in high and lower density carriers  





Chapter 3. Materials and Methods  
3.1  Materials  
3.1.1 Reagents     
Reagents       Supplier  
Acid: phenol: chloroform: isoamyl alcohol       Thermo Fisher Scientific, UK 
RNaseZap solution       Thermo Fisher Scientific, UK 
Tris-EDTA buffer      Sigma-Aldrich Co. Ltd, UK 
Absolute ethanol       Sigma-Aldrich Co. Ltd, UK 
Sodium acetate       Sigma-Aldrich Co. Ltd, UK 
Lysozyme       Sigma-Aldrich Co. Ltd, UK 
Isovitalex enrichment      Becton Dickinson Ltd, UK 
Phosphate buffered saline with Mg and Ca  P.A.A. Laboratories Ltd, UK 
RNase free Phosphate buffered saline   Thermo Fisher Scientific, UK 
2-Mercaptoethanol      Sigma-Aldrich Co. Ltd, UK 
Deferoxamine mesylate salt     Sigma-Aldrich Co. Ltd, UK 
Glacial acetic acid                      Sigma-Aldrich Co. Ltd, UK      
Horse blood        Oxoid Ltd, UK  
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Reagents       Supplier  
Proteinase K       Qiagen Ltd, UK 
Nuclease free water      Qiagen Ltd, UK 
RNAlater        Thermo Fisher Scientific, UK 
RNAprotect        Qiagen Ltd, UK  
Reporter probes      NanoString technologies, USA 
Capture probes      NanoString technologies, USA 
NanoString hybridisation buffer     NanoString technologies, USA 
RNasin® Ribonuclease Inhibitor    Promega UK, UK 
Tryptic Soya broth       Becton Dickinson Ltd, UK 
Reagent A        NanoString technologies, USA 
Reagent B       NanoString technologies, USA 
Reagent C       NanoString technologies, USA 
Hybridisation buffer      NanoString technologies, USA 
Tag polymerase      Thermo Fisher Scientific, UK 
Hot start (dNTPs)      Thermo Fisher Scientific, UK 
DNase        Promega UK, UK 
Reverse transcriptase      Thermo Fisher Scientific, UK 
Fast SYBR green       Thermo Fisher Scientific, UK 
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Reagents       Supplier  
JAMES reagent       Biomerieux Ltd, UK 
ZYM B        Biomerieux Ltd, UK 
NaCI         Biomerieux Ltd, UK 
Mineral oil       Biomerieux Ltd, UK 
Horse blood       TCS Biosciences Ltd, UK 
Columbia agar with horse blood    Thermo Fisher Scientific, UK 
G.C. Selective Agar with VCNT    E & O laboratories, UK 
XT_GX CodeSet       NanoString technologies, USA 
nCounter master kit      NanoString technologies, USA 
BHI broth       Thermo Fisher Scientific, UK  
BHI agar        Thermo Fisher Scientific, UK 





Material        Supplier  
25ml universal tubes     University store  
Vented cap tubes      Sigma-Aldrich Co. Ltd, UK 
15ml and 50ml graduated yellow top tubes  Sigma-Aldrich Co. Ltd, UK 
2ml RNase/DNase free microfuge tubes   STARLAB, UK 
1.5 ml RNase/DNase free microfuge tubes   STARLAB, UK 
RNase free 1000,200,20,10 tips     Thermo Fisher Scientific, UK 
Spectrophotometer with cuvettes    Sigma-Aldrich Co. Ltd, UK 
Spectrophotometer without stoppers   Sigma-Aldrich Co. Ltd, UK 
2ml microcentrifuge Tubes     STARLAB, UK 
Barrier (filter) tips      Thermo Fisher Scientific, UK 
RNase DNase free 1.5ml microfuge tubes  STARLAB, UK 
SPRINT Cartridge      NanoString technologies, USA  
MAX Cartridge      NanoString technologies, USA 
Ampule rack       Biomerieux Ltd, UK 




3.1.3 Commercial kits  
Kits        Supplier 
RNeasy mini kit      Qiagen Ltd, UK 
RNeasy minElute Cleanup kit    Qiagen Ltd, UK 
RNase free DNase set      Promega UK 
nCounter master kit      NanoString technologies, USA 
nCounter CodeSet Kit      NanoString technologies, USA 
RNase protect bacteria mini kit     Qiagen Ltd, UK 
nCounter gene expression CodeSet    NanoString technologies, USA  
API_NH       Biomerieux Ltd, UK 
NanoString Cartridge (SPRINT and MAX)   NanoString technologies, USA 





Instruments       Supplier 
Spectrophotometer      Thermo Fisher Scientific, UK  
Heating block      Grant Instruments, UK  
Mini-microfuge (nano)     Thermo Fisher Scientific, UK 
Microcentrifuges       Thermo Fisher Scientific, UK 
Vortex        Scientific Industries, UK  
Shaker        Stuart Scientific, UK 
CO2 Incubator       Thermo Fisher Scientific, UK 
Microcentrifuge       Labnet, UK 
NanoString nCounter pre-station    NanoString technologies, USA 
NanoString nCounter digital analyser   NanoString technologies, USA 
PCR thermal cycler       MJ Research Inc, USA 
Denovix DS-11 spectrophotometer    DeNovix Inc, USA  
Plate counter       Stuart Scientific, UK 
Water bath       Grant Instruments, UK  
Pipettes L10, L20, L200, L1000    Sartorius Ltd, UK  
Rainin pipettes L10, L20, L200, L1000   Mettler-Toledo Ltd, UK 
Tube-strip picofuge 200µl      Thermo Fisher Scientific, UK 
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Instruments       Supplier  
 
200µl PCR tubes      STARLAB, UK 
nCounter reagent plates      NanoString technologies, USA 
NanoString Prep plates     NanoString technologies, USA 
Racked tips for prep station     NanoString technologies, USA 
NanoString SPRINT      NanoString technologies, USA 
Mixing robot (QIAgility)     Qiagen Ltd, UK  




3.2  Methods  
3.2.1 Sterilisation of equipment 
All glassware was washed and sterilised at 160ºC for 3 hours to minimise RNases that 
could degrade RNA in the samples. 25ml screw capped universal tubes were soaked 
in 100% ethanol for 30 mins, rinsed three times with double distilled water and baked 
for 3 hours at 160ºC in a dry oven. All the sterilised materials were handled with 
protective gloves to avoid skin contact that could contaminate the glassware with 
RNases.  
3.2.2 Nm cultures and growth media 
3.2.2.1 Culture (Colombian blood agar)  
American Type Culture Collection (ATCC)-BAA-335 MC58 Nm strains were cultured 
on Colombian blood agar (CBA) containing 5% horse blood at 37ºC for 16 hours in 
5% carbon dioxide (CO2). The bacteria were stocked in tryptic soy broth plus 15% 
glycerol and kept at -80ºC. All the subsequent experiments were performed from a 
fresh stock of Nm.  
3.2.2.2 Suspension feeder culture  
Single Nm colonies were taken from an overnight growth culture on CBA with a plastic 
loop and emulsified slowly into a tube containing 3ml phosphate buffered saline with 
calcium and magnesium (PBS-B) by rubbing the colonies onto the inside wall of the 
tube. After leaving the suspension to settle for 1 minute, 2ml was transferred to another 
sterile universal tube, avoiding aggregated bacteria at the bottom of the tube. The 
suspension was made to have an absorbance value OD600 = 1 for use as a feeder 
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culture to inoculate brain heart infusion (BHI) broth (enriched by 10% heat inactivated 
horse blood and 2% isovitalex) at 1:100 dilution.  
3.2.2.3 Culture (GC agar)  
GC selective culture media was used to isolate Nm from the BrisMenNHC pharyngeal 
swab samples (Appendix D). GC agar contains antibiotics which inhibit the growth of 
gram negative and positive bacteria and supports the growth of Nm. Samples stored 
in STGG at -80ºC were thawed on ice for 2 hours. 100ml of the defrosted sample was 
plated onto GC plates. The media was incubated for 24, 48 and 72 hours until a typical 
Nm colony was observed. 
3.2.2.4 Liquid culture in GC broth 
A broth GC culture media was prepared and enriched before adding the bacterial 
suspension. The media were enriched using 10% heat inactivated horse blood and 
2% isovitalex. The GC broth was prepared to have 12.5µM Fe (NO3)3.9H2O.  
3.2.2.5 Liquid culture in BHI broth supplemented with 10% horse blood 
BHI broth was used to grow Nm from a feeder Nm culture, enriched by 10% heat 
inactivated horse blood and 2% isovitalex.  A suspension of Nm was made (3.2.2.2.), 
inoculated in 1:100 dilution to the broth and incubated at 37ºC in a 5% CO2 incubator, 
shaking at 100rpm.  
3.2.2.6 Heat inactivated horse blood  
Horse blood was heat inactivated in the department laboratory. The blood in a sterile 
bottle was heated in a water bath set at 56ºC for 30 minutes, swirling the bottle every 
10 minutes. The heat inactivated blood was cooled to room temperature and 
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dispensed into 15ml and 50ml sterile tubes. The tubes containing the heat inactivated 
blood were frozen at -20ºC until needed. The sterility of the heat inactivated blood was 
checked by culturing a drop of it on CBA overnight.  
3.2.3 Pharyngeal swab collection, transport and storage  
Informed consent was obtained from subjects prior to taking pharyngeal swab 
samples. The samples were taken using a double headed swab, sweeping from one 
tonsil, behind the uvula to the other tonsil. The two heads of the swab were snapped 
off and put into two different media. One head of the swab was stored in 1.5ml skim 
milk, tryptone, glucose, and glycerine (STGG) in a 2ml Eppendorf tube, and the other 
was kept in 1.5ml RNAlater. The tubes were stored at 2-8ºC during sampling and 
transported to the laboratory within 2-6 hours of collection. On arrival at the UoB 
laboratory, the STGG samples were vortexed for 30 seconds before storage at -80ºC, 
whereas the RNAlater samples were vortexed and stored at 4ºC overnight before 
being transferred to a -80ºC freezer.     
3.2.4 Ethical clearance 
Ethical approval to use the samples held in the Bristol Biobank (project ID: U-II-0023) 
was obtained for 267 Nm positive BrisMenNHC samples collected both in RNAlater 
and STGG.  Analysis of swab samples from the SPIT study was approved by the South 
West - Frenchay Research Ethics Committee  (REC reference: 16/SW/0269) and from 
the Portugal study was approved by the Ethics Committee of the Coimbra School of 
Medicine, Portugal  (CE-6/2012). Subjects who did not give consent for further DNA 




3.2.5 RNA extraction from culture and pharyngeal swab samples  
Prior to RNA extraction, 1.5ml RNAlater bacterial culture and pharyngeal swab 
samples were thawed on ice, diluted with an equal volume of ice cold 1x phosphate 
buffered saline (PBS) and centrifuged at 5000g for 2 minutes. The supernatant was 
discarded with careful pipetting. The pellets were re-suspended with 20µl RNase free 
water and treated with 15mg/ml lysozyme plus Tris-EDTA buffer in the presence of PK 
(proteinase K) to lyse the bacteria cells for 30 minutes at room temperature, shaking 
for 11 seconds every 2 minutes.  
Bacterial RNA was extracted and purified using the RNeasy mini kit. Once the bacterial 
cells were lysed and homogenised, a 1:10 diluted 700µl pre-prepared mixture of beta 
2-mercaptoethanol to RLT Qiagen buffer was added and vortexed vigorously. 2-
mercaptoethanol prevents the degradation of RNA by nonspecific RNases. Absolute 
ethanol (500µl) was added and mixed to promote selective binding of RNA to the 
RNeasy membrane, then 700µl of the mixture was applied into the RNeasy mini-
column at a time. The RNA binds to the column and other contaminants are washed 
through during micro-centrifugation for 15 seconds at 10,000rpm. 500µl RW1 wash 
buffer was added to remove biomolecules such as carbohydrates, proteins, fatty acids 
etc. Molecules with >200 bases remain bound to the column. On-column DNA 
digestion was performed for all the samples (3.2.6). A second wash was done using 
RW1 followed by 500µl RPE buffer, a mild wash buffer that removes traces of salt in 
the column. The column was centrifuged for 1 minute to dry the column and the RNA 
was eluted from the column by adding 30µl RNase-free water.  
39 
 
3.2.6 DNA digestion using Qiagen DNase kit (on column DNA digestion) 
On-column DNase digestion was performed for all the samples using RNase free 
DNase set. DNase l stock solution was prepared by injecting 550µl RNase-free water 
into a DNase I vial using sterile needle and syringe. The DNase solution was mixed 
by gently inverting the vial and 50µl of the solution was aliquoted and kept at -20ºC. 
When needed, DNase solution was thawed at room temperature and gently mixed 
with 10ul DNase stock with 70µl of buffer RDD and centrifuged briefly. The DNase 
solution was added directly to the RNeasy column containing the sample and left at 
room temperature for 15 minutes. 350µl RW1 buffer was added to the RNeasy column 
to remove biomolecules such as digested DNAs, carbohydrates, proteins and fatty 
acids etc. that are non-specifically attached to the silica membrane.  
 
3.2.7 DNA digestion using TURBO DNase (off column DNA digestion)  
The total RNA samples extracted using RNeasy mini kit and stored at -80ºC were 
thawed on ice. After adding 10X TURBO DNase buffer to 1x concentration of the 
thawed RNA sample, 1µl TURBO DNase was added and incubated at 37ºC for one 
hour. Inactivation reagent was added to inactivate the TURBO DNase. Samples were 
kept at -80ºC until needed.  
3.2.8 Isolation of Nm from STGG collected pharyngeal swab sample  
Pharyngeal swab samples in STGG stored at -80ºC were thawed slowly on ice for 2 
hours. The samples were vortexed for 30 seconds at high speed to homogenise the 
samples. 100ml samples were then plated out on GC selective media. The samples 
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were left to grow for 24 hours, 48 hours and 72 hours at 37ºC in a 5% CO2 incubator 
before doing sub-culture. Typical Nm colonies were selected from the GC media, sub-
cultured on CBA agar, and incubated at 37ºC for 24 hours in a 5% CO2 incubator. Any 
media contaminated with bacteria other than Nm were further sub-cultured on CBA 
agar as above, whereas visually uncontaminated media went on for Gram-stain, 
oxidase test and API biochemical tests.  
3.2.9 Bacterial lysate preparation 
Bacterial cell lysate was prepared using lysozyme with TE and RLT buffers from 
Qiagen. The frozen Nm samples in RNAlater were defrosted on ice, added to an equal 
volume of ice-cold PBS and centrifuged for 2 minutes at 5000g. After treating the 
bacterial pellet for 30 minutes with 15% lysozyme and TE buffer in the presence of 
PK, RLT buffer was added before proceeding to hybridisation reaction and gene 
expression analysis.   
 
3.2.10 Oxidase test 
A single colony from an overnight culture on CBA was taken using a sterile plastic loop 
and emulsified onto a filter paper with 50µl oxidase reagent 
(tetraethyl_p_phenylenediamine dihydrochloride). The colour change when applying 
the bacteria was observed after 10 seconds and recorded. If the bacteria produce 
cytochrome oxidase, the oxidase reagent is hydrolysed to a purple colour (oxidase 




3.2.11 Gram stain    
One colony was taken from the overnight grown Nm CBA plate and a thin smear was 
applied on a glass slide with a drop of (50µl) distilled water covering an area of 
approximately 2x3cm.The smear was air dried, fixed using a flame by passing the slide 
through the flame 2 to 3 times and left to cool for 1 minute at room temperature. The 
smear was covered with a primary stain, crystal violet, for 30 seconds and washed off 
gently with distilled water. Logol’s iodine was added as a mordant for 30 seconds and 
washed off as above. Finally, the smear was covered with safranin, a secondary stain, 
for 30 seconds, washed and air dried before examining the morphology and Gram 
reaction of the bacteria under a microscope.  
3.2.12 Biochemical test with API_NH  
A bacterial suspension was made from samples identified as oxidase-positive Gram-
negative diplococci to assess the biochemical behaviour of the bacteria to identify 
putative meningococci. The bacterial suspension was made in 0.85% NaCI (normal 
saline) from a purified growth of Nm on a CBA plate by selecting well-isolated colonies, 
with a MacFarlane strand of 4.0.  The suspension was distributed into ten microtubes 
avoiding formation of air bubbles. 50µl suspension and 100µl mineral oil were added 
to each of the first 7 microtubes containing dehydrated substrate, and 150µl 
suspension was added to each of the last three microtubes. The tubes were incubated 
for 2.5 hours at 35ºC in aerobic conditions. The results were read visually by referring 
to the reading table provided by the company. The last three microtubes were read 
before adding reagent. A drop of ZYM B reagent was added to microtubes 8 (LIP/ProA) 
and 9 (PAL/GGT) and JAMES reagent was added into microtube 10(βGAL/IND). After 
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three minutes the result was read again.  The results were read and interpreted using 
the table provided. A control ATCC strain was run alongside the test.  
3.2.13 RNA Preservation media  
3.2.13.1 RNAlater  
RNAlater is a liquid RNA preservative solution that allows rapid stabilisation and 
protection of cellular RNA integrity. This solution was used to preserve RNA collected 
on swab samples, during transport to the laboratory within 2-6 hours of sample 
collection, and on pelleted Nm cultures in the laboratory.  
 
3.2.14 Nucleic acid quantification and integrity testing  
3.2.14.1 NanoDrop 
Quality and quantity of the RNA extracted from carriage samples or cultures was 
measured using a Nanodrop Denovix D-11+ spectrophotometer. The quality of the 
samples was measured by taking the ratio of absorbance at 280nm to 260nm. A ratio 
of 1.9 to 2 was taken as sufficiently pure. The quantity of RNA was measured after 
blanking the spectrophotometer with 1µl of RNase DNase-free water. The same 
volume of total RNA was used to measure the absorbance of the samples.  
3.2.14.2 RNAtape station  
Total RNA samples, extracted using RNeasy mini kit from culture, were assessed 
using electrophoretic separation on micro-fabricated chips. RNA concentration and the 
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ribosomal ratio of 16S/23S, automatically generated from the electrophoretic 
bioanalyzer as a RIN number, were used to assess the integrity of the samples.  
Quality and quantity of RNA was checked using the Agilent 2200 tape station system, 
an automated RNA screening technique using prepacked reagents. The assay also 
provides the ability to detect gDNA contamination of the total RNA samples. Fifteen 
samples from the iron/temperature stress experiments (chapter 4) were diluted to 
100ng/µl from the stock RNA samples and analysed using Nanodrop and RNA screen 
tape analysis. The samples were aliquoted in 3µl to two 0.2ml PCR tubes. One was 
sent to the Department of Life Sciences, UoB, where sample quality was checked 
using RNA tape station and the other was assessed using Nanodrop. Contamination 
of the RNA samples with gDNA was assessed with the RNA screen tape assay.  
 
3.2.15 NanoString nCounter instruments and techniques 
3.2.15.1 Instruments  
The NanoString nCounter system is a new and powerful technique of gene detection 
and counting developed by NanoString Technologies, Seattle, USA. The platform uses 
high resonance microscopic imaging and molecular barcoding of genes using specific 
colour coded probes. This system can be used to profile RNA, DNA and protein 
simultaneously in a single reaction, measuring up to 800 gene labels.  
Two different types of nCounter profilers were used in these studies for assaying gene 
expression of Nm from culture and pharyngeal swab samples. The culture samples 
were assayed at University College London using the MAX/FLEX nCounter instrument 
whereas the in vivo pharyngeal swab samples were assayed in Bristol using the 
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SPRINT analyser. The MAX/Flex nCounter system comprises two instruments, a prep-
station fluidic handling robot and a digital data analyser whereas the fully automated 
SPRINT profiler is a one-set digital analyser with an embedded prep station and digital 
analyser.   
Below is the workflow of Nm gene expression from RNA extraction to obtaining mRNA 
to data analysis (Figure 3.1).  
 
 




3.2.15.2 Sample hybridisation  
Hybridisation was performed according to the manufacturer’s recommendations 
following the total RNA XT protocol (108). All reagents were brought to room 
temperature and the samples were thawed on ice. A master mix was prepared by 
adding 70µl hybridisation buffer to the tube containing the reporter probe set and 
mixed by tube inversion. After a quick spin of the master mix, 8µl were aliquoted into 
12 pre-labelled 200µl PCR tubes. 5µl total RNA/lysate and 2µl capture probe set were 
added to each tube before placing the samples in a pre-heated thermocycler at 65ºC. 
The mixture was incubated in a heated lid thermocycler at 80ºC for 19 hours to let the 
probes hybridise to the target sequences (Figure 3.2).  
 
Figure 3.2 Schematic representation of steps involved in NanoString nCounter 
hybridisation and gene detection 
 
3.2.15.3 Post hybridisation reaction  
The overnight hybridised samples were taken out of the thermocycler after 19 hours 
incubation. 15µl RNase DNase free water was added to each tube to bring the final 
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volume to 30µl and loaded into a room temperature thawed NanoString cartridge. The 
cartridge was put in the SPRINT/MAX FLEX profiler for mRNA transcript counting. 
Each of the hybridised samples was loaded in the cartridge according to the 
manufacturer’s protocol by pushing the pipette plunger to the second stop, creating an 
air bubble and removing the pipette before releasing the plunger to avoid sucking the 
sample out. The top of the cartridge was wiped with a clear dry wipe and the sample 
port sealed with a transparent seal. The removable green seal was removed from the 
cartridge before putting into the SPRINT analyser for gene detection and counting 
The post hybridisation process for the MAX/FLEX requires loading the overnight 
hybridised samples onto a fluid handling prep station. All the ready-to-load reagents 
(the master kit) required for sample processing on the prep station were provided by 
NanoString with the CodeSets. These reagents and consumables were loaded onto 
the prep station prior to loading the hybridised samples onto the instrument. All the 
reagents were brought to room temperature before processing. The prep plates 
containing the magnetic beads were spun for 1 minute at 2000rpm to make sure that 
the beads were at the bottom of the well. Other materials such as the sample cartridge, 
empty strip tubes, tips, tip sheaths and tip wastes for liquid waste were placed in 
specified places on the instrument. The overnight hybridised samples were then 
placed on the sample port along with the reagents for two-step magnetic bead-based 
purification. Magnetic beads capsulated with a short sequence complementary to the 
capture probes and the reporter probes bound to the complementary sequences. 
Excess unhybridized probes and non-target cellular transcripts that are not attached 
to the cartridge were removed using the prep-station leaving the hybridised complexes 
attached. The process on the prep station took two and a half hours to process 12 
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samples. A cartridge containing the captured hybridised probes was transferred to the 
digital analyser for transcript detection and counting.  
3.2.15.4 nCounter Digital data capturing and analysis  
The reporter library file (RLF), generated by NanoString to contain information about 
the unique custom CodeSet was loaded onto the nCounter digital analyser. The data 
were captured from the cartridge by taking images of the immobilised florescent 
reporter probes with a charge coupled device (CCD) camera at the highest data 
resolution, 600 or 194 fields of view (FOVs) according to the machine used (Max/Flex 
or SPRINT), corresponding to the reporter code count (RCC). The data were exported 
as comma separated value (CSV) files using a memory stick for analysis.  
3.2.15.5 Internal QC 
For mRNA gene expression assays, 6 internal positive and 8 negative controls had 
been added to the CodeSet by NanoString Technologies during manufacturing to 
assess the overall technical performance of the assay. The positive and negative 
controls were synthetic oligonucleotides made to be non-homologous to any known 
organism and validated by the External RNA Control Consortium (ERCC). The six 
internal negative controls denoted alphabetically from A-H (NegA-NegH) were made 
to have no transcript to estimate the non-specific background signal, positive controls 
were pre-mixed with the reporter probe. The positive controls were spiked in at 
concentrations of 128, 32, 8, 2, 0.5 and 0.125fM when manufacturing the probe set. 
The background count (“raw” data) were adjusted using negative control counts of the 
eight negative controls included with the CodeSet. The geometric mean of the eight 
negative controls were calculated for each lane and deducted from each raw count to 
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adjust the background count. Positive spiked controls were used to assess the quality 
and linearity of imaging. The normalisation was done on nSolver and the data were 
exported to Stata version 15 for further analysis (109). 
3.2.15.6 Data QC  
The data on raw gene counts for every gene assayed were extracted and data QC 
performed using four QC metrics (positive control linearity, imaging, binding density, 
and limit of detection). The QC was done following the manufacturer’s manual (110). 
 
(i) Positive control linearity  
The positive control linearity was checked automatically using nSolverTM 3.0 analysis 
software using the positive controls included in each assay in different concentrations 
( 3.2.15.5). As the lowest value positive control (POS_F) is considered below the limit 
of detection of the system, it was excluded from this calculation. The Pearson 
correlation coefficient is calculated from the regression between the known 
concentration of each of the positive controls and their actual counts. This measures 
the efficiency of the hybridisation reaction.  A correlation of R2 =0.95 was taken as the 







R2 = linear regression of    log2 known (positive controls)     >= 0.95 




Figure 3.3 Linear regression of positive controls calculation to check the linearity 




(ii) Imaging QC 
The image on a NanoString cartridge is taken in small subdivided sections/areas 
(FOVs) where the genes (barcodes) are scanned and counted (Figure 3.4). The sum 
of gene counts in FOVs from a single lane gave the final raw count for each gene and 
was reported as FOVs counted. The SPRINT analyser counts 194 FOVs and the 
MAX/FLEX analyser counts 600 FOVs as set by the NanoString company. 
The imaging percentage is a ratio of the number of FOVs that have been successfully 
scanned (FOVs counted) divided by the total number of FOVs that the instrument 
makes an attempt to scan (FOV count). Percentages greater than 75% were taken as 
a good technical performance of the assay as recommended by the company. This 




Figure 3.4 The image of a SPRINT cartridge showing the 12 gene counting areas 
and Imaging quality control calculation. Each counting area has several fields of view 
(FOVs).  
 
(iii) Binding density QC 
The binding density is the number of fluorescent spots per square micron that are 
bound to the slide surface. The imaging unit counts individual unambiguous 
molecules.  Signal saturation (overlap of an image) can affect the linearity of the assay. 
The binding density is assessed after the experiment has been run. By assessing the 
binding density, future sample inputs can be adjusted for future runs. The amount of 
RNA loaded in the assay can be affected by the number of targets being quantified 
and expression level of certain highly expressed genes. Degraded RNA can affect the 
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value of binding density. The binding density of the samples should lie between 0.1-
2.25 for the MAX/FLEX instrument and 0.1-1.8 for the SPRINT analyser.  
 
(iv) Limit of detection 
The limit of detection of the nCounter was checked for each assay. Samples passed 
this QC if the positive control count for (POS_E) was higher than the mean + 2SD of 
the eight negative control counts (Figure 3.5).  
 
 
Figure 3.5 Linearity of positive controls and positive control limit of detection 
(the lowest positive control POS_E is higher than the average negative (Neg) control 




3.2.16 RT-qPCR for fhbP  
To evaluate the NanoString gene expression results for the fhbP gene, the same 
samples were analysed by RT-qPCR to cross-validate the transcript detection and 
count result obtained from the NanoString SPRINT. 
3.2.16.1 cDNA synthesis using reverse transcriptase 
cDNA of Nm was prepared by using the total RNA extracted using RNeasy mini kit 
and double digested on column with Qiagen DNA digest during extraction and off 
column using TURBO reagent. 48 samples were reverse transcribed to their cDNA 
and this template cDNA was used to assess the expression of different variants of 
fHbP.  
A master mix was prepared by mixing 4µl DEPC (diethyl pyrocarbonate) water, 10µl 
2x buffer (deoxyribonucleotide triphosphates (dNTPs), random oligonucleotides, 
buffer) and 1µl RT. Once the master mix was mixed properly, 5µl total RNA was added. 
The mixture was incubated in the thermocycler for one hour at 37ºC and 5 minutes at 
98ºC and stored at -20ºC until needed.   
3.2.16.2 qPCR reaction for fHbP variants  
Two qPCR reactions were done using a protocol developed at the University of 
Leicester for the three different variants of fHbP. Variant 1 was done independently 
and Variants 2 and 3 were done together since the latter two variants have sequence 
homology that makes it difficult to design variant specific primers. A master mix was 
prepared by adding primers (forward and reverse) for the different qPCR reactions 






Table 3.2 or Variant 1 and Variant 2 and 3 respectively. A control targeting a 
housekeeping gene (gdh) was run with the different qPCR reactions. The reaction was 




Table 3.1 Master mix for Variant 1 fhbP qPCR 




Fast SYBR green 2x 5.00 1x 
fhbP forward primer  10 0.40 400 
fhbP reverse primer 10 0.40 400 
fhbP probe  10 0.20 200 
gdh forward primer 10 0.20 200 
gdh reverse primer 10 0.20 200 
ghd probe 10 1.45 200 
water NA 1.45 NA 





Table 3.2 Master mix for Variants 2 and 3 qPCR 




Fast SYBR green  2x 5.00 1x 
fhbP forward primer  10 0.30 300 
fhbP reverse primer 10 0.30 300 
fhbP probe  10 0.20 200 
gdh forward primer 10 0.20 200 
gdh reverse primer 10 0.20 200 
ghd probe 10 1.45 150 
water NA 1.45 NA 
Sample (cDNA)  NA 2 NA 
 
 
Table 3.3 The real time PCR programme for Variant 1 and Variant 2 and 3 together 
Step type  Temperature  Time   
UNG 50ºC 2 minutes  
Activation  95ºC 20 seconds  
Denaturation  95ºC 3 seconds 50cycles  






Table 3.4 qPCR primers for Variant 1 and Variant 2 and 3 together information 
Primer name  Target gene Direction  Primer/probe sequence Reference  
FHbp_229C_F 
fhbP variant1 
forward  ACTTTATCCGCCAAATCGAAGT Cayrou et al. 2018 (72) 
FHbp_229T_F forward  ACTTTATCCGTCAAATCGAAGT Cayrou et al. 2018 (72) 
FHbp_313_R reverse  GCGGAATGGCTTTGTTTGTA Cayrou et al. 2018 (72) 
FHbp_253_P probe  [6FAM]ACGGGIAGCTCATTACCTTGGAGA[BHQ1] Cayrou et al. 2018 (72) 
gdh350F 
gdh 
forward  TCGCCATTAAAGCCGAAATC Cayrou et al. 2018 (72) 
gdh416R2 reverse  TTGCCGGTACGCAGGTAGA Cayrou et al. 2018 (72) 
gdh374T probe  [JOE]ACGAACGCTGGAAGGGCGTTC[BHQ1] Cayrou et al. 2018 (72) 
FHbp_system_2_586F 
fhbP variant 2 and 3 
forward  GCCGAACTCAAAGCAGATGA 
Christopher D. Bayliss lab, 
University of Leicester 
(unpublished) 
FHbp_system_2_636PR reverse  [6FAM]CGTGTCGCCCAAAATGACGGC[BHQ1] 
Christopher D. Bayliss lab, 
University of Leicester 
(unpublished) 
FHbp_system_2_671R probe  AGGTGGTAAGTGCCTTTTTCTT 
Christopher D. Bayliss lab, 




3.2.16.3 A standard for RT-qPCR 
A standard was prepared from a synthetic sequence of nucleotides and copy number 
was determined by the concentration of the standard added in different dilutions (from 
6 to 60,000 copies).  A standard run was done for each run for both Variant 1 and 
Variants 2 and 3. The lower limit of detection is 100 copies/µl.  
3.2.17 sodC qPCR to check DNA contamination of RNA samples 
SodC qPCR was done to test for contaminating DNA in the total RNA pharyngeal 
samples extracted using RNeasy mini kit. On column DNA digestion was done for 
those samples.  
A pre-prepared mix containing 300nM of Nm sodC forward and reverse primers, 
100nM Nm sodC FAM and molecular grade water stored at -20ºC was thawed at room 
temperature. A master mix was prepared in a clean biosafety cabinet by adding 5µl of 
this pre-prepared mix to 10µl of tag polymerase.  This master mix (15µl) was loaded 
on to a QIAgility pipetting robot and pipetted into each of the test wells on a 96 well 
microplate. 5µl of three positive and negative control samples were added to specific 
control wells, and 5µl total RNA samples thawed at room temperature were pipetted 
manually into all the other wells making a final reaction volume of 20µl in all the wells. 
The plate was sealed and spun for 3 minutes at 1800g. The qPCR was done using 
QIAsyphony real time PCR machine according to the qPCR programme shown in 






Table 3.5 sodC qPCR programme 
Step type  Temperature  Time  Number of cycles 
UNG 50ºC 2 minutes - 
Activation  95ºC 20 seconds - 
Denaturation  95ºC 3 seconds - 
Annealing /extension  60ºC 1 minute 50  
 
 
Table 3.6 sodC PCR primers and probe 
Gene Primers/ Probe name  Sequence (5'-3') References  
sodC Nm-sodC-F351   GCACACTTAGGTGATTTACCTGCAT 
Finn et al (65)  
 
Nm-sodC-R478  CCACCCGTGTGGATCATAATAGA 
Finn et al (65)  
Probe Nm-sodC-P387 FAM   
[6FAM]CATGATGGCACAGCAACAAA
TCCTGTTT[BHQ1] 
Finn et al (65)  
 
3.3  Data Analysis  
All analyses were done using Stata 15 software. Detail on specific analyses is given 





Chapter 4. Development of RNA extraction 
methodology and gene expression profiling of Nm 
from culture samples using NanoString nCounter 
technology  
4.1  Introduction  
Analysis of gene expression is becoming more widely used as a method to understand 
the lifecycles of bacteria and the pathogenesis of the diseases they cause. 
Transcriptomic analysis of in vivo pharyngeal samples of Nm to measure levels of 
gene expression relating to vaccine proteins could help to predict whether such 
vaccines might interfere with colonisation and lead to herd protection. It may also lead 
to the discovery of novel vaccine candidates with a potential impact upon acquisition 
and clearance of Nm.  
The development of an effective gene expression profiling platform is necessary for 
detection of Nm transcripts from pharyngeal samples. Gene profiling from such 
samples is particularly challenging due to the presence of a mixed population of 
bacteria and the low density of Nm in a high percentage of pharyngeal carriers (65). 
One potential method to overcome these challenges is the use of direct gene transcript 
detection and quantification technology, the NanoString nCounter system, which has 
been shown to detect and quantify mRNA from low quantity samples accurately (103). 
NanoString, a digital direct nucleic acid counting technology, uses fluorescently colour 
coded barcodes and microscopic imaging to count up to 800 different transcripts in a 
single hybridisation reaction (3.2.15.2).  Probe pairs are used to capture and detect 
61 
 
individual molecules, in this case mRNA transcripts, from a given sample. This method 
can directly detect and quantify gene transcripts from mixed bacterial samples using 
species-specific nucleotides without the need for bacterial isolation, cDNA synthesis 
or amplification (102, 103, 111, 112). This reduces error by avoiding the need to 
amplify the genes or enzymatic processing of samples, reducing sample handing time, 
and reducing the input of total RNA which is often low quantity in in vivo samples(113, 
114). NanoString technology has been successfully used to profile other bacteria such 
as Staphylococcus aureus (102, 111, 114) but no published reports of its use to 
measure gene expression in Nm have been found. 
Bacterial RNA purity and integrity alongside adequate yield is critical for successful 
gene expression assays and requires high quality RNA extraction. Most methods used 
for RNA extraction are designed for high density pure in vitro samples. For 
transcriptomic analysis, the extraction method is key to obtaining intact high-quality 
intact RNA that is free of RNase, protein and DNA. RNA has been successfully 
extracted from in vivo samples of pneumococci using acid:phenol:chloroform (115-
119). An alternative method is the use of commercially-available RNA extraction kits 
such as RNeasy, which has successfully been used for Nm in vitro samples (95, 120) 
Optimising RNA extraction from Nm cultures and evaluating the capacity of the 
NanoString system to measure mRNA from Nm isolates grown under different 
environmental stresses, when up and down regulation of different genes would be 
expected, are necessary developmental steps before attempting to measure gene 




4.2  Aims  
To optimise RNA extraction methods from Nm culture isolates and to evaluate the 
NanoString nCounter gene profiling technology to measure gene expression in 
cultured samples of Nm.  
4.3  Objectives  
➢ To select Nm genes for gene expression studies  
➢ To produce a growth curve of Nm to identify the mid logarithmic phase for 
analysis 
➢ To establish methodology for extraction and quantification of RNA from isolates 
of Nm cultured from meningococcal carriers 
➢ To assess the feasibility of using different sample types (lysate and total RNA) 
for gene extraction   
➢ To establish mRNA transcript detection assays (NanoString)  
➢ To compare the gene expression profiles of meningococci cultured under 
different environmental conditions, thus confirming the potential to detect 
changes in expression.  
➢ To evaluate performance of the system in detection and quantification of Nm 




4.4  Methods  
4.4.1 Gene selection 
A literature review was done to select genes that encode proteins of the two MenB 
vaccines, other surface expressed proteins that are potential vaccine candidates, and 
proteins with an important role in colonisation and metabolism of Nm.  A search was 
done in December 2015 for published papers using MedLine and Google Scholar with 
search terms such as gene expression, gene profiling, transcriptomics, carriage 
density, Neisseria, meningococcus, meningococcal vaccines. 
4.4.2 Probe design  
The list of gene targets was sent to NanoString Technologies (Seattle, USA) for gene 
CodeSet design. A unique pair of capture and reporter probes of 100bp length (50bp 
attached to a biotin molecule and 50bp attached to a colour barcode respectively) 
complementary to the target sequence of the gene of interest was designed for each 
gene to make a CodeSet by the NanoString bioinformatics team. The capture probe 
attaches the complex of target sequence and probe mixture through a biotin molecule 
to a streptavidin coated cartridge, and the reporter probe through a colour barcode 
signals capturing of the transcripts. The probes for each mRNA target were designed 
to target as many isoforms as possible for all the genes.  
The probes were screened against the human genome and all available neisseria 
transcriptomes (N. gonorrhoeae, N. lactamica, N. elongata, N. wadsworthii, N. 
macacae, N. cinerea, N. bacilliformis and N. subflava) for potential cross-reactivity. 
Screening was also undertaken for hybridization efficiency, potential for cross-
hybridization, GC content and predicted secondary structure. All the sequences were 
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cross-checked by aligning the 100nt sequences in pubMLST and refseq databases 
with all the alleles present at the time. After the best scoring probes for the targets 
were selected by NanoString, a CodeSet Design Report was sent to me for review. 
The hybridisation efficacy of the probes was tested and certified by the company as 
having a high correlation (R2 >0.95).  NanoString Technologies then manufactured the 
CodeSet.  
4.4.3 Growth curve 
Colonies of Nm were suspended in RNase-free PBS-B, optical density (OD) measured 
at 600 nanometres (OD600 = 1). The bacterial suspension was inoculated into 10ml 
BHI broth supplemented with 10% horse blood and 2% isovitalex enrichment in 1:100 
dilution. The experiment was run in duplicate. The liquid culture was incubated at 37°C 
with 5% CO2 and shaken at 150rpm. Growth of Nm was monitored every two hours by 
measuring optical density of 1ml samples of the broth culture at OD600 using (Denovix 
D-11+ spectrophotometer). A growth curve was plotted by taking the mean of the 
duplicate measurements. 
4.4.4 RNA extraction and optimisation  
Two RNA extraction methodologies were compared for the yield and quality of total 
RNA from Nm cultures: the acid:phenol:chloroform method, which had successfully 
been used to extract pneumococcal RNA from in vivo samples, and a commercially 
available RNeasy mini kit.  
Nm ATCC_BAA-335 strains were cultured on CBA agar and a suspension of the 
organism prepared as explained in section 3.2.2.2. The suspension was inoculated in 
broth culture, as for the growth curve, in four different tubes. 1ml samples were 
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collected at three different points during growth: early log phase (2 hours) and mid-log 
phase (4 and 6 hours) from each of the four tubes. The OD600 was measured at each 
point. The cultures were pelleted immediately to remove the culture media, suspended 
in 20µl RNase free PBS before adding 1ml RNAlater, a stabilising reagent, and stored 
at -80°C until RNA extraction.  
Total RNA was extracted from the stored samples using (i) Qiagen RNeasy protect 
mini kit, and (ii) the method adopted from Ogunnyi et al using acid:phenol:chloroform 
(115, 117). All glassware was washed and decontaminated to avoid ribonuclease 
contamination (3.2.1). RNase free filter tips, test tubes and solutions were used in all 
experiments.  
4.4.4.1 RNeasy mini kit  
Bacterial RNA was extracted following the RNeasy mini kit procedure (3.2.5). On-
column DNase digestion (3.2.6) was performed for all the samples.  
4.4.4.2   Acid phenol chloroform  
Samples collected into RNAlater were mixed with an equal volume of pre-warmed 
(65°C) acid:phenol:chloroform (125:24:1, ph 4.5) and were incubated in a heat block 
for 5 minutes at 65°C with vortexing at the mid-point and at the end of the incubation. 
The mixture was cooled on ice for one minute before centrifugation at 15,500g for one 
minute. Samples were phase separated and the aqueous phase was re-extracted with 
500µl of warm acid:phenol:chloroform. Sodium acetate (40µl) at a concentration of 
300µM and 2µl glycerol were added to the supernatant. Two volumes of absolute 
ethanol were added to precipitate the RNA overnight at -80°C. On the following 
morning, the samples were washed twice with 70% cold ethanol and DNase digestion 
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was performed using RQ1 RNase free DNase, 10x DNase buffer and RNasin® 
Ribonuclease Inhibitor. RNA clean-up was subsequently performed to improve RNA 
quality using RNeasy minElute clean-up kit.  
For both methods, RNA quantity and quality were measured using the NanoDrop 
(Denovix D-11+) spectrophotometer. Absorbance of 1µl samples was measured at 
260nm and 280nm.  An optical density ratio A260/A280 of approximately 2 was taken 
to indicate good quality RNA (3.2.14.1).  
4.4.5 Bacterial lysate and total RNA preparation  
Since the sensitivity of detecting transcripts from a crude lysate could eliminate the 
need to go through the process of RNA extraction, gene expression from a crude 
lysate preparation of Nm cultured in optimum conditions was compared with the gene 
count from total RNA extracted using RNeasy minikit.  
ATCC-BAA-335 Nm strains were cultured on CBA. Three different broth cultures 
containing 10ml heat inactivated BHI were each inoculated with a suspension of Nm 
from the overnight culture. For each of the three broths, 1ml Nm culture was collected 
into two different tubes after 1, 2 and 3 hours of incubation. All the collected samples 
were kept in RNAlater until processing. 
The lysate was prepared by resuspending Nm pelleted in lysozyme plus TE buffer and 
treating the suspension using RLT buffer (3.2.9). One set of samples underwent total 
RNA extraction using the RNeasy minikit, the other set went directly to hybridisation 
(Figure 4.1). 5µl samples of the total RNA and the crude lysate were hybridised at the 





Figure 4.1 Workflow showing (i) RNA extraction from lysate and (ii) lysate alone 
before NanoString hybridisation  
4.4.6 PrimeStore and RNAlater for Nm culture RNA extraction 
Nm was cultured on CBA agar overnight and colonies were suspended in PBS-B to 
make a feeder culture (3.2.2.2). 100µl of the suspension was inoculated in 10ml BHI 
broth and left to grow to mid log phase (4 hours). Samples (1ml) were taken into eight 
different tubes. Four of the samples were stored in RNAlater and the other four were 
stored in PrimeStore. RNA was extracted using RNeasy mini kit and PrimeXtract.  
 
4.4.7 Analysis of total RNA concentration from Nm broth culture samples 
collected in undiluted and diluted (1:2) RNAlater  
A feeder culture was prepared, inoculated in BHI broth and left to grow to mid log 
phase (as 4.4.4.). Samples (1ml) were taken into four different tubes. Two samples 
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were store in undiluted RNAlater and the other two in a 1:2 diluted RNAlater. Total 
RNA was extracted using RNeasy mini kit.  
4.4.8 Bacterial strain and culture conditions 
Experiments were set up to assess performance of the nCounter system for Nm gene 
detection and technical reproducibility, and to measure changes in gene expression 
under environmental stress conditions (temperature variation) and nutritional stress 
(iron starvation) that Nm faces in the microenvironment of the host. The lower limit of 
detection, technical reproducibility of the platform, and fold change in expression were 
assessed for the genes selected from the review.  
For temperature shock, standard ATCC-BAA-335 Nm strains were cultured on CBA 
at 37°C for 16 hours in 5% CO2. Colonies were suspended in PBS-B to OD600 = 1 and 
inoculated at 1:100 dilution into 10ml BHI supplemented with 2% isovitalex and heat 
inactivated horse blood. At mid-logarithmic phase (OD600 = 0.5/8x108), the liquid 
cultures were split into three and exposed to cold shock 26°C (to mimic the internal  
temperature of the nose when the environmental temperature falls to zero degree 
(121-123)), heat shock 40°C (to mimic the highest temperature that the human body 
can reach during infection (124) and 37°C as a control. The cultures were left to grow 
for another three hours at these temperatures. The broth cultures were collected and 
pelleted at 5,000g for 2 minutes and re-suspended in 20μl RNase free RNase free 
PBS. RNAlater (1ml) was added to the suspension and samples were left overnight at 
4°C and stored at -80°C until RNA extraction. The experiment was done in triplicate.  
For iron starvation, iron-defined GC media were used. Nm was grown on GC agar for 
16 hours at 37°C in 5% CO2. Colonies were suspended in PBS-B to OD600 = 1 and 
inoculated at 1:100 dilution into 10ml GC broth containing 12.5μM Fe(NO3)3 and 2% 
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isovitalex supplement. The experiment was run in triplicate. The bacterial suspension 
was split into two 4 ml volumes at mid-log OD600 = 0.3 (after 5 hours of incubation). 
One 4ml sample was exposed to 100μM deferoxamine, an iron chelator and the other 
4ml sample was used as a control without a chelator. Both cultures were grown for an 
additional 15 minutes before collecting the samples into RNAlater. The bacterial cells 
were pelleted by centrifugation for 2 minutes at 5000g and re-suspended with 20μl 
RNase free water. 1μl RNAlater solution was added to the resulting suspension, stored 
overnight at 4°C and transferred to -80°C until RNA extraction. 
4.4.9 RNA extraction for the heat shocked /cold shocked and iron depleted and 
replete samples 
Prior to RNA extraction, the stored bacteria were thawed on ice and diluted with an 
equal volume of ice cold 1xPBS to the RNAlater and centrifuged at 5000g for two 
minutes. The pellets were treated with 15mg/ml lysozyme plus Tris-EDTA buffer to 
lyse the bacteria cells for 20 minutes at room temperature, shaking for 11 seconds 
every 2 minutes. Bacterial RNA was extracted using the RNeasy mini kit following the 
manufacturer’s protocol (section 2.2.4).  
4.4.10 DNA digestion of the culture samples 
DNA digestion was done on-column to remove double stranded DNA during RNA 
extraction process to all the samples following RNeasy mini kit procedure (3.2.6). 
4.4.11 Sample preparation and shipment to University College London 
Forty-eight RNA samples were prepared for analysis. Of these, 24 were generated 
from Nm cultured at 37°C for measurement of technical reproducibility of the 
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NanoString platform. To assess this, one sample was taken and split into two 
replicates (replicate 1 and replicate 2). Each of the samples was diluted four-fold from 
100ng to 0.097ng/µl total RNA (100ng, 25ng, 6.25ng, 0.4ng, 0.097ng). The other 24 
samples were from Nm cultures in iron restricted/ replete conditions (12 samples) and 
from the heat/cold shocked Nm cultures (12 samples). All the RNA samples were 
diluted to 100ng total RNA concentration in 5µl. The samples were diluted to the 
desired concentration using RNase free water, frozen at -80°C and shipped on dry ice 
to University College London for the NanoString assays.   
4.4.12 Gene expression profiling using nCounter platform 
Gene expression profiling of the 48 Nm culture samples was done on the University 
College London NanoString nCounter platform, with four runs of 12 samples/run on 
the prep-station and digital analyser. The technical replicates were run independently 
in duplicate (12 reactions at a time), followed by the heat and cold shock samples (12 
each). The samples were tested on consecutive days using one batch of probes and 
reagents.  
The methods below are explained in Chapter 3 (see specific sections)  
Sample Hybridisation (3.2.15.2) 
Transcript count (3.2.15.4)  
Internal QC (3.2.15.5) 
Image QC (3.2.15.5) 
For fold-change expression analysis, the ratio of the log2 of treatment over control was 
calculated using nSolver software version 3.0, and visual plots were done using Stata 
15 (109). Fold change was defined as the mean gene count from three replicates 
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divided by the mean of the control replicates.  All gene counts were normalised for the 
three housekeeping genes. If the quotients were less than one, the reciprocal was 
taken and a minus sign was added for ease of reading (125).  One-way ANOVA was 
used to assess the difference in gene counts between heat/cold treated and iron 
depleted /replete samples and controls. The log10 transformed data were used to plot 
the correlation graphs between the technical replicates. Bonferroni correction was 
done to adjust for the 47 genes tested, and P<0.001 taken as the cut off value for the 
significance.  
4.4.13 Negative control run using pharyngeal swab samples  
Nm-negative samples that did not generate any sodC qPCR amplification up to 50 
cycles were selected from BrisMenNHC samples to estimate the amount of RNA that 
could be obtained from the pharyngeal swab samples and the specificity of the probes 
in detecting Nm genes. Twelve Nm-negative samples were randomly selected from 
individuals who had negative samples on two or more visits. Total RNA from these 
samples was extracted using the protocol optimised for Nm culture samples (3.2.5).  
The total amounts of RNA were measured using Nanodrop (3.2.14.1).  
4.5  Results  
4.5.1 Gene selection 
Forty-seven Nm genes were selected for probe design using the following criteria (i) 
genes coding for proteins in current vaccines, (ii) genes which are potential vaccine 
candidates, (iii) genes which are important in colonisation and adhesion of the bacteria 
to the pharyngeal mucosa (Table 4.1 ,Table 4.2 and Appendix B).  
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(i) Genes coding for proteins in current vaccines  
One of the main criteria for gene selection for mRNA transcript detection assays using 
NanoString technology was those coding for meningococcal proteins in the two 
recently licensed MenB vaccines (Bexsero and Trumenba). The vaccine coverage of 
proteins expressed by high density carriers may be important in understanding the 
effectiveness of these vaccines in preventing transmission.  
Three main components of Bexsero (28) were identified through reverse vaccinology 
as conserved proteins that generate bactericidal antibodies (i) Factor H binding protein 
(fHbp) a surface exposed lipoprotein which binds to human factor H, an inhibitor of the 
alternative complement pathway (ii) Neisseria adhesin A (NadA), a pathogenicity 
factor with a role in host cell adhesion and invasion (iii) Neisserial heparin-binding 
antigen, a lipoprotein which binds heparin and protects against complement-mediated 
killing. The fourth component consists of outer membrane vesicles whose dominant 
antigen is PorA. PorA is known to be highly variable, but important in generating 
bactericidal antibodies and a component of previous outer membrane vesicle vaccines 
(126). The Trumenba vaccine is made up of two fHbp protein variants from subfamilies 
A and B  (24). Carriage of Nm serogroups B, C, W, Y is, or has been, frequent in the 
UK, and ACWY quadrivalent vaccine was introduced in 2015 for UK teenagers. The 
genes involved in capsule biosynthesis for serogroups B, C, W, Y have been recently 
reclassified (20).  
(ii) Potential vaccine candidates  
Other proteins have been proposed as vaccine candidates that are surface expressed 
and may generate bactericidal immunity. There is less certainty about the ability of 
these antigens to generate bactericidal antibodies in humans though they may do so 
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in mice, and they may be more variable. Granoff published a review of MenB vaccines 
in 2010 (24), referring to a number of additional potential vaccine targets such as 
Neisserial surface protein A, Transferrin binding proteins, Opacity proteins, and FetA. 
Tsolakos et al did proteomic analysis of surface expressed proteins that reacted with 
immune sera from mice (127). They identified new possible vaccine antigens including 
Macrophage infectivity potentiator, NMB 1946, NMB 1468, NMB 1612, NMB 0888, 
PilP and PilE. Other possible vaccine genes have been found through reverse 
vaccinology. Genome-derived neisserial antigens GNA33 and GNA992 are highly 
conserved, and elicit bactericidal antibodies in mice (128). Other vaccine candidates 
have been put forward, for example, T cell stimulating carrier protein A that may 
enhance the effectiveness of vaccines by acting as protective immunogen (127) and 
Adhesin Complex Protein that is upregulated under iron-depleted conditions. 
(iii) Proteins important in colonisation: adhesion  
The first step in the colonisation process is adhesion, attachment of bacteria to the 
epithelium of the nasopharynx, a coordinated process mediated through Type IV pili. 
Over 20 proteins are required including PilE, PilQ, PilV, PilN, PilO, PilC  (93, 96, 129) 
(130). Other components play a role in bonding of Nm to the pharyngeal cells such as 
LPS and PorA. The opacity proteins Opa and Opc promote intimate adhesion. Opa 
binds carcino-embryonic antigen cell adhesion molecules (CEACAMs), heparin 
sulphate proteoglycan and integrins (36). Opa proteins are able to elicit innate human 
defences that favour the survival of Nm, while actively suppressing adaptive immune 
responses that would eliminate pathogens (131). Opc binds to host extracellular matrix 
proteins such as vitronectin as also does meningococcal surface fibril (Msf). They 
inhibit complement mediated killing and help meningococcal survival during 
colonisation (132). Other proteins thought to play an important role in establishing 
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carriage include Neisseria hia/hsf homologue A (NhhA), Adhesion and penetration 
protein (App), NadA, and Heat shock protein A (HspA) (129). 
 
4.5.1.1 Proteins important in colonisation: adapting to the host  
The ability to cope with the hostile microenvironment of the host by responding to 
limitations of oxygen and nutrients in the nasopharynx allows the bacteria to adapt to 
the ecological niche. For example, meningococci can grow in oxygen limited 
environments using nitrite as an alternative substrate. Temperature can act to trigger 
immune evasion by Nm as demonstrated by Loh et al who identified three 
thermosensor regions necessary for capsule biosynthesis, the expression of factor H 
binding protein and sialylation of lipopolysaccharide (133).  
Jamet et al identified four genes that were needed for bacterial adaptation to host cells 
(narP, estD, fadD1, nnrS), mostly with a role in adapting to hypoxic stress during 
colonisation (Jamet 2013). Together with narP, NMA 0797 and NMA0798 are part of 
a two component system required for colonization of host cells (134-136).  
Iron is a basic element needed for Nm to survive in the host, but no extracellular free 
iron is available in the body of the host, being bound to specific proteins. Growth of 
Nm in iron-regulated conditions has been shown to be associated with the up or down 
regulation of 235 genes with a high percentage of the genes upregulated. Virulence 
genes involved in iron uptake include fbpB, tonB, lpbP, and expB  (93, 96). Other 
genes involved in iron acquisition (hpuA, hmbR) show phase variation in persistent 
meningococcal carriers  (137). Transcriptional regulation is controlled through the 




Alamro also showed phase variation during carriage in six other gene loci, namely 
porA, opc, feta, nadA, mspA, and nalP. The last two are autotransporter genes. Early 
changes in transcriptomes on adhesion to epithelial cells are seen in genes that induce 
sulphate ABC transporter genes cysW, cysA and cysT (138). The regulator gene 
NMB0573 controls the response to nutrient availability and has an important role in 
colonisation as an indicator of general amino acid abundance (138). Another gene that 
is critical for adaptation to the host is xseB (139) responsible for an inducible repair 
system that upregulates when Nm interacts with host cells.  
 
4.5.2 Probe design  
Probes were designed for the 47 selected genes and three housekeeping genes.  Of 
the 47, 31 did not have any cross reactivity with other neisseria species or other 
organisms, but it was not possible to design a species-specific probe for 16 genes. 




Table 4.1 Neisseria meningitidis genes and target sequences of NanoString probes (n=50 including three housekeeping genes), 











2 nadA NMB0394.1 606-705 CGAAACGGGCGCGGATATGCTGTTGTGGCAGGGTTCGTGCATCGTTCACAACGAATTCAAAGGGCAAGAG
CTGGCGGCGTTGAAGGCGGAACACCCCGAA 
84 84 
3 nhba NMB2132.1 598-697 AGCAATTTTGGAAGGGTTGATTTGGCTAATGGCGTTTTGATTGACGGGCCGTCGCAAAATATAACGTTGACC
CACTGTAAAGGCGATTCTTGTAGTGGCA 
78 79 
4 porA NMB1429.1 392-491 CGAATCAGTTTGACGATGCCAGCCAAGCCATTGATCCTTGGGACAGCAATAATGATGTGGCTTCGCAATTG
GGTATTTTCAAACGCCACGACGACATGCC 
83 80 
5 cssA (synX) NMB0070.1 308-407 AAGCACTAGCAGGCGCAGCTGTAGGTGCATTAAGCAGCCGTTTAGTTTGCCATATCGAAGGTGGTGAACTA
TCTGGTACAGTAGATGACTCCATTCGTCA 
84 80 
6 cssB (siaB) NMB0069.1 265-364 GCTTTAGAAACAATTGGCAGTAATTCCGGCACAGTAACCCTATTACAACCAACCAGTCCATTACGCACAGGG
GCTCATATTCGTGAAGCTTTTTCTCTAT 
79 77 
7 cssC (siaC) NMB0068.1 584-683 TGGGTGGTATGAACGATTTATCTGAAGCCTTTCCAGACGCAATCATTGGCCTGTCTGACCATACCTTAGATA
ACTATGCTTGCTTAGGAGCAGTAGCTTT 
80 79 
8 GNA1030 NMB1030.1 428-527 TGGAGAAAACCGAAGTTTGTGGCGGCGACTTCAGCACCACCATCGACCGCACCAAATGGGGCATGGACTA
CCTCGTTAACGTTGGTATGACCAAAAGCGT 
85 85 
9 nspA NMB0663.1 304-403 GGCGCGCGCTTGAGCCTCAACCGCGCCTCCGTCGACTTGGGCGGCAGCGACAGCTTCAGCCAAACCTCC
ATCGGCCTCGGCGTATTGACGGGCGTAAGCT 
86 85 





11 tbpB NMB0460.1 1538-1637 TGAAATACGGAATGTTGACGCGCAAAAACAGCAAGTCCGCGATGCAGGCAGGAGAAAGCAGTAGTCAAGC
TGATGCTAAAACGGAACAAGTTGAACAAAG 
86 85 
12 fetA NMB1988.1 1298-1397 TGCGTTACGACCGCTTCAAGGTGAAAACCCACGACGGCAAAACCGTTTCAAGCAACAACCTTAACCCGAGT
TTCGGCGTGATTTGGCAGCCGCACGAACA 
83 84 
13 opc NMB1053.1 406-505 GAATCTTCAAAAGACAGCATTAAAACCACCAAGCATACGCTTCACAGCAGCCGTCAGTCGTGGTTAGCCAA
AGTTCACGCGGATTTGCTTTCCCAACTGG 
82 79 
14 mip NMB1567.1 248-347 AAGCCATGCAGGCAGTGTATGACGGCAAAGAAATCAAAATGACCGAAGAGCAGGCTCAGGAAGTCATGAT
GAAATTCCTTCAGGAACAACAGGCTAAAGC 
85 86 
15 NMB1946 NMB1946.1 402-501 ATCGCTGGAAGAAGTCAAAGACGGCAGCACCGTATCCGCGCCCAACGACCCGTCCAACTTCGCCCGCGTC
TTGGTGATGCTCGACGAACTGGGTTGGATC 
87 84 
16 NMB1612 NMB1612.1 370-469 ACCCAAGTCGTCCTCGTTCCGAAAGGCAAAAAAGTATCTTCTTCCGAAGATTTGAAAAACATGAACAAAGTC
GGCGTGGTAACCGGCTACACGGGCGATT 
79 84 
17 NMB0088 NMB0088.1 558-657 ATATGCCGACTGGGGGATTAAGAGTAAAGCAGAGATATTGACGGCAAAACCGCCCAAACCTAACGGTGTAG
CCGAAGCTGCAAAAATTCAGGCCGACGGA 
86 86 
18 pilP NMB1811.1 356-455 CTGTCGGTGTCGGCAACTATTTGGGACAAAACTACGGTAGAATCGAAAGCATTACCGACGACAGCATCGTC
CTGAACGAGCTAATAGAAGACAGCACGGG 
83 85 
19 pilE NMB0018.1 41-140 TGATTGTGATTGCCATCGTCGGCATTTTGGCGGCAGTCGCCCTTCCTGCTTATCAAGACTACACAGCCCGC
GCACAAGTTTCCGAAGCCATTCTTTTGGC 
81 81 
20 dsbA-2 NMB0294.1 352-451 GCCGCAGTGGAAATGGCCGGTGAATCAGATAAAGCCAACAGCCATATTTTCGATGCGATGGTTAATCAAAA
AATCAATCTGGCCGATACCGATACCCTGA 
84 80 
21 GNA33 NMB0033.1 842-941 ACAAAAACGAACATCCCTACGTTTCCATCGGACGCTATATGGCGGATAAGGGCTACCTCAAACTCGGACAA
ACCTCCATGCAGGGCATTAAGTCTTATAT 
81 84 





23 msf NMB0992.1 548-647 GTTCGACTTTGACCGATACGCTGCTGAATACCGGAGCGACCACAAACGTAACCAACGACAACGTTACCGAT
GACGAGAAAAAACGTGCGGCAAGCGTTAA 
84 84 
24 pilC1 NMB1847.1 1120-1219 CCAAATTTTCCTGCAAAACCTTTCCCGCAAGGATGACACAAGCAAACCGGGCCGCTATTCCCTCAAACCCTT
GAGTACGTCGGAGATTAAAAGTAAAGAG 
82 81 
25 xseB NMB0262.1 88-187 GAAGACGCGCTTGCCGCCTATCAGGAAGGCAACGAACTGGTCAGGTACTGCCAAACCAAACTGGCACAAG
TCGAACAAAAGCTACAGGTTTTAGACACAG 
85 84 
26 nnrS NMB0439.1 448-547 TTCCACGTCCAGCTGCACAACGGCAACCTAGGCGGACTCTTGAGCGGATTGCAGTCGGGCTTGGTGATGG
TGTCGGGTTTTATCGGTCTGATTGGTACGC 
84 81 
27 estD NMB1305.1 396-495 CTTTCCTACCAACGGCAAACGTTCCATTATGGGACATTCAATGGGCGGACACGGCGCATTGGTATTGGCGC
TGCGGAATCAGGAACGTTATCAAAGTGTT 
82 81 
28 fadD1 NMB1276.1 333-432 CGGCCTGTCAAAAGAATTGGCGGGCTTGAAGGCGCAAACGCCCGTCGAAAAAATCATTTGGACGGACAAA
AGCCGTCCGACCGGCGAAACGGCGGAAGGC 
85 85 
29 NMB1845 NMB1845.1 109-208 GGTGCGGCAGGGCGGCCTTTGACCCTGCTGTCGGGGCAGCGGCTGACTTTGGGACAGTTTAGCCGAGAT
AAGGCGGTTTTGGTGTATTTTTGGGGGAGCT 
85 80 
30 cysW NMB0880.1 422-521 TCTTCGCCATCCCCGGTATTGTTTTGGCGACGCTGTTCGTTACCTTCCCCTTTGTCGCACGCGAAATCATCC
CGCTGATGCAGGCACAGGGCGACAGCGA 
77 85 
31 cysT NMB0881.1 481-580 CCGGTATTGGAAGAATTGTCGGGCGAATATGAGGAAGCGGCGGCAACTTTGGGCGCAAGCCGTTGGACTA
CGTTTCGCCGTGTCCTCTTGCCTGAAATCA 
84 84 
32 cysA NMB0879.1 867-966 ACCGATGATTTGTGCCGAAATCGAAAAAATCCACGCCGTCGGCGCATTGACGCATATTCTGGTAAAACACG
ACAAACAGGACGTACATATCACGCTGGCA 
81 83 
33 NMB0573 NMB0573.1 397-496 ACCGACTACCTGCTTCAGGCGTTTTTTACCGATATGAACGCGTTTTCCCATTTTGTTTTGGATACGCTCCTGT
CCCACCACGGCGTACAAGATGCGCAAT 
76 80 





35 pilO NMB1810.1 324-423 TCATCAGGCAGGTTCGAGCAACGGTCTGCGCTTGGACAGCGTTATGCCCCAACCTCCCGTAGATGACGGC
CCCATCAAAAGATTACCCTATTCCATTTCC 
85 81 
36 pilV NMB0887.1 233-332 GCAACAAGAAAAACTATAATCTTTACATGGGAAACCATACACTATCAGCTGTGGATGGCGATTTTGCGATTG
ATGCCATGAAAACTAAGGGGCAATTGGC 
80 83 
37 app NMB1428.1 972-1071 CGAGTTTGAAGACATCATCGGCAACGGCGGCAGCCTGACCGAAATCGACGTGGACACCATGCTTTATCGC
CACCGCAGCGTGCGCCCAGGCTTCATTTCA 
85 84 
38 iga NMB0700.1 2224-2323 ATCACCGCCAACATCACCGCAACAGACAACGCCAAAGTAAATTTGGGTTACAAAAACGGCGATGAGGTTTG
CGTGCGCTCGGACTATACCGGTTACGTTA 
83 81 
39 fbpB NMB0633.1 1312-1411 GCCGCATTCGCACTCGTCTTCCTCAAACTGATGAAAGAGCTGACCGCCACCCTGCTGCTGACCACCGACGA
TGTCCACACACTCTCCACCGCCGTTTGGG 
85 87 
40 tonB NMB1730.1 282-381 GGATATTCAGCAGCCTAAGGAAGAGCCGAAACCTGAAGAAAAGCCGAAACCCGAAGAAAAACCGAAACCA
GAGCCTAAGCCGGAAGCGAAGCCTGTCCCG 
86 85 
41 lbpB NMB1541.1 560-659 GTCCTTCCCAATCTTTACCGAGCGCGGGAACGGTGCAATATTCCGGTAACTGGCAATATATGACCGATGCC
AAACGTCATCGGACAGGTAAGGCGGTTTC 
82 84 
42 csb NMB0067.1 369-468 TCATCTCTATATGCTGTCTTTTACAGGCCACTACTCCTATCTGATTAGTATTGCAAAAAAAAAGAATATTACGA
CTCATTTAATTGATGAAGGGACTGGA 
75 75 
43 frpC NMB1415.1 1015-1114 TTGGCTCAAGCCGCCAAAGAAGCATACGAAAATGCCAAATCCACAGCCGAGAAGGCTGCTCAAGCAGCTC
GAGAATTTTTTAAGGGCTTGCCCAGTTTTA 
86 78 
44 fur NMB0205.1 120-219 TGTGTACCGCATTTTGTTGGAAGAGGGTGTGGAAATCGGTGTGGCGACGATTTACCGTGTGCTGACCCAGT
TTGAGCAGGCGGGCATTTTGCAACGCCAT 
83 83 
45 aroE NMB0358.1 220-319 CTGGCGGACGAGCATTCCGAACGCGCATTGGCGGCAGGTGCGGTCAATACGCTGATTCCGTTGAAAAACG
GCAAGCTGCGTGGCGACAACACCGACGGTA 
84 85 





47 abcZ NMB1051.1 1167-1266 GTTCCGCAGCGCGTTGAATGAAAACGACACCGTGTTTTACACCCTCGGACAGGGAAACGATTACGTTGAAG
TCGGCGGTAAGAAAAAACACGTCATGAGC 
82 83 
48 hmbR NMB1668.1 768-867 TTTGGGTAAGATTGCTTACCAAATTAACGATAACCACCGCATCGGCGCATCGCTTAACGGCCAGCAGGGAC
ATAATTACACGGTTGAAGAGTCTTATAAC 
79 82 
49 opaD NMB1465.1 177-276 TGCCAGTTACAGAAAATGGAACAACAATAAATATTCCGTAAACACAAAAGAGTTGCAAAAAAACAATAGCAG
TGGCATCTGGCAAGAACTGAAGACGGAA 
78 85 







Table 4.2 NanoString probes for Neisseria meningitidis gene detection (n=50 genes including three housekeeping genes), Flags 
(Cross hybridization potential), HUGO gene (Common name for mRNA target sequence, as defined by RefSeq) 
 Ser.NO Customer Identifier Accession Flags  HUGO Gene Design Remarks 







will give signal for N. gonorrhoeae hits @95% - may give signal for N. lactamica; N. elongata; N. bacilliformis 
hits @93-94% 




















8 GNA1030 NMB1030.1 X NMB1030 will give signal for N. gonorrhoeae & N. lactamica - hits @95% 
9 nspA NMB0663.1 X nspA will give signal for N. lactamica hits @95% and may give signal for N. gonorrhoeae hits @91% 


















14 mip NMB1567.1 X NMB1567 will give signal for N. gonorrhoeae; N. lactamica; N. cinerea - hits @95-97% 
15 NMB1946 NMB1946.1 X NMB1946 will give signal for N. gonorrhoeae & N. lactamica - hits @95% 
16 NMB1612 NMB1612.1 X NMB1612 will give signal for N. gonorrhoeae & N. lactamica - hits @97-98% 




18 pilP NMB1811.1 X pilP will give signal for N. gonorrhoeae - hits @98% 
































27 estD NMB1305.1 X NMB1305 may give signal for N. gonorrhoeae; N. lactamica; N. elongata - hits @93-94% 
28 fadD1 NMB1276.1 X fadD-1 also targets N. gonorrhoeae hits @97% 
29 NMB1845 NMB1845.1 X NMB1845 small risk of signal for N. gonorrhoeae & N. lactamica - GP will bind RP hits @88% 
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30 cysW NMB0880.1 X cysW may give signal for N. gonorrhoeae; N. lactamica; N. elongata - hits @89-92% 








33 NMB0573 NMB0573.1 X NMB0573 will give signal for N. gonorrhoeae & N. lactamica - hits @95% 




35 pilO NMB1810.1 X pilO will give signal for N. gonorrhoeae - hits @97% 












39 fbpB NMB0633.1 X fbpB will give signal for N. gonorrhoeae & N. lactamica - hits @95% 
















44 fur NMB0205.1 X fur may give signal for N. gonorrhoeae & N. lactamica - hits @92% 




46 adk NMB0823.1 HK adk 
 
47 abcZ NMB1051.1 HK;X NMB1051 small risk of signal for N. gonorrhoeae - GP will bind RP hits @88% 













**Hits percentage = the percentage closely related sequences 
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4.5.3 RNA extraction and optimisation 
To determine the mid-logarithmic phase to inform sampling in subsequent 
experiments, a standard growth curve of Nm was obtained. The duplicate curves 






Figure 4.2  Duplicate growth curves of Neisseria meningitidis serogroup B strain 
ATCC_BAA_335 




4.5.4 Comparison of the quality and quantity of RNA purified using two 
methods  
To decide the best method of RNA extraction for subsequent experiments, two 
established methods were compared. At OD600 0.222 (2 hours) the 
acid:phenol:chloroform method yielded a mean of 5478.2ng/µl total RNA 
concentration compared with 67.1ng/µl using RNeasy mini kit from samples in 
RNAlater  ( Table 4.3) At OD600 0.345 (4 hours) the mean yields were 3617ng/µl from 
the first method compared with 39.5ng/µl using the RNeasy mini kit. The 
acid:phenol:chloroform method gave lower purity RNA with absorbance ratios 
(A260/A280) of 1.6 at 2 hours and 1.6 at 4 hours, whereas the samples extracted using 
RNeasy mini kit had an absorbance ratio of approximately 2 for all samples, indicating 
higher purity RNA. The quantities of RNA obtained using the RNeasy mini kit were 
much less variable than those obtained using the acid:phenol:chloroform technique 
(Table 4.4)  
Table 4.3 Quantity and quality of RNA extracted using acid:phenol;chloroform and 
RNeasy mini kit 
Sample taken at RNA extraction methods 
Acid:phenol:chloroform RNeasy mini kit 
(RNAlater) 
2 hours growth 5478.2ng/µl (1.6) 67.1ng/µl (2.2) 
4 hours growth 3617.0ng/µl (1.6) *39.5ng/µl (2.2) 
Each RNA value is an average of quadruplicate measures unless specified. The 




Table 4.4 Variability of RNA concentration at 2 hours and 4 hours using 
acid:phenol;chloroform and RNeasy mini kit 
 RNA extraction methods  
Acid:phenol:chloroform RNeasy mini kit 
(RNAlater) 
RNA concentration 
(ng/µl) at 2hours  
1657.4 93.9 
 8130.5 72.5 
                                            4735.2 54.7 
 7389.7 47.2 
Mean (standard error)  5478.2 (1467.3) 67.1 (10.3) 
RNA concentration 
(ng/µl) at 4 hours  
486.7 57.7 
 272.9 21.3 
 4918.9 ND 
 8789.7 ND 
Mean (standard error)  3617.0 (2029.8)                                   *39.5 (18)
ND-not done, *n=2 
 
In view of the low quality and high variability of RNA obtained using the 
acid:phenol:chloroform method, RNA clean-up was subsequently done on the 
remaining samples for the same experiment (Table 4.5) Error! Reference source not 
found.The mean RNA concentration dropped from 501.5 to 8.5ng/µl, well below that 
in the higher purity samples obtained from the RNeasy mini kit but still with absorbance 




Table 4.5  RNA quantity and quality using acid:phenol:chloroform, before and after 
clean-up using RNeasy minElute cleanup Kit 
sample RNA concentration(ng/µl) using 
acid:phenol:chloroform 
Before clean-up After clean-up 
6 hours  426.9 (1.5) 7.5 (3.2) 
 425.3 (1.5) 2.3 (25.2) 
 842.7 (1.6) 17.1 (2.6) 
 310.9 (1.4) 7.2 (3.8) 
The numbers in brackets are the nucleic acid absorbance ratio A260/A280. 
 
4.5.5 Comparison of bacterial lysate vs total RNA  
To explore whether crude lysate could be used to measure gene expression instead 
of total RNA extracted using the RNeasy minikit, Nm genes were detected from both 
total RNA and the crude bacterial lysate using the nCounter SPRINT analyser. The 
gene counts from the total RNA extract were higher for all genes tested than from the 
equivalent crude lysate. The results were consistent for different concentrations of 






Figure 4.3 Comparison of gene counts from total RNA and crude lysate prepared 
from the same Nm culture samples.   
The blue dots are counts from the total RNA extract and the red triangles are counts 
from the crude lysate of the same sample at different concentration of RNA 
 
4.5.6 Comparison of diluted and undiluted RNAlater  
To determine if dilution of RNA improved the yield of RNA using RNeasy minikit, RNA 
extraction was comparted using undiluted and diluted RNA.  Undiluted RNAlater 
stored samples yielded approximately twice as much total RNA as 1:2 diluted 









































































































Figure 4.4 Analysis of total RNA concentration from Neisseria meningitidis broth 
culture samples collected in undiluted and diluted (1:2) RNAlater (n=1 for each bar) 
 
4.5.7 Comparison of total RNA collected into two RNA storage media 
(PrimeStore and RNAlater) 
RNA extraction was compared after storage in RNAlater and PrimeStore to determine 
the better storage media.  RNA stored in RNAlater and extracted using RNeasy mini 
kit yielded a far higher quantity of RNA than from RNA stored in PrimeStore (Figure 
4.5)Error! Reference source not found.. PrimeXtract yielded low quantities of RNA 





Figure 4.5 Analysis of total RNA collected into two RNA storage medias (PrimeStore 
and RNAlater) and extracted using two RNA extraction kits (PrimeXtract and RNeasy 
mini kit)(n=1 for each bar) 
4.5.8 RNA extraction assessment from heat shock / cold shock culture samples 
The quality and integrity of RNA extracted from the culture samples were confirmed 
by Nanodrop and a bioanalyzer (Agilent 2200 RNA tape station) (3.2.14.2). All the 
samples measured with RNA tape station had good quality and quantity with a value 





Figure 4.6 Gel image showing RIN number (RNA integrity) of Nm culture samples 
A1-C1 (iron replete), D1-F1 (iron depleted) G1-A2 (cold shock 26ºC), B2-D2 (control 
37ºC), E2-G2 (heat shock 40ºC), using Agilent 2200 tape station system. The RIN 
score is highlighted in yellow and green. The three bands indicate the 23s and 16s 
RNA fragments and the lower marker.  
 
4.5.9 Detection limit and technical reproducibility 
The technical reproducibility and lower limit of gene detection of the nCounter platform 
was checked using Nm culture samples. A high degree of correlation between gene 
transcript counts of Nm from two technical replicates of 100ng RNA (Figure 4.7, 
R2=0.99) was shown. Serial dilution of RNA preparations demonstrated that gene 
expression signals could be detected from RNA concentrations as low as 0.1ng/μl. 
The heat map below shows the similarity of the 47 gene counts from two technical 






Figure 4.7 Technical reproducibility of the NanoString nCounter system for Neisseria 
meningitidis culture samples. 
Gene transcript count of Nm from two technical replicates of 100ng RNA, Replicate 1 
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Figure 4.8 Heat map showing technical reproducibility of the nCounter platform 




4.5.10 Nm gene detection 
Ability of the NanoString custom CodeSets to detect Nm genes was assessed. 
Transcript counts were obtained for all 47 genes. The genes were detected from 
different concentrations of Nm culture isolates. Samples assayed from 100ng total 
RNA showed signal saturation since the transcript quantity in those samples was 
greater than the upper limit of detection by the NanoString instrument. However, 
samples which were assayed from as low as 0.1ng total RNA yielded gene counts for 
a few genes (Figure 4.8). 
4.5.11 Fold change in gene expression  
The performance of the nCounter system was assessed by measuring a change in 
gene expression under three different environmental conditions. A range of log2 fold 
changes in expression of the 47 gene transcripts (up to six-fold) was observed after 
exposure to high and low ambient temperatures and after iron depletion (FError! 
Reference source not found.)  
After cold shock, 30% of the genes showed up-regulation of gene expression from 
minimal up to six-fold change. cysA, cysW, and tonB genes showed highest up-
regulation compared to gene expression in Nm cultured at 37°C (Figure 4.9A) (Table 
4.6) . The genes showing most down-regulation were tspA, znuD, and fadD1. Nineteen 
genes showed a statistically significant (p=0.001) up or down regulation of gene 
expression.  
A similar percentage of genes were up-regulated in the heat shock samples. porA, 
dsbA and nadA showed most up-regulation, whereas tspA, cysT and opaD were the 
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most down-regulated (Error! Reference source not found.B)  Twenty-one genes had 
significant log2 fold change when compared with the control samples. (Table 4.7).   
For iron depletion, pilE, dsbA_2, NMB1612, porA, tonB, opc, NMB1646, cssA, pilO, 
mip and frbP showed most up-regulation and cysA, cysT, tspA, app and Iga were 
down-regulated in the absence of iron (Figure 4.9C) (Table 4.8)All the iron regulatory 






Figure 4.9 (A)  Log2 fold change in gene expression across a panel of 47 Neisseria meningitidis genes induced by incubation at 
26°C. The fold change is a normalised gene transcript count plotted by taking the ratio of the mean of cold exposed (26°C) gene 














































































































































































































































 Figure 4.9 (B) Log2 fold change in gene expression across a panel of 47 Neisseria meningitidis genes induced by incubation at 
40°C. The fold change is a normalised gene transcript count plotted by taking the ratio of the mean of heat exposed (40°C) gene 
















































































































































































































































     
Figure 4.9 (C). Log2 fold change in gene expression across a panel of 47 Neisseria meningitidis genes induced by iron depletion. 
Each bar represents a different gene. The fold change is a normalised gene transcript count plotted by taking the ratio of the mean 
iron depleted gene count to the mean iron replete gene count.  
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Of the four genes relating to the novel protein vaccines (porA, fhbP, nhba, nadA) all 
showed down-regulation after cold shock (Table 4.6). After heat shock, porA and nadA 
were up-regulated’ and fhbP and nhba were down-regulated (Table 4.7). After 
exposure to iron depletion, porA was up-regulated and the other three were down- 
regulatedTable 4.8  
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Table 4.6 Expression of 47 Neisseria meningitidis genes after incubation at 26°C 
(cold shock) compared to incubation at 37°C (control) 
Gene name  
Mean 
difference 
(n=6)  95% CI     
Mean control 
(n=3) P value  
GNA1030 -3287 -4749 -1826 11755 0.001 
GNA33 477 -411 1364 9995 0.292 
NMB0088 -7856 -8848 -6863 19797 0.001 
NMB0573 -2811 -5243 -380 20724 0.023 
NMB1612 -269 -1580 1041 19393 0.687 
NMB1845 1090 380 1800 3547 0.003 
NMB1946 1741 234 3248 17304 0.024 
opaD 44672 25962 63382 59581 0.001 
znuD -654 -1075 -233 1126 0.002 
app -2890 -4075 -1706 8491 0.001 
csb -3811 -5011 -2611 11783 0.001 
cssA 6985 3425 10544 20069 0.001 
cssB -20193 -24948 -15437 60276 0.001 
cssC -37833 -48983 -26682 105111 0.001 
cysA 4457 3603 5310 879 0.001 
cysT -303 -872 265 793 0.296 
cysW 945 710 1180 389 0.001 
dsbA-2 -8175 -28210 11860 130221 0.424 
estD -264 -793 265 2102 0.327 
fadD1 -301 -508 -94 484 0.004 
fbpB -1537 -2147 -927 7260 0.001 
fetA -312 -901 277 1762 0.299 
frpC -227 -801 348 3725 0.439 
fur -8664 -12632 -4697 38647 0.001 
hmbR -422 -874 30 3155 0.067 
lbpB -697 -1222 -172 2682 0.009 
iga 25651 22893 28409 34549 0.001 
mip 5792 -6998 18583 108547 0.375 
msf 180 -129 489 7306 0.253 
nnrS -1357 -2413 -302 11942 0.012 
opc -61431 -80681 -42182 175267 0.001 
pilC1 19817 144421 25192 39239 0.001 
pilE -4693 -55407 46021 466476 0.856 
pilN -63 -218 92 2829 0.428 
pilO 3654 1388 5920 24375 0.002 
pilV 6668 4395 8941 17602 0.001 
pilP -1075 -4003 1853 28221 0.472 
tbpA 514 -322 1351 11930 0.228 
tbpB 429 -253 1111 2391 0.218 
tonB 16509 21032 20986 9784 0.001 
tspA -2314 -3080 -1548 4163 0.001 
xseB -39 -1714 1637 14378 0.964 
porA -13245 -44151 17661 152732 0.401 
fhbP -736 -4087 2614 51152 0.667 
nhbA -454 -991 83 3440 0.098 
nadA -404 -670 -139 1219 0.003 




Table 4.7 Expression of 47 Neisseria meningitidis genes after incubation at 40°C 
(heat shock) compared to incubation at 37°C. 




95% conf. interval  
Mean control 
(n=3)  
P value  
GNA1030 -429 -1901 1022 11755 0.556 
GNA34 281 -607 1168 9995 0.535 
NMB0088 -391 -1384 601 19797 0.44 
NMB0573 -4130 -6561 -1699 20724 0.001 
NMB1612 -1698 -3008 -388 19393 0.011 
NMB1845 -561 -1271 149 3547 0.121 
NMB1946 4055 2548 5562 17304 0.001 
opaD -23452 -42162 -4742 59581 0.014 
znuD -152 -573 269 1126 0.479 
app -1464 -2648 -279 8491 0.015 
csb 2356 1156 3556 11783 0.001 
cssA -1657 -5217 1902 20069 0.361 
cssB -21965 -26720 -17209 60276 0.001 
cssC 1985 -9166 13136 105111 0.727 
cysA -216 -1070 637 879 0.619 
cysT -426 -995 142 793 0.142 
cysW -115 -350 119 389 0.336 
dsbA-2 99590 79555 119625 130221 0.001 
estD -355 -883 174 2102 0.189 
fadD1 -191 -398 16 484 0.071 
fbpB -1670 -2280 -1060 7260 0.001 
fetA 69 -520 658 1762 0.819 
frpC -180 -754 394 3725 0.539 
fur -5119 -9086 -1151 38647 0.011 
hmbR -1208 -1660 -756 3155 0.001 
lbpB -1015 -1540 -490 2682 0.001 
iga 17583 14826 20341 34549 0.001 
mip 27461 14670 40252 108547 0.001 
msf 168 -141 477 7306 0.287 
nnrS 3659 2604 4715 11942 0.001 
opc -70307 -89556 -51057 175267 0.001 
pilC2 -741 -6116 4634 39239 0.787 
pilE 9690 -41024 60404 466476 0.708 
pilN -122 -277 34 2829 0.125 
pilO -4784 -7050 -2518 24375 0.001 
pilV -3510 -5784 -1236 17602 0.002 
pilP -10437 -13366 -7509 28221 0.001 
tbpA -3109 -3946 -2273 11930 0.001 
tbpB 13 -669 695 2391 0.971 
tonB -2297 -6774 2180 9784 0.315 
tspA -2566 -3332 -1800 4163 0.001 
xseB 1052 -624 2727 14378 0.218 
porA 96803 65897 127710 152732 0.001 
fhbP -12401 -15752 -9051 51152 0.001  
nhbA -1417 -1954 -880 3440 0.001 
nadA 712 447 977 1219 0.001 




Table 4.8 Expression of 47 Neisseria meningitidis genes after iron depletion 
compared to controls  








P value  
GNA1030 -567 -1139 4 5072 0.052 
GNA33 -81 -734 571 2659 0.808 
NMB0088 -758 -1151 -366 5697 0.001 
NMB0573 -314 -702 75 4572 0.113 
NMB1612 1091 -874 3056 11369 0.277 
NMB1845 -158 -909 592 6304 0.679 
NMB1946 620 -489 1729 9398 0.273 
opaD -1359 -2961 243 18948 0.096 
znuD -143 -488 203 892 0.419 
app -494 -784 -205 2400 0.001 
csb -111 -536 315 1184 0.609 
cssA (synX) 429 -111 968 7847 0.12 
cssB (siaB) -564 -1011 -117 9234 0.013 
cssC (siaC) -437 -1900 1026 6336 0.558 
cysA -183 -592 227 785 0.382 
cysT -131 -404 141 473 0.345 
cysW -66 -205 73 411 0.351 
dsbA-2 7232 -890 15354 57671 0.081 
estD -195 -460 69 1732 0.148 
fhbP -510 -774 -246 9548 0.001 
fadD1 -27 -144 91 264 0.657 
fbpB -329 -790 131 2080 0.161 
fetA -184 -5564 196 927 0.342 
frpC 35 -277 347 2966 0.828 
fur -639 -2859 1580 28296 0.572 
hmbR -59 -376 258 1210 0.714 
lbpB -118 -473 236 794 0.512 
iga -1090 -2402 222 5379 0.104 
mip 1259 -2308 4825 66547 0.489 
msf -445 -897 7 5266 0.054 
nadA -37 -124 50 577 0.404 
nhba -358 -634 -82 2042 0.011 
nnrS -1645 -4619 1330 18484 0.279 
nspA -65 -264 134 491 0.52 
opc 3198 -1058 7453 40690 0.141 
pilC1 -476 -1641 690 18176 0.424 
pilE 45681 21617 69745 263266 0.001 
pilN 24 -65 114 1856 0.594 
pilO 234 -687 1155 8685 0.619 
pilV -43 -1008 922 10448 0.93 
pilP -827 -2192 538 6069 0.235 
porA 3889 -909 8686 43294 0.112 
tbpA -109 -279 61 3936 0.209 
tbpB -201 -635 233 1051 0.364 
tonB 749 -523 2021 96363 0.248 
tspA -362 -707 -17 1368 0.04 




4.5.12 Nm-negative pharyngeal samples, probe validation  
To assess specificity of the probes, gene expression was measured in Nm negative 
samples. Out of the 31 Nm specific genes, one was found to have a high gene count 
(dsbA_2) in six of the twelve Nm-negative pharyngeal samples. All the other genes 
had either a zero count or were below the maximum internal negative control count. 
The result confirms that nearly all gene counts detected from the SodC Nm positive 
samples are true gene counts. 
 
4.6  Discussion  
This study showed for the first time that mRNA can be successfully detected and 
quantified from Nm cultures using custom designed CodeSets for a digital multiplexed 
gene detection system, without the need to amplify the genes, and from very small 
quantities of total RNA. The technique showed high reproducibility in technical 
replicates assayed independently. Sensitivity, reproducibility and ability to detect fold 
change using this novel technique were established.  
The RNeasy technique was easier to perform, gave more reproducible results, and 
delivered a higher quality and quantity of RNA than the acid:phenol:chloroform 
method. The acid:phenol:chloroform method is less expensive, but (i) it uses 
hazardous chemicals and (ii) the need to change to different size tubes between the 
first and second extractions may reduce quality and quantity of the RNA. The RNeasy 
method is more expensive, but easier to perform without the need for special 
equipment or potential exposure to hazardous reagents. Both methods take equivalent 
hands-on time to extract the RNA even though the acid:phenol:chloroform technique 
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needs overnight incubation. Although the initial results from the 
acid:phenol:chloroform technique suggested that much higher quantities of RNA had 
been obtained, RNA quality was low, and the results were highly variable. After clean-
up, RNA quantity dropped considerably, suggesting that the initially high levels were 
due to contamination. As the RNeasy technique also gave higher gene expression 
counts than from crude lysate without RNA extraction, it was selected as the extraction 
method for the subsequent experiments. In addition, the processing time from 
sampling to storage in RNAlater was subsequently shortened, which improved the 
RNA yield while maintaining high quality.   
Forty-seven genes were selected for study based on actual or potential vaccine 
antigens or proteins important in colonisation and metabolism of Nm. Some of these 
genes (n=16) were highly conserved among other neisserial species, so it was not 
possible to design a fully species-specific Nm probe for these. Among the other 31 
genes, zero counts were validated for 30 genes against PCR confirmed Nm negative 
samples. Cross-reactivity would be expected to have an impact when processing 
samples from non-sterile sites such as pharyngeal samples, where other commensal 
neisseria species may be present. This is explored by WGS in Chapter 5.  Where the 
probe is not specific for a particular gene, other methods such as RNA-Seq would be 
needed to confirm expression. For multi-copy genes, as the probes were targeted at 
conserved regions, a limitation is that it may be difficult to identify which copies are 
transcribed. Although the reliability of the NanoString platform has been extensively 
reported for other organisms (102, 103, 111, 114, 140), ideally the results should be 
cross-validated with other methods such as reverse transcriptase qPCR for selected 
genes in subsequent experiments (see Chapter 4).  
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Although this study was intended to assess the method and not specifically to identify 
which genes were expressed under different conditions, a range of gene expression 
was successfully detected. The up/down regulation and fold change in gene 
expression of the selected 47 genes was shown for samples cultured under different 
environmental and nutritional stress conditions. Guckenberger et al (124), who used 
micro-arrays to measure Nm gene expression after heat shock at 45°C, had results 
consistent with those in our study, including for example, up-regulation of dsbA_2 and 
down-regulation of pilO and genes involved in ABC transport system (cysA, cysW, 
cysT in our panel). In contrast, two of these genes (cysA, cysW) were up-regulated on 
cold exposure in my study, cysA gene expression increased approximately six-fold in 
response to Nm incubation at 26°C.  
Iron is a vital element for growth and survival of Nm (141, 142). After Nm was cultured 
in iron-depleted conditions, up and down regulation of genes in response to this iron 
stress was seen.  Most of the sulphate ABC transporter genes from the panel of genes 
such as cysT and cysA were down-regulated, as also reported in a study by Mellin 
(125). fur, an important gene for ferric uptake regulation that prevents gene expression 
initiation in an iron-replete environment (125), showed little evidence of down 
regulation in response to iron depletion but exposure was of short duration (15 
minutes) and longer term exposure to these conditions may be needed before 
changes in expression of this gene are observed. The cys genes responded quickly 
to stress conditions, possibly related to their importance in colonisation, and they 
provide an example of proof of principle of the NanoString technique where down-
regulation of cys genes in response to heat and to iron depletion are both consistent 
with previous research.  
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A better understanding of Nm gene activities in meningococcal carriers will give 
insights as to whether the bacteria could be eliminated from carriage by specific 
protein vaccines and as to which genes are important for the survival of the pathogen 
in a normal commensal state. Much research has been done to study in vitro Nm gene 
expression of potential vaccine candidates such as those in the Bexsero vaccine. 
However, little is known about in vivo gene expression, which has relied on indirect 
evidence from animal studies. Application of this technique to Nm pharyngeal samples 
is expected to be challenging as RNA concentrations in such samples will be relatively 
low, variation in levels of gene expression is wide, and RNA from other pharyngeal 




Chapter 5. Gene expression profiling of Neisseria 
meningitidis from pharyngeal carriage samples and 
its association with carriage density  
5.1  Introduction  
Gene expression profiling is a powerful tool for studying the activity of a cell or cellular 
function by measuring the pattern and quantity of mRNA in a given sample. For Nm, 
gene profiling has the potential to increase understanding of genes involved in 
meningococcal colonisation and invasion (143-145). Pharyngeal carriage of the 
bacterium is the first critical step leading to infection and potentially to disease (146, 
147). Several genes are involved in the attachment of Nm to the endothelial cells and 
establishment of carriage (143, 146). Studying the expression level of those genes 
may contribute to understanding which genes are more actively involved (145). 
It is also important to assess the relationship between gene expression and bacterial 
density, since density in pharyngeal carriers of Nm shows extensive variation, with the 
majority of carriers having relatively low density (<103 gene copies/ml) (65). 
Transcriptomic analysis of the levels of expression of Nm genes in pharyngeal swab 
samples may help to predict the impact of meningococcal candidate vaccine protein 
antigens on transmission.  
Most gene expression studies of Nm have previously been done either in laboratory-
cultured samples, by mimicking the internal environment of human host, or in cell line 
experiments (93, 143, 148).  Gene expression patterns of Nm from in vivo pharyngeal 
carriage samples is challenging due to the presence of host mucosal cells and multiple 
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bacterial species in the nasopharynx and because Nm is only present at low density 
in most pharyngeal carriers. Results demonstrating the reproducibility and sensitivity 
of detecting Nm genes directly from culture samples are shown in Chapter 4 using the 
NanoString nCounter system (1). In this chapter, work describing application of this 
method to Nm to transcript detection in complex pharyngeal samples is presented. 
Cross validation of the NanoString transcript count results will also be validated for 
one gene (fhbP) using RT-qPCR.  
5.2  Aim  
To examine the expression pattern of 47 Nm genes from pharyngeal carriage samples 
collected from healthy carriers and evaluate the association between expression and 
Nm carriage density.   
5.3  Objectives  
➢ To extract total RNA from Nm positive pharyngeal carriage samples  
➢ To profile 47 selected Nm genes using the NanoString nCounter system  
➢ To assess the technical reproducibility of the NanoString platform for Nm 
pharyngeal samples  
➢ To compare Nm gene expression in different bacterial carriage densities 
➢ To assess the association between Nm gene expression and carriage density 
➢ To compare the pattern of gene expression between three carriage studies  
➢ To cross-validate the NanoString transcript count for fhbP with RT-qPCR  
➢ To assess gene expression pattern within individuals from BrisMenNHC 
longitudinal samples  
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5.4  Methods  
5.4.1 Pharyngeal swab sample collection, transport and storage  
A total of 3643 pharyngeal swab samples were collected in the BrisMenNHC study 
from Bristol students aged 16-19 years in up to five monthly visits (Appendix D) using 
a double headed swab. One head of the swab was put into RNA-preservation medium 
RNAlater and the other head into STGG. RNAlater is an RNA preservative medium, 
which improves the integrity and yield of RNA in the samples (3.2.13.1). 
Of 267 Nm positive samples, gene expression profiling was done on samples with 
bacterial density >100 gene copies per ml (n=53). Samples with bacterial density >100 
gene copies per ml from two other meningococcal carriage studies in teenagers, SPIT 
(n=19) and a Portuguese study (n=22), were also selected for gene profiling. The SPIT 
study swab samples were collected from students aged 16 to 18 years in Bristol 
(Appendix E) and the Portuguese study samples were collected as stated previously 
(149), using the same methodology as BrisMenNHC. For the Portuguese study, STGG 
prepared in the UoB was sent to Portugal. The Portuguese samples were transported 
to the UoB using dry ice. For all three studies, bacterial identification by qPCR using 
sodC gene and carriage density measurement was done in Bristol by the Finn 
laboratory group. The sodC qPCR was done using a protocol published in 2016 (65), 
explained briefly in 3.2.17.  
5.4.2 RNA extraction from pharyngeal swab samples and DNA digestion  
Total RNA was extracted from pharyngeal samples stored in RNAlater and purified 
using RNeasy mini kit (Qiagen, 76506) following the manufacturer’s protocol as 
explained in Chapter (3.2.5). Both on and off-column DNA digestion was performed 
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using RNase-free DNase set (Qiagen) and TURBO DNase respectively (3.2.6 and 
3.2.7). The quality and quantity of the total RNA was measured using a NanoDrop 
Denovix D-11+ Spectrophotometer (3.2.14.1). 
5.4.3 NanoString nCounter system  
The nCounter assays for the pharyngeal swab samples were done using a SPRINT 
profiler (3.2.15.1). 
5.4.4 NanoString probe design and hybridisation  
The probe design for the custom CodeSet is explained in Chapter 4 (4.4.2). Forty-
seven different genes were profiled from each sample simultaneously using 
NanoString XT formulation following the manufacturer protocol using Nm custom 
CodeSets (Nm_YKT01)(1) (3.2.15). The total RNA samples extracted from the 
pharyngeal swab samples were thawed on ice with the reporter CodeSet and capture 
probe set reagents before hybridisation (3.2.15.2).  
5.4.5 Validation with RT-qPCR 
In order to validate the NanoString nCounter transcript count for the fhbP gene, a RT-
qPCR was performed (3.2.16). RT-qPCR is a technique that is commonly used for 
gene expression assays. It allows the amplification of cDNA, which is reverse 
transcribed from RNA using a reverse transcriptase enzyme. The cDNA is then used 
as a template to do RT-qPCR. As the sample volumes were small, a two-step RT-
qPCR was done because of the higher sensitivity and ability to test more than one 
target. The two-step RT-qPCR involves changing RNA to cDNA by reverse 




Figure 5.1 The steps for the two step RT-qPCR 
 
The crucial step in RT-qPCR is to make sure that the RNA samples contain no DNA 
to avoid false positive results. After DNA digestion using on-column Qiagen DNase, 
the 48 total RNA samples were tested for the presence of genomic DNA using sodC 
PCR and half of the samples were found to have gDNA contamination. Further DNA 
digestion off-column using TURBO DNase was done to remove any remaining gDNA 
present in the sodC PCR positive samples (3.2.7). The double digested total RNA was 
then checked again for the presence of gDNA and all samples were found to be free 
of DNA. The clean total RNA was then dry ice shipped to the University of Leicester 
where the RT-qPCR was done. The total RNA was thawed on ice at room temperature 
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and reverse transcribed to cDNA using reverse transcriptase (RT) in the presence of 
oligo-dNTPs and random hexamers using a protocol developed by University of 
Leicester (3.2.16). A stable cDNA was amplified using Fast SYBR green. Two 
separate PCR reactions for (i) Variant 1/ subfamily A and (ii) Variant 2/3 / subfamily B 
was made. Housekeeping gene gdh was used as an internal control assay protocol.  
The expression of fHbp variants was tested in 48 of the 53 Nm positive samples that 
previously had been tested with the NanoString SPRINT profiler. Five samples were 
not tested as expression had not been completed at the time of the sample shipment 
to the University of Leicester. All the samples were run in triplicate for RT-qPCR. A 
standard was prepared and used as a calibrator. The standard was synthetic 
oligonucleotides prepared from known gene sequences for the two sets of variants, 
using H44176(154) for Variant 1/subfamily B and 240588(138) for Variant 
2/3/subfamily A. The standard was prepared to cover the lowest and highest dilution, 
from 6.16x104 copies/µl - 6.16x100 copies/µl. A calibrator was used for each variant 1 
and variant 2/3 (4 and 138 respectively). The standards and the samples were 
assayed in parallel on the same plate. The reaction mixture was done in a 96 well 
microamp fast optical reaction plate. Once all the reaction mixture was in the plate, it 
was sealed with a MicroAmp adhesive film to avoid evaporation.  Primers, Probes and 
real time programme for the fHbp variant tests are listed in (3.2.16).   
5.4.6 Checking for the presence of genomic(g)DNA in the RNA samples 
Genomic DNA (gDNA) contamination of RNA samples obtained from the pharyngeal 
samples can lead to inaccurate measurement of gene expression using RT-PCR but 
will not affect NanoString analysis since the hybridisation temperature does not reach 
denaturation temperature.  A qPCR was used to detect gDNA in the RNA samples 
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using the sodC gene. 48 BrisMenNHC RNA samples which were ready to take to the 
University of Leicester at the time were checked for the presence of contaminating 
DNA in the total RNA samples. The assay followed a sodC protocol as explained in 
(3.2.17). The stored RNA samples were thawed on ice and spun briefly. A master mix 
was prepared using a QIAagility pipetting robot to pipette all the reagents: a fast-
universal mix(10µl), primer pairs(300nM) and probes (100nM). 5µl of each sample was 
pipetted manually into each reaction mixture. The primer and probes used for sodC 
qPCR are listed in (3.2.17 and Table 3.6) 
 
5.4.7 Statistical analysis  
The raw gene count data were obtained from the SPRINT profiler as a count (RCC) 
zip file for each set of 12 samples. The RLF that contains all the probe design 
information was first uploaded on nSolver software in order to read the RCC files. 
Once the unzipped data is exported to nSolver, QC checks were done for each run 
using four quality measures (3.2.15.6). The geometric mean count of the negative 
controls was calculated and subtracted from each count. This normalised count was 
then used to calculate transcript count in 30µl of total RNA extracted from the RNAlater 
collected pharyngeal swab samples. Gene count per bacteria was calculated from the 
respective densities of each samples and expressed as gene count per 1000 bacteria. 
The final value was then transformed to its logarithmic to the base 10 value to plot the 





5.4.7.1 Linear regression data analysis of gene expression  
The relationship between gene expression, the dependent variable, and bacterial 
density, the independent variable, was assessed by simple linear regression using 
Stata version 15.  The linear regression was done to model the relationship between 
gene expression and bacterial carriage density that could take account of other 
variables.  
A total of 39 subjects from BrisMenNHC study who had independent observations 
were included in the analysis (26 had one visit only, 12 had two visits and one had 
three visits, making 53 samples in total).  The result from the first visit was used to do 
the regression analysis.  
Before performing linear regression, the gene expression data was checked if it meets 
the assumptions of regression. In order to assess the distribution of the gene 
expression data, the data were first visually checked by plotting a scatter plot and 
histogram on Stata. Since the data were positively skewed, the values were 
transformed to log10 values (150).  Before proceeding to fit the line of regression, the 
log data were checked for their approximate linear association using a two-way scatter 
plot (supplementary table 2) and a distributional diagnostic plot (qnorm) (Figure 5.11) 
was done on Stata to test the normality of the log transformed data.(Figure 5.10B).  I 
assessed the association between gene expression and bacterial density using a 
simple linear regression model (Yi= β0+ β1Xi+ei) for each of the genes.  
Gene expression= β0+ β1 bacterial density + ei 
β0 and β1 are regression coefficients which are unknown parameters to be estimated.  





Figure 5.2 The intercept and slope of the regression equation, 
gene expression= B0 +B1 bacterial density, the intercept B0 is the point where the 
line crosses the y-axis and gives the value of Y for x=0. The slope B1 is the increase 
in Y corresponding to a unit in X.  
 
5.4.7.2 Spearman’s rank correlation 
Spearman rank correlation was also used to assess the association between gene 
expression and bacterial carriage density. Spearman rank correlation test is a non-
parametric test which measures the association between ranked variables. A 
Spearman rank correlation was done to assess the strength and direction of the 
monotonic relationship between gene expression and bacterial carriage density. 




Figure 5.3 Example showing the monotonic relationship of gene expression and 
bacterial carriage density. 
  
 
5.4.8 Trend of longitudinal BrisMenNHC samples 
Thirteen paired longitudinal pharyngeal swab samples from different visits were 
examined to assess trends of gene expression between the samples obtained at 
different visits for each gene and subject.  The trend for those samples was plotted 
using paired samples using Stata 15 and assessed visually.  
5.4.9 Cohen’s Kappa  
Cohen’s Kappa analysis was done to calculate the inter-rater agreement between 
NanoString transcript counts for fhbP compared with RT-qPCR 
Cohen’s weighted kappa analysis was done to compare the agreement of gene 
expression pattern of Nm in three carriage studies (BrisMenNHC, SPIT and 
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Portuguese study). The percent agreement and k (kappa) were tested using Stata 
software after ordering expression from 1-47.  The P values were also calculated.  
5.5  Results  
5.5.1 Density distribution of carriage in BrisMenNHC Nm-positive samples  
Samples suitable for gene expression analysis were identified through measurement 
of carriage density. The density distribution of samples from carriers were skewed to 
the right with most carriers having low numbers of gene copies/ml (Figure 5.4).  Of 
267 Nm positive samples from 5 visits for which consent had been given for further 
analysis, 56 samples had sufficient density (>100 gene copies/ ml) for gene expression 
analysis. whereas genes with less than 100 gene copies per ml had no measurable 
gene count and were excluded from the analysis. Out of the 56 samples, gene 
expression was measured in 53 samples. Three samples were excluded because 
consent was not obtained for further DNA analysis. Those with bacterial carriage 
density log value >=3 were termed high density and those with a carriage density log 
count 2 to <3 were termed medium density (65). Density in these samples ranged from 





Figure 5.4 Bacterial density distribution of Neisseria meningitidis positive samples 
from carriers expressed in gene copies per ml. 
The x-axis is the number of samples and the y-axis is the bacterial carriage density 
expressed in gene copies/ml in each category. The total number of samples is 267.   
 
5.5.2 Demographic characteristics of BrisMenNHC Nm-positive subjects  
To describe the demography of the study subjects, their characteristics are shown in 
Table 5.1. There were 25 male and 14 female students from 7 different schools in 





Table 5.1 Demographic factors of Neisseria meningitidis positive BrisMenNHC 
subjects, N= 39 
Variables  
Total number of 
observations Percent 
Gender    
Male  25 64.1 
Female  14 35.9 
School year    
year 12  16 41.0 
year 13 22 56.4 
Other  1 2.6 
Ethnicity   
White  34 87.2 
Asian 3 7.7 
Black 1 2.6 
Mixed/other 1 2.6 
Age group   
15/16 8 20.5 
17 24 61.5 
18 6 15.4 
19 1 2.6 
URTI symptoms at time of sampling   
No  26 66.7 
Yes  13 33.3 
Antibiotics    
No  35 89.7 
Stopped in last month 3 7.7 
Currently taking   1 2.6 
Cigarette smoking    
No  38 97.4 
Yes  1 2.6 
Other smoker at home   
No 32 82.1 
Yes, outside  7 18.0 
Visits to pub in last week    
0 24 61.5 
1 9 23.1 
2 to 7 6 15.4 
Number of boys/ girls kissed in last week  
0 22 56.4 




5.5.3 Quantity of the total RNA from pharyngeal swab samples 
To document RNA quantity among the samples, the total RNA for each sample was 
measured. The 53 pharyngeal samples had total RNA quantities ranged from 1-
31ng/µl measured using nanodrop (3.2.14.1).  
5.5.4 The range of Nm transcript detection  
Numbers of transcript counts per gene by sample were documented to show the extent 
of variation in expression among individual samples. The expression showed an 
extensive range of mRNA transcript counts from 0 to 45,921 transcript count in 5µl 
total RNA (Figure 5.5). Transcript counts of zero after normalisation were taken as “not 
expressed” or “turned off”, transcript counts >=1 were taken as “expressed”. This count 
was then adjusted to the density of samples and expressed in gene copies per 1000 













Figure 5.5 Transcript count of Neisseria meningitidis in 5ul of total RNA after 
negative control normalisation. 
The blue dots indicate individual gene counts (A. untransformed count B. log10 
transformed counts). 
 
5.5.5 The range of Nm transcript count 
Mean expression per gene was compared to show the overall extent of variation in 
expression for each gene. Of the 53 samples, 12 were from two repeat visits for the 
same individuals. One individual had three visits and 26 individuals had single visits. 
The analyses comparing gene expression were restricted to results of 39 independent 
samples i.e. the first visit from those who had more than one visit.  
Twenty-two genes were expressed in more than half of the samples, one (cysT) was 
detected in all 39 samples.  fur, pilE, dsbA_2, opc and nadA had the highest mean 
gene expression (>3000 transcript counts/ 1,000 bacteria) whereas fadD1, csbA, 
cysW, frpC , pilV, nhbA,  gna33 and fhbP had the lowest mean expression (<50 gene 
counts/1000 bacteria) (Figure 5.6, Figure 5.7).  Most carriers had a low transcript count 






Figure 5.6 Mean transcript count of Neisseria meningitidis 47 genes (N=39). 
The x-axis shows the 47 genes and the y-axis shows mean of the transcript 
count/1000 bacteria (log10) as a measure of gene expression. The mean was 







Figure 5.7 This heatmap shows the gene expression patterns of 47 genes in 53 Neisseria meningitidis-positive samples. The 
values indicate the normalised gene transcript count/1000 bacteria (log10). The transcript count is depicted using different colours. 
The bright red colour shows a low transcript count while yellow or white represent a high transcript count.  
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5.5.6 Technical reproducibility of Nm mRNA count of pharyngeal carriage 
samples  
The reproducibility of the NanoString nCounter platform for technical variability was 
assessed using Nm positive pharyngeal samples, which had been gene counted in 
pervious different runs.  The randomly selected samples showed high technical 




Figure 5.8 NanoString technical replicates showing the reproducibility of technical 
replicates of Neisseria meningitidis positive pharyngeal swab samples 
128 
 
5.5.7 Gene expression profile by bacterial carriage density  
To compare transcript count by carriage density, a scatter plot was done using the log 
transcript count per 1000 bacteria for two groups according to their bacterial carriage 
density.  
The expression of genes from high and medium bacterial density is demonstrated in 
(Figure 5.9A and Figure 5.9B) respectively. Most genes in medium density carriers 
had transcript counts >log 1 (Figure 5.9A). In the high density group, there were two 
genes with negative log transcript counts (Figure 5.9B).  Both high and medium density 
groups had genes that were switched off (that is with 0 transcript count values) 
regardless of density. 
In general, high density samples had lower gene expression than low density samples. 
This is demonstrated clearly in (Figure 5.9C), which shows the overlay of the gene 














Figure 5.9  Scatter graphs of Neisseria meningitidis gene expression profile (n=53) 
for 47 genes 
Each dot is the log10 transcript count per 1000 bacteria for one subject. The y-axis 
shows log10 transcript counts per 1000 bacteria and the x-axis shows the gene 
names.  Transcript counts with zero values were changed to one before log 
transformation for the sake of avoiding getting undefined results. 3A shows the gene 
expression from low density samples (gene copies <1000), 3B shows the count from 
high density samples (gene copies >1000),), and 3C shows the two groups overlaid. 
Blue circles indicate samples with bacterial density log value >= 3 and red triangles 
indicate those with bacterial density <3.  
5.5.8 Data distribution of gene count and normality testing 
In order to inform the statistical analysis, the distribution of the transcript count data 
for each gene was visually assessed on scatter plots. These are shown in Appendix 
C. Most of the expressed genes had a linear relationship with bacterial carriage 
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density. On the histograms that include the unexpressed counts (Figure 5.10A), all the 
genes had a positive skewed distribution and the data was transformed to its log 10 
value before performing linear regression (Figure 5.10). The data for porA are shown 
as an example (Figure 5.10A, Figure 5.10B). The inverse normality plots for the log10 
transformed data of each gene was linear, indicating a normal distribution (Figure 
5.11).  
 
Figure 5.10 Frequency distribution of porA transcript count per 1000 bacteria A. 




Figure 5.11 Inverse normal plot of the transcript count per 1000 bacteria (log10) of 
porA gene 
  
5.5.9 mRNA expression and bacterial carriage density  
To assess the relationship between carriage density and gene expression, regression 
analyses were performed for 42 of the 47 genes that had >10 independent 
observations. The genes with too few positive observations to permit linear regression 
were csb, tbpB, frpC, nhbA and fadD1. All 42 genes analysed had a negative 
association with bacterial carriage density (decreasing gene expression with 
increasing density) in the unadjusted analysis (Table 5.3).  Six genes (cssA, cysA, 
cysT, cysW, msf, tbpA) had a strong negative association with bacterial carriage 
density (p<0.001) (Table 5.3). The negative associations between density and gene 
expression remained unchanged after normalising the transcript counts against the 
housekeeping genes.  
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5.5.10 The association of gene expression with bacterial carriage density using 
Spearman rank correlation 
Using an alternative statistical method, the association was also assessed by 
Spearman rank correlation analysis. All 47 genes showed a negative association 
between gene expression and bacterial carriage density.  There was strong negative 
association in five of the genes after performing Bonferroni correction for 47 genes. 
These genes were cssA (rs(34)=-0.724, cysA (rs(13) =0.797), cysT (rs(39) =-0.812), 
nadA (rs(26) =-0.640), tbpA (rs(29) =-0.781) (Table 02) (p=0.001 for all five). 
Similarly, a negative association between gene expression and bacterial carriage 
density using Spearman rank correlation analysis was observed in the other two 
studies (SPIT and Portugal) (Table 5.4).  
 
5.5.11 Trends of density and gene expression in paired longitudinal samples  
Trends in bacterial carriage density and variation in gene expression in the same 
individuals over time were assessed. Density varied between visits (Figure 5.12). No 
specific trend in gene expression was observed, the example below showing the trend 





Figure 5.12 Bacterial carriage density of Neisseria meningitidis from paired 
longitudinal BrisMenNHC samples, each line indicates an individual 
 
 




5.5.12 Validation of NanoString transcript count results with RT-qPCR 
As one validation of the NanoString results, fhbP transcript counts were compared 
with results from RT-qPCR. Out of the 48 samples tested using the nCounter 
platform,15 (31%) samples had >1 transcript count indicating gene expression and 33 
(69%) had a zero-transcript count suggesting no expression. Of those 15 samples that 
had expression with NanoString, 6 samples gave the same result when tested with 
RT-qPCR and 9/15 samples were negative using RT-qPCR. From those with no 
expression using NanoString 4/33 samples were found to be positive using RT-qPCR 
(Table 5.2).  
The fhbP gene expression result was grouped into two categories as expressed and 
not expressed. The inter-rater agreement between the two platforms was assessed 
using a Cohen’s Kappa test. Overall, there was a 72% concordance between the two 
platforms.  
 





quantitative PCR  
  Total  
  Not expressed Expressed   
Not expressed 29 4 33 
Expressed 9 6 15 
Total 38 10 48 
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5.5.13 fHbp variants of BrisMenNHC samples tested with RT-qPCR  
 
In order to compare RT-qPCR with WGS (see 6.5.8.), the expression of 48 
BrisMenNHC carriage samples was analysed using RT-qPCR for the different variants 
of fHbp. From the 48 samples assayed, ten samples had fhbP gene expression. Of 
these, six were fHbP variant 1/family B, three were fHbP variant 2&3/family A and one 
had both variants.   
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Table 5.3 The association of gene expression and bacterial carriage density 
Gene name  No of observation  coefficient  95% CI  p value  
gna1030 16 -0.512 -1.164        0.140 0.114 
gna33 16 -0.302  -0.975        0 .372 0.353 
nmb0088 16 -0.127  -0.732       0.478 0.660 
nmb0573 16 -0.793 -1.587        0.002 0.050 
nmb1612 23 -0.773  -1.338      -0.207 0.010 
nmb1845 25 -0.564   -0.916       -0.211 0.003 
nmb1946 18 -0.420 -0.987       0.147 0.136 
opaD 13 0.188 -0.774        1.149 0.676 
znuD 14 -1.039   -0.916       -0.211 0.027 
app 17 -0.483  -1.033       0.067 0.081 
csb 7 ND ND ND 
cssA(synx) 33 -0.954  -1.245       -0.662 0.001 
cssB(siaB) 10 -0.217  -1.345      0.911 0.669 
cssC(siaC) 13 -0.283  -1.308      0.742 0.556 
cysA 13 -1.240  -1.851      -0.629 0.001 
cysT 38 -0.921  -1.087      -0.755 0.001 
cysW 13 -0.837 -1.243      -0.430 0.001 
dsbA_2 32 -0.759  -1.280      -0.238 0.006 
estD 19 -1.001  -1.631      -0.369 0.004 
fhbP 14 -0.376  -1.127        0.376 0.298 
fadd1 7 ND ND ND 
fbpB 22 -0.414 -0.922       0.094 0.105 
feta 19 -0.696 -1.362      -0.030 0.042 
frpC 7 ND ND ND 
fur 30 -0.606 -1.217        0.005 0.052 
hmbR 15 -0.591 -1.388       0.207 0.134 
lbpB 21 -0.463 -1.079       0.152 0.132 
iga 26 -0.475 -0.955       0.005 0.052 
mip 26 -0.480 -1.003       0.044 0.071 
msf 28 -0.649 -0.937       -0.360 0.001 
nadA(gna1994) 26 -0.865  -1.403       -0.327 0.003 
nhbA(gna2132) 9 ND ND ND 
nnrS 17 -0.616  -1.172       -0.058 0.033 
nspA 21 -0.583 -1.087      -0.078 0.026 
opc 16 -0.176  -1.311       0.959 0.744 
pilC1 16 -0.550 -1.208       0.109 0.095 
pilE 28 -0.343 -0.997       0.311 0.291 
pilN 16 -0.341  -0.991       0.309 0.280 
pilO 21 -0.619 -1.208       -0.029 0.041 
pilV 13 -0.326  -0.991       0.339 0.304 
pilP 22 -0.534 -1.123        0.054 0.073 
porA 20 -0.549 -1.133        0.036 0.064 
tbpA 29 -1.390 -0.959        0.278 0.259 
tbpB 9 ND ND ND 
tonB 22 -0.468  -0.994        0.058 0.078 
tspA 17 -0.341 -0.959        0.278 0.259 




Table 5.4 Spearman rank correlation between bacterial carriage density and gene expression for BrisMenNHC, SPIT and Portugal 
study samples 





















gna1030 16 -0.182 0.499 13 -0.588 0.035 11 -0.773 0.005 
gna33 16 -0.259 0.333 6 -0.657 0.156 12 -0.846 0.001 
nmb0088 16 -0.085 0.754 6 -0.657 0.156 8 0.000 1.000 
nmb0573 16 -0.309 0.245 17 -0.779 0.001 12 -0.846 0.001 
nmb1612 23 -0.515 0.012 12 -0.790 0.002 13 -0.742 0.004 
nmb1845 25 -0.510 0.009 2 -1.000   20 -0.860 0.000 
nmb1946 18 -0.166 0.510 13 -0.489 0.090 14 -0.481 0.081 
opaD 13 -0.115 0.707 2 1.000   7 -0.929 0.003 
znuD 14 -0.618 0.019 2 -1.000   8 -0.929 0.001 
app 17 -0.289 0.260 5 -0.700 0.188 9 -0.717 0.030 
csb 7 -0.464 0.294 0     3 -0.500 0.667 
cssA 34 -0.724 0.001 6 -0.371 0.469 21 -0.848 0.000 
cssB 10 -0.067 0.855 3 -1.000   8 -0.548 0.160 
cssC 13 -0.214 0.482 8 -0.571 0.139 11 -0.518 0.103 
cysA 13 -0.797 0.001 3 1.000 0.001 8 -0.857 0.007 
cysT 39 -0.812 0.001 0     22 -0.898 0.001 
cysW 13 -0.764 0.002 7 -0.714 0.071 12 -0.706 0.010 
dsbA_2 33 -0.418 0.016 14 -0.688 0.007 20 -0.471 0.036 
estD 19 -0.635 0.004 16 -0.779 0.001 11 -0.846 0.001 
fhbP 14 -0.077 0.794 6 -0.600 0.208 9 -0.800 0.010 
fedD_1 7 -0.893 0.007 0     11 -0.900 0.001 
fbpB 22 -0.307 0.165 7 -0.750 0.052 14 -0.864 0.001 

























frpC 7 -0.143 0.760 5 -0.600 0.285 13 -0.758 0.003 
fur 31 -0.340 0.061 14 -0.547 0.043 16 -0.350 0.184 
hmbR 15 -0.443 0.098 8 -0.452 0.260 7 -0.536 0.215 
lbpB 21 -0.142 0.541 17 -0.681 0.003 15 -0.836 0.001 
iga 26 -0.190 0.351 13 -0.390 0.188 17 -0.596 0.012 
mip 26 -0.256 0.207 15 -0.396 0.144 18 -0.416 0.086 
msf 28 -0.550 0.003 14 -0.710 0.005 17 -0.721 0.001 
nadA 26 -0.640 0.001 2 -1.000   16 -0.665 0.005 
nabA 9 0.017 0.966 3 -0.500 0.667 2 -1.000   
nnrS 17 -0.331 0.195 5 -0.900 0.037 9 -0.600 0.088 
nspA 21 -0.358 0.111 11 -0.546 0.083 16 -0.635 0.008 
opc 16 -0.085 0.754 10 -0.188 0.603 13 -0.610 0.027 
pilC 16 -0.406 0.119 4 -0.200 0.800 14 -0.939 0.001 
pilE 28 -0.138 0.484 13 -0.374 0.209 18 -0.331 0.179 
pilN 16 -0.232 0.387 7 -0.821 0.023 10 -0.952 0.001 
pilO 21 -0.338 0.134 13 -0.308 0.331 14 -0.464 0.095 
pilV 13 -0.192 0.529 4 -1.000   8 -0.762 0.028 
pilP 22 -0.298 0.179 12 -0.350 0.265 14 -0.534 0.049 
porA 20 -0.301 0.198 17 -0.380 0.133 15 -0.429 0.111 
tbpA 29 -0.781 0.001 10 -0.212 0.556 19 -0.619 0.005 
tbpB 9 -0.350 0.356 7 -0.821 0.023 5 -0.900 0.037 
tonB 22 -0.147 0.417 10 -0.612 0.060 15 -0.561 0.030 
tspA 17 -0.147 0.573 10 -0.697 0.025 10 -0.576 0.082 





5.5.14 Pattern of gene expression from BrisMenNHC, SPIT and Portugal carriage 
studies  
To investigate consistency of gene expression from different carriage studies, gene 
expression of Nm in pharyngeal isolates from three studies was compared. All three 
showed a similar pattern of expression for all the genes tested (Figure 5.14). There 
was an 86% agreement between the two Bristol carriage studies (BrisMenNHC and 
SPIT) (k= 0.576, p<0.0001). There was a similar level of agreement between 
BrisMenNHC and Portuguese study with 83.4% agreement (k=0.5, p<0.0001).  
 
 
Figure 5.14 Neisseria meningitidis mean transcript count (log) from three carriage 
studies (blue is BrisMenNHC, red is Portugal, and green is SPIT carriage studies). 
Table 5.5 Results of interrater reliability of transcript count of Neisseria meningitidis 








error Z prob>Z 
BrisMenNHC with 
SPIT study 86% 64.0% 0.576 0.0923 6.24 0.0001 
BrisMenNHC with 
Portuguese study 83.4% 66.0% 0.511 0.0923 5.53 0.0001 
Portuguese with 






5.6  Discussion 
This is the first study to directly detect and count Nm genes from pharyngeal carriage 
samples. Forty-seven different meningococcal genes were successfully profiled from 
pharyngeal carriage samples in three different studies. This study advances our 
knowledge of the genes involved in colonisation and carriage, and the expression of 
different genes of meningococcus in their natural environment. The variation of gene 
expression patterns was also examined, and the correlation was measured between 
gene expression and density of carriage.  
Use of the NanoString nCounter system will improve with experience. This technology 
has the power to overcome some of the usual difficulties with studies of gene 
expression, such as the ability to obtain unbiased absolute gene counts for multiple 
genes at a time (151, 152).  Limitations include the inability to prepare a specific probe 
for some Nm genes because of the close relatedness of the Nm genome with that of 
other neisseria species.  
Fur, dsbA_2, pilE, opc, opa, and nadA were the main genes with a relatively high 
expression in the pharynx of carriers, suggesting a major role in colonisation. It is well 
established that the survival and pathogenesis of Nm depends on the ability to acquire 
iron within the host (94). Previous studies have identified genes which respond 
significantly to iron modulation in a positive or negative way (94, 141, 153). Fur, the 
most highly expressed gene is a well-known regulator of gene transcription of iron 
responsive genes(154, 155). High expression of fur was seen in all the three sample 
sets analysed (BrisMenNHC, SPIT and Portuguese carriage studies). This shows the 
importance of this gene for the survival of the organism when encountering a low iron 
environment during infection of the human host (141, 156). This gene regulates iron 
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balance between obtaining enough iron to grow and avoiding excess iron which can 
be toxic for the bacterial cell. This gene is multi-functional and is known to be important 
for energy metabolism, oxidative stress, acid tolerance, essential in small regulatory 
RNA metabolism (154, 157) and others.  
Another highly expressed gene was dsbA_2, a periplasmic thiol disulphide 
oxidoreductase protein folding catalyst important in the folding of periplasmic and 
membrane proteins in Nm (158).  
A third highly expressed gene in most individuals was pilE, a major subunit of type IV 
pili which helps the bacteria to adhere to the host cell (159).  pilE is highly variable and 
key in pathogenesis and virulence of Nm. pilE is another multifunctional gene, 
important for attachment of the bacteria to the host cell, twitching motility, call 
aggregation and biofilm formation, adhesion to the host cell and intracellular signalling 
(159-161).  Expression of pilE is important in the attachment of the bacteria to the host 
epithelial and endothelial cells whereas non-piliated bacteria cannot adhere to the 
surface of the cell(162). It is also important in keeping the cellular integrity of the 
bacteria. Type IV pili and opa are the major adhesion proteins that facilitate anchoring 
of Nm to the host cell which is a critical process for the attachment and survival of the 
bacteria(163). It was reported that in vitro studies of carriage isolates lose their type iv 
pili(164), This is a surprising finding given their function, and our study shows that 
carriage isolates taken from three studies express pilE relatively highly.  
The association analysis showed that expression and bacterial carriage density were 
negatively associated, with five genes showing a strong negative association. A similar 
association was seen in the three different carriage studies.  One explanation for this 
negative trend may be because the bacteria form micro-colonies at higher densities 
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and become partially dormant, or that some organisms may no longer be live. The 
density measurement is of bacterial DNA as opposed to live colonies. Dormancy or 
death of the organisms at higher bacterial density is supported by the persistent 
negative association after normalising for the stably expressed housekeeping genes.  
Density of carriage and gene expression varied between paired longitudinal samples 
taken at 1-5-month intervals. It is probably not surprising that bacterial growth and 
activity vary over time in the changing environment of the pharyngeal mucosa.  
Genes which encode for proteins in currently licensed MenB protein vaccines, fhbP, 
nadA, porA and NhbA were evaluated. PorA was the most highly expressed gene 
among the 4CMenB encoding genes, being expressed in 26/39 individuals in the 
BrisMenNHC study. nadA was expressed in more (29/39) individuals, but this could 
be due to the presence of other neisseria species due to cross-reactivity of the nadA 
probe. nhbA and fhbP were expressed in less than half of the carriers. Even though 
the expression of fhbP was relatively low in these carriage isolates, fhbP expression 
in disease isolates is high(145). Low expression of fhbP in carriage means that fHbp 
protein-based vaccines may not have an impact on carriage and transmission, hence 
herd protection may not be gained. This study showed a higher proportion of variant 
1/subfamily B fhbP expression, unlike a study in France (145).  
The concordance between RT-qPCR and NanoString was good with a kappa of 72 
concordance, but there were some discrepant results. The samples tested with RT-
qPCR were double digested with on column TURBO DNA digest which could explain 
why some genes positive with NanoString were negative with RT-qPCR. This could 
not be checked with other genes because no samples remained. This was one 
drawback of this study, not being able to test as many genes as I would have liked. 
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The four samples that were negative with NanoString and positive with RT-qPCR 
could be due to the low quantities of RNA in these samples.  
This novel study shows that we can detect and quantify Nm genes using the 
NanoString nCounter system from pharyngeal carriers. There are limitations of the 
technique arising from cross-reactivity with other bacteria and low RNA quantity, and 
further validation is needed (also discussed in Chapters 6 and 7). Expression is 
important for a gene to be recognised by the immune system and may indicate 
potential for a protein vaccine to affect carriage and transmission. Highly expressed 
genes, especially if consistently present, could be used to propose new vaccine 





Chapter 6. Whole genome sequencing of 
BrisMenNHC carriage samples to confirm presence 
or absence of Neisseria meningitidis genes and 
predict level of fhbP expression 
6.1  Introduction 
A genome is a complete set of nucleotide bases representing a physical map of an 
organism’s genetic content. The Neisseria genome contains 2,227,351 base pairs and 
2158 predicted protein coding regions, of which 1158 have been assigned a biological 
role(23). The whole genome sequence gives us information about the presence or 
absence of genes in the genome. Studies have shown that some genes are not found 
in some strains of Nm such as nadA (165, 166).  
fHbp is a surface-expressed lipoprotein that helps the bacteria to survive in the human 
blood by binding to human factor H thus downregulating the alternative complement 
activation pathway of the human immune system and assisting escape from killing 
(167, 168). fHbp is a component of two meningococcal protein vaccines, Bexsero and 
Trumenba. This protein is classified into three variants (Variant 1-3) and two sub-
families (1-2) according to the amino acid sequence of the proteins. 
The Variant 1, 2 and 3 classification is used by one vaccine manufacturer (Pfizer) and 
the sub- family A or B classification is used by another vaccine manufacturer (Novartis, 
now GSK). Variant 1 is equivalent to Subfamily B, Variant 2 and 3 make up Subfamily 
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Figure 6.1 Phylogenetic distribution of fHbp by SplitsTree analysis showing the 
clustering of the proteins in the three main variants (Var1, Var2, and Var3) and in the 
two subfamilies (A and B)(169) 
 
The level of fhbP expression in Nm isolates is associated with clonal complex, fhbP 
peptide and more strongly with IGR sequence (72). The IGR sequence is a region 
between the fhbP and cbbA genes, as indicated in Figure 6.2, that contains the core 





Figure 6.2 Schematic representation of the cbbA and fhbP genes and intergenic 
region (IGR) in the Neisseria meningitidis genome. 
The blue arrows indicate the transcriptional orientation of the genes and the double 
arrow indicates the IGR containing the promoter signal of fhbP. (bP) base pairs 
 
Clustered IGR sequences have been used successfully to predict the level of fhbP 
expression in disease isolates (72). Biagini et al also predicted fhbP expression using 
mass spectroscopy and showed an association between particular promoter 
sequence clades with fhbP expression (169).  
 
In order to confirm the presence or absence of 47 genes detected using the 
NanoString nCounter platform in BrisMenNHC Nm carriage isolates and to determine 
whether detected levels of fhbP expression are consistent with predicted levels, the 
whole genome sequences of 47 isolates were obtained and analysed.   
 
6.2  Aims  
To assess the presence or absence of selected genes in the genome of Nm and 




6.3  Objectives  
➢ To undertake WGS of Nm isolates from BrisMenNHC carriage samples with 
gene expression results 
➢ To assess the presence or absence of 47 Nm genes measured by the 
NanoString nCounter system in the genome of these isolates  
➢ To characterise the isolates by clonal complex, sequence type, capsular group 
and fHbp diversity  
➢ To compare observed and predicted levels of fhbP expression by clonal 
complex, peptide and IGR  
➢ To compare identification of fHbP variants by WGS with RT-qPCR results   
➢ To assess genetic diversity in paired longitudinal carriage samples 
 
6.4   Methods  
6.4.1 Culture of selective and enriched media for Nm  
Of 53 BrisMenNHC samples stored in STGG in which gene expression had been 
tested previously using NanoString SPRINT profiler, 47 were cultured on GC selective 
media containing four antibiotics to minimize the growth of other micro-organisms. Six 
samples could not be cultured. 100µl of each STGG sample was plated out onto GC 
media, and incubated in 5% CO2 at 37ºC for 72 hours with observation at 24, 48 and 
72 hours for identification of typical colonies of Nm. One typical colony of Nm was sub-
cultured onto CBA agar for 16 hours in the same incubation conditions as above. The 
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colonies were examined visually for cross-contamination with other atypical colonies 
and checked by Gram stain and oxidase test.  
 
6.4.2 Gram stain and oxidase test 
Gram staining was done to assess the Gram reaction as positive/negative and the 
shape of bacteria. The Gram reaction is based on differential staining with crystal 
violet-iodine complex and a counterstain, safranin. Gram positive bacteria retain the 
primary colour crystal violet; Gram negative bacteria such as meningococci do not 
retain the primary crystal violate colour after decolourisation of the primary colour and 
iodine complex. Gram staining procedure is described in (3.2.11). Oxidase testing was 
done to assess the production of cytochrome C oxidase by Nm which shows a colour 
change to purple in the process of oxidising tetramethyl-p-phenylenediamine to 
indophenols (3.2.10).  
 
6.4.3 Biochemical testing for identification of Nm (API_NH) 
Gram negative, oxidase positive diplococci from 47 Nm positive samples were tested 
with API_NH for their biochemical properties according to the manufacturer’s protocol 
(3.2.12). API_NH is a battery of biochemical tests done to identify Nm by their 
utilisation of different carbohydrates. The test includes fermentation of glucose, 
fructose, maltose, sucrose, and enzymatic reactions ornithine decarboxylase (ODC), 
urease, lipase, alkaline phosphatase, B-galactodisase, proline arylaminidase, gamma-




6.4.4 Sending Nm isolates to Manchester PHE 
The Nm isolates (250µl sample suspended in TSB + 10% glycerol) were sent in dry 
ice to the PHE Meningococcal Reference Unit (MRU) Manchester for WGS. 
 
6.4.5 DNA extraction  
Bacterial DNA extraction was done by PHE MRU following the manufacturers’ 
instructions using a semi-automated platform MagMAX KingFisher. If samples were 
contaminated in the initial run, a manual kit called Wizard® Genomic DNA Purification 
Kit (Promega) was used for extraction.  
 
6.4.6 Sequencing of the isolates  
WGS was done by PHE Colindale using an Illumina Hiseq 2500 sequencing platform 
and a Nextera XT kit was used to prepare a library file using 1ng DNA. The read length 
was 2 x 100bp paired end (dual indexed). The genome sequences were sent to the 
University of Oxford (Keith Jolley) to enter into the pubMLST database in the 
Meningococcus Genome Library. Each sequence was assigned a pubMLST ID (from 
61935 to 61982) (170). 
6.4.7 Identification of presence or absence of genes 
Forty-seven Nm genes were systematically screened from the whole genome 
sequence using the Neisseria pubMLST database presence/absence status of loci 
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genome comparator tool. The pubMLST ID was used to retrieve the genome 
sequences from the database and the specific loci of each of the 47 genes were 
selected to do the analysis. Genes not identified by automatic scanning using the 
presence/absence analysis tool were scanned individually. Individual scanning 
involved the extraction of the gene sequences using the specific pubMLST ID numbers 
to identify genes that had a partial or truncated sequence or were difficult to assemble.  
The alignment was done using the pubMLST BLAST link. The pubMLST ID was 
submitted to the isolates field and the sequence of each genome downloaded from 
pubMLST was pasted and aligned with the whole genome of Nm in the database. The 
presence of the gene was then assessed using the alignment percentage identity and 
the number of mismatches.   
 
6.4.8 Genome analysis for sequence type and clonal complex analysis 
The genomes of 47 Nm isolates were automatically searched and scanned using the 
pubMLST ID of the isolates in pubMLST website for the presence of 47 genes. The 
Sequence type (ST) and clonal complex (CC) were assigned based on the seven 
MLST genes (abcZ, adk, aroE, fumC, gdh, pgm, pdhC). The strain designation of the 
isolates for the porA and fetA genes were determined.  
6.4.9 IGR identification  
Identification of the IGR region igr_up_NEIS0349 was done in the Meningococcus 
Genome Library using the pubMLST ID. The IGR region sequences were obtained 
and aligned on BioEdit sequence alignment software to identify the polymorphic sites. 
The strain designations of each of the isolates were assessed. 
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6.4.10 Identification of fHbP variants  
The variants of fHbp were identified using the pubMLST Neisseria species database. 
The fHbP allele number for each sample was obtained using the isolate ID and 
choosing the fhbP loci (NEIS0349) from the database. The different peptides were 
searched using fhbP alleles and peptide menu, and the summary of each fhbP allele 
was done using the peptides summary for their allele ID.  
6.4.11 Identification of Nm genogroups  
The capsular groups of the samples were identified using the pubMLST automatic 
gene search. Meningococcal capsules play an essential role in the virulence of the 
organism (171). Genes involved in polysaccharide biosynthesis, termed cp (for 
capsule synthesis) are located on a single chromosome (20), and are given a region 
name (6 regions) from A-D, D’, and E (Figure 6.3). Genes in region A encode enzymes 
for biosynthesis of the capsular polysaccharide, e.g. csb, csc, csw, and were used to 
identify the capsular groups of the isolates. Regions B and C are used in translocation 
of high molecular weight polysaccharides to the cell surface, Regions D and D’ are 
involved in lipopolysaccharide synthesis (20). Meningococci which lack the capsule 







Figure 6.3 Genetic organisation of the capsule locus among Neisseria meningitidis serogroups (20) 
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6.4.12 Statistical analysis  
Genomic analysis of the isolates was done in pubMLST using the genome comparator 
analysis tools with the annotated reference genome as a comparator. The output was 
exported to Stata 15 to plot some of the descriptive bar graphs. splitTree4 software 
was used to plot the phylogenetic tree using a distance metric after extracting the 
sequences of the genes from pubMLST.  
 
6.5  Results  
6.5.1 Nm growth on GC and CBA  
To obtain Nm isolates for WGS, Nm positive swab samples that had gene expression 
results were cultured. Of 53 samples, 47 were successfully cultured. One sample 
yielded two distinct Nm colonies (different size and morphology) that were sent 
separately for sequencing. The two colonies had the same CC, ST, capsular group 
and strain designation, so were considered to be the same strain. This left 47 isolates 
for analysis. 
 
6.5.2 Presence of 47 genes in the 47 whole genome sequenced samples  
To compare results obtained by WGS and the nCounter system, presence or absence 
of the 47 genes was checked. Of the 47 genes tested, 42 (89.4%) were present in all 
the genomes of the carriage isolates tested. Of genes not found using the automatic 
search and scanned individually on pubMLST database, the sequences were found to 
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be either partially present, fully present or absent from the genome. Partially present 
gene sequences were either at the end of a contig or were truncated.  The pilin genes 
(pilE and pilC_1), fetA, humR, tspA, iga, fadD1 were found in all samples as full or 
partial sequences.  
Five genes were absent from some or all isolates. One gene (frpC) was absent from 
all isolates. nadA was absent in 32/47 (68.1%) of the samples. The capsule synthesis 
genes (cssA, cssB and cssC) were absent in 23/47 (48.9%) of isolates (cnl (n=14), 
capsule not determined (ND) (n=5), genogroup B (n=2) and genogroup E (n=2)).  
 
6.5.3 NanoString gene counts in samples with absent genes  
To validate the comparison further, NanoString transcript counts were examined in 
samples where genes had not been found by WGS.  
The frpC gene was absent from the genomes of all Nm isolates, yet eight samples had 
an expression result for this gene. Of the eight positives, seven had a gene count of 
<50 transcripts per 1000 bacteria and one isolate had 198 transcripts per 1000 
bacteria.  
Although the nadA gene was absent in 33 isolates, transcript counts for nadA were 
detected in 19 of these 33 isolates.  The six highest nadA transcript counts (all >458-
4222/1000 bacteria) were found in isolates that did not contain the nadA gene.  
The expression of the cssA, cssB and cssC genes found in the capsule synthesis 
region A of Nm (Figure 6.3) were assessed in cnl isolates. Two of 14 cnl had no 
transcript count for cssA, 13/14 cnl samples had no expression for cssB, and cssC.  
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6.5.4 Genotypic diversity of BrisMenNHC carriage isolates  
To document the genetic diversity of the isolates and inform subsequent validation 
(see 6.5.7.), their clonal complexes, genogroups and fHbp variants of the isolates were 
described. Thirteen different clonal complexes were identified (Table 6.1, Figure 6.4, 
Figure 6.5). Of the 47 samples, four (8%) were not assigned to any clonal complex 




Table 6.1 Distribution of genogroups and fHbp variants of BrisMenNHC carriage 
isolates (N=47) within clonal complexes 
Clonal complex  
Frequency of 
isolates Genogroup  fHbp_ variants 
cc11           2 2 W 2 (var 1) 
cc1157 8 3 E, 4ND, 1 B 8 (var 1) 
cc162           1 1 B 1 (var 1) 
cc198        7 7 cnl 6 (var 2), 1(var 1) 
cc213       2 2B 2 (var 1) 
cc22      3 3 W 3 (var 1) 
cc23    5 5 Y  5 (var 2) 
cc269     1 1 ND 1 (var 3) 
cc32          2 1 cnl & 1 B       2 (var 1) 
cc35           4 4 B 1 (var 1), 3 (var3) 
cc41/44           1 1 B 1 (var 1) 
cc461     1 1 B 1 (var 1) 
cc53          6 6 cnl 6 (var 1) 










                      
Figure 6.5 Analysis against all MLST loci showing Neisseria meningitidis clonal complex (ST complex) for 47 BrisMenNHC carriage 




Of the genogroups, the highest number were cnl 14 (29.8%), 13 were genogroup B 
(27.7%), 7 (14.9%) genogroup Y, 5 (10.6%) genogroup W and 3 (6.4%) genogroup E 
(Figure 6.6, Table 6.1). In five (10.6%) samples, the genogroup could not be identified 
(ND) from the sequence. Genogroup B had the most diverse range of clonal 
complexes. Two genogroup W isolates belonged to the hypervirulent clonal complex 
cc11. 
6.5.5 Distribution of Nm in different ST variants  
The distribution of sequence types among the isolates was described The most 
frequent sequence type was ST-1157 found in 7 (14.9%) of the isolates (4 cnl, 3 E) 
(Figure 6.6) 
 
Figure 6.6 Distribution of sequence types of BrisMenNHC carriage isolates from the 
47 Neisseria meningitidis positive isolates 
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6.5.6 Genetic diversity of fHbp in BrisMenNHC isolates  
To also inform subsequent validation (see 6.5.7, 6.5.8), WGS analysis of fHbp variants 
and IGR sequences was described. Variant 1 (29/47, 61.7%) was the predominant 
variant in BrisMenNHC carriage isolates tested.  Variant 2 was less frequent, 14 
(29.7%) followed by Variant 3 accounting for four (8.5%) samples. The most frequent 
peptides were 209, 206, 2 and 26 (Figure 6.7).  
                 
 
Figure 6.7 The distribution of fHbp peptides among 47 Neisseria meningitidis positive 
carriage isolates 
               
Six fHbp IGR sequences were identified in 45 isolates, the commonest being 
fhbP_IGR 1 (Table 6.2). Two isolates did not have a recognised IGR. The alignment 
of fhbP_IGR sequences in the six alleles identified nine polymorphic sites (Table 6.2). 
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Table 6.2 The frequency of igr_up_NEIS0349 alleles in 47 BrisMenNHC carriage 
isolates 
Igr_up_NEIS0349 Frequency Percentage 
1 24 51.1 
3 9 19.2 
8 8 17.0 
No value 2 4.3 
12 2 4.3 
98 1 2.1 






Figure 6.8 Intergenic region sequence alignment of fhbP showing the polymorphic 
sites between six different alleles of BrisMenNHC carriage isolates 
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6.5.7 Expression of fhbP between different CC, fHbP peptides and IGRs and 
comparison with predicted levels 
In order to validate the NanoString results, expression of the fhbP gene by clonal 
complex, peptide and IGR was compared with levels predicted from previous 
research. Expression levels of fhbP as measured by NanoString varied by clonal 
complex. Highest counts were seen in cc32 and cc1157 (n= 763/1000 and 316/1000 
bacteria respectively, Figure 6.9A), some such as cc162, cc213, cc22, cc269 and 
cc461 showed no fhbP expression. Expression by fhbP peptide and IGR were also 
highly variable (Figure 6.9B and Figure 6.9C).  
Of the clonal complexes (cc32, cc269) associated with higher fhbP expression (72), 
only one isolate in this study had fhbP gene expression. Similarly, of fHbp peptides (1 
and 15) associated with higher fhbP expression, only one isolate had gene expression 
detected by NanoString. Therefore, numbers were too small to make a valid 
assessment. For IGR comparison, most samples were IGR_1, part of an IGR cluster 
predicted to have intermediate level of fhbP expression. The IGR_1 expression results 
showed a broad range of expression, and the one isolate in an IGR cluster predicted 
to have a high level of expression (IGR_6) had the highest gene expression of the 












Figure 6.9 Comparison of fhbP expression by A. clonal complexes B. peptides C. 
Intergenic region (IGR) alleles. Isolates with no fhbP expression by NanoString are 
not shown 
 
6.5.8 Comparison of fhbP variant identification using RT-qPCR and WGS 
As a validation of the RT-qPCR results in Chapter 5, fhbP variants confirmed by WGS 
were compared with those identified by RT-qPCR. Among the 10 samples tested with 
RT-qPCR for the three variants of fhbP (5.5.13), seven had the same fhbP variant 
when tested with WGS. Three samples had discordant results.  Two isolates were 




6.5.9 Genetic diversity between paired carriage samples in longitudinal study 
To investigate  genetic diversity in carriage samples taken from the same individual at 
different times, ten paired longitudinal samples were compared based on MLST allelic 
distance metrics and presented as a Neighbor-net network phylogenetic tree 
generated using the core MLST (Figure 6.10). From the 10 paired samples, four 
samples had a one-month interval, 3 a two-month interval, 1 a three-month interval 
and 2 a 5-month interval. 
The ten paired samples belong to seven different clonal complexes. Most 9/10 of the 
paired samples were closely related between the pairs. One pair had different strains 
at the two visits (one of the 5-month interval pairs) with different genogroup, ST, fhbP 
variant and strain designation (ND: P1.22-1,14: F4-1: ST-35 (cc35) at visit two and 
ND: P1.5-1,10-26: F5-5: ST-6798 at Visit 6 (Table 6.3) and are denoted by 
alphabetical letters and numbers.  
The ten paired samples were collected from 6 different schools. Of three pairs who 
carried the same ST (ST53) at all visits, (Table 6.3), two subjects were from the same 
school, both male, white ethnic and school year 13. There were no data on social links 




Table 6.3 The distribution of ST, CC, capsular group and strain designation of 10 
paired pharyngeal carriage isolates 
The red font indicates the pair with different STs from the same subject. 
ID Visit ST CC Capsule group Strain designation 
1A 2 ST-35 cc35 B ND: P1.22-1,14: F4-1: ST-35 (cc35) 
1B 6 ST-6798   Y ND: P1.5-1,10-26: F5-5: ST-6798 () 
2A 2 ST-53 cc53 cnl ND: P1.7,30: F1-2: ST-53 (cc53) 
2B 3 ST-53 cc53 cnl ND: P1.7,30: F1-2: ST-53 (cc53) 
3A 4 ST-53 cc53 cnl ND: P1.7,30-8: F1-6: ST-53 (cc53) 
3B 5 ST_53 cc53 cnl ND: P1.7,30-8: F1-6: ST-53 (cc53) 
4A 3 ST-53 cc53 cnl ND: P1.7,30-3: F1-2: ST-53 (cc53) 
4B 5 ST-53 cc53 cnl ND: P1.7,30-4: F1-2: ST-53 (cc53) 
5A 4 ST-3651 cc22 W ND: P1.5-1,2-2: F5-1: ST-3651 (cc22) 
5B 6 ST-3651 cc22 W ND: P1.5-1,2-2: F5-1: ST-3651 (cc22) 
6A 3 ST-1157 cc1157 cnl ND: P1.22,14: F5-36: ST-1157 (cc1157) 
6B 5 ST-1157 cc1157 cnl ND: P1.22,14: F5-36: ST-1157 (cc1157) 
7A 3 ST-823 cc198 cnl ND: P1.18,25-44: F1-18: ST-823 (cc198) 
7B 4 ST-823 cc198 cnl ND: P1.18,25-44: F1-18: ST-823 (cc198) 
8A 2 ST-823 cc198 cnl ND: P1.18,25: F5-5: ST-823 (cc198) 
8B 5 ST-823 cc198 cnl ND: P1.18,25: F5-5: ST-823 (cc198) 
9A 2 ST-1167 
 
B ND: P1.22-1,14: F1-20: ST-1167 () 
9B 6 ST-1167 
 
B ND: P1.22-1,14: F1-20: ST-1167 () 
10A 2 ST-213 cc213 B ND: P1.22,14: F3-7: ST-213 (cc213) 




Figure 6.10  Phylogeny of paired meningococcal carriage isolates Split tree based on allelic differences in Neisseria meningitidis 
core genome MLST genes. 
The number 1-10 indicates the ID from the paired samples, A and B indicates the different visits, The STs outlined in red indicate 




6.6  Discussion  
Using WGS, the presence or absence of 47 Nm genes was assessed in BrisMenNHC 
carriage isolates for which gene expression analysis had been done using NanoString. 
The different clonal complexes, capsular genogroups, fHbp variants and peptides 
were identified in all carriage isolates.  
Most genes were confirmed present in the genome of all isolates. Exceptions were 
(frpC) which was completely absent from all isolates, nadA which was absent in 70% 
of the isolates and the capsule synthesis genes (cssA, cssB and cssC) which were 
absent in isolates whose capsular group was either cnl or ND. Genes with highly 
variable sequences such as the pilin genes, which are known to have difficulty in 
genome assembly were scanned and partial sequences of those samples were found 
to be present in all isolates.  
Therefore, most genes for which no expression was detected were probably switched 
off as opposed to absent in the genome. However, although the nadA gene was 
present in 30% (15/47) of the isolates, transcript counts for nadA were detected in 
28/47 isolates. A potential explanation for the false positive gene counts for nadA is 
the known potential cross-reactivity of the nadA probe with other neisserial species 
including N. gonorrhoeae, N. lactamica, N. elongata, and N. bacilliformis. Bacteria of 
these species may have been present in pharyngeal samples (see Chapter 3.4.5) and 
this is a recognised limitation of this technique when testing samples from a non-sterile 
site that is likely to contain mixed bacterial populations. Indeed, the five highest nadA 
transcript counts were found in isolates that did not contain the gene, suggesting that 
these transcript counts were from cross-reactive organisms.  
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The frpC gene was absent from the genomes of all Nm isolates yet 8 samples had an 
expression result for this gene although mostly at levels of <50 gene counts/1000 
bacteria. Similarly, expression of three capsule synthesis genes was seen in some cnl 
isolates, particularly cssA.  All the three genes were absent in these isolates in addition 
to those with undetermined capsular group. As the probes did not show cross reactivity 
for these genes, this suggests that there is a low specificity of detection at low 
transcript counts or that other Nm were present that did not grow or get selected for 
sequencing. To improve specificity, one option would be to subtract the maximum 
count of the negative controls instead of the geometric mean. This should eliminate 
most false positive counts but would also mean that some true positives are missed.  
Of the six IGR sequences related to the fhbP gene identified, 50% belonged to IGR 
allele number 1. IGR_1 has also been shown to be the predominate IGR in carriage 
isolates in previous studies (72). The variation of the IGR alleles was assessed by 
aligning the IGR sequences. The levels of fhbP expression in IGR_1 samples were 
consistent with expected levels from a previous study of expression among invasive 
strains of Nm(72). It was not possible to compare predicted against actual levels of 
fhbP expression among these carriage isolates by statistical analysis due to the small 
numbers of samples. 
The WGS data were used to determine fhbP variants in the genome of the isolates 
and cross validate with the RT-qPCR results. Three of ten isolates had a discordant 
variant result, possibly because expression of fhbP in the carriage samples was below 
the detection limit by RT-qPCR, but this does show inaccuracy in some PCR results.  
Forty-two isolates belong to five capsular genogroups (cnl, B, W, Y &E). No genogroup 
was identified for five isolates (ND). The majority of the BrisMenNHC carriage isolates 
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had no capsule synthesis genes (cnl), consistent with findings from previous carriage 
studies in Europe and Africa (145, 165, 172). The carriage isolates showed 22 different 
sequence types belonging to 13 clonal complexes. The predominant clone was 
cc1157.  
Of the ten paired longitudinal isolates only one isolate had a different variant after a 
five-month interval. All the others had the same clonal complex, capsular group, fhbP 
variant and strain designation after intervals of 1-5 months. Of two sets of paired 
isolates with indistinguishable strains taken from two students at the same school, 
both students were male, age 17 years, and of white ethnic group from the same 
school year. These results suggest that carriage of Nm with the same strain may 
persist at least five months (the maximum time we tested). Similar results have been 
found in a study done in Italy on students aged 14-22 years (165) and in another study 
in Ethiopia (172). Modelling estimates have suggested that carriage can persist for 
over 12 months (173).  
WGS was used successfully to characterise the isolates and assess the gene 
expression results obtained by NanoString. Some limitations of the technique were 
shown, particularly potential cross reactivity between different species in samples 
containing multiple organisms and possible false positive results at low levels of gene 
expression.  Refinement of the cut off points may be needed to get the right balance 
between sensitivity and specificity at low levels of gene expression.   
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Chapter 7. General discussion and conclusion 
Previous research in the field of Nm transcriptomics has relied on indirect evidence 
using different models to mimic the in vivo carriage transcriptional changes of Nm. 
This is the first study of the transcription profile of Nm carried out directly on in vivo 
carriage samples collected from healthy carriers. This thesis has presented the 
process of a sequence of optimisation of RNA extraction through detection of Nm gene 
transcripts from Nm cultures to detection of gene expression from in vivo carriage 
samples and validation of the methods. Strengths and limitations of the technique, and 
future development of this work will be discussed.  
7.1  Summary of study findings  
Optimisation of RNA extraction 
As the RNeasy technique gave both a higher yield and higher quality of RNA than the 
alternative acid:phenol:chloroform method, the RNeasy minikit was used to extract 
RNA from Nm culture and pharyngeal swab samples. The use of bacterial lysate for 
gene expression analysis to avoid the process of RNA extraction was explored, 
however using undiluted RNA doubled the yield of RNA and had a higher purity. 
RNAlater was used for storage as it performed better than the alternative PrimeStore 
method. 
Detection of gene expression using NanoString technology  
The use of custom designed probe sets targeting 47 Nm genes plus three 
housekeeping genes established that Nm genes can be detected and counted from 
Nm ATCC samples cultured under different nutritional and temperature conditions. 
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The range of RNA detection from low and high bacterial density samples using 
different dilutions of RNA demonstrated the sensitivity of the NanoString technique. 
The high specificity of the probes was also confirmed using Nm negative controls. One 
of the important qualities of the NanoString platform should be its reproducibility. 
Running technical replicate samples and measuring gene expressions at different time 
points showed a high reproducibility with an R2 of 0.99. The ability of the system to 
detect fold change in gene expression between control and test samples was also 
confirmed.  
Transcript detection of gene expression of Nm from in vivo carriage samples, the first 
time that this has been attempted, was successful. All previous studies to try to 
understand gene expression of Nm in the pharynx had been done using cell lines (93, 
95, 120, 174). Forty-seven Nm genes were detected in the CodeSet from pharyngeal 
carriage samples collected during three different studies. Genes expressed in 
relatively high quantity from the 47 selected genes were identified.  
The NanoString nCounter system not only helped to assess the different degrees of 
gene expression, but also to assess the association of expression with pharyngeal 
carriage density. The density of bacteria carried in the nasopharynx is linked to risk of 
invasive disease for some organisms such as the pneumococcus  (175, 176). It is not 
known if this is true for Nm. Interestingly, bacterial carriage density had a negative 
association with expression of many of the genes assayed. Although unexplained, it 
should be emphasized that all samples assayed were at a relatively high level of 
density, so that the association between expression and density could only be 
assessed among samples with >100 gene copies/ml. It is possible that at higher 
densities the bacteria form microcolonies and become partially dormant, or that there 
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is a mix of live and dead bacteria since the density measurement is of bacterial DNA 
as opposed to live colonies and that the lower expression reflects this.   
Validation  
Gene expression results for one gene (fhbP) from NanoString were compared with 
gene detection in the same Nm isolates by RT-qPCR. There was a good level of 
consistency between the two gene expression platforms (72% concordance), but there 
were some discordant results. This variability could be due to technical errors in either 
of the two platforms. Manipulation of RNA samples before performing RT-qPCR 
(double digestion to remove gDNA to avoid false positive results) means however that 
RNA can be lost or degraded in the digestion process, and the sensitivity of RT-qPCR 
in detecting very small quantities of RNA may be low. For the NanoString platform, 
specificity may be lower in samples with low gene counts. WGS showed that some 
genes that were absent from the genome were measured as having low levels of gene 
expression. 
There was an association between the expression of fhbP with the different clonal 
complexes and IGR type, a finding consistent with other recent research (72). The 
clonal complexes and their capsular genogroups were identified, as well as the 
duration of carriage with the same strain over several months from the longitudinal 
BrisMenNHC samples.  
7.2  Strengths 
This is the first time that Nm genes have been profiled from in vivo Nm pharyngeal 
carriage samples. A total of 47 Nm genes was measured, including the expression 
pattern of 4CMenB protein vaccine genes. This could give an insight into which genes 
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are predominantly expressed and could generate protective immunity against 
carriage. For example, one the vaccine genes, nadA, was not found in most samples 
indicating that antibodies to this protein would be unlikely to protect against carriage. 
Proteins from genes expressed in many individuals in abundance could be potential 
vaccine targets.  
The NanoString platform has a great advantage over other techniques in assessing 
the expression of Nm gene transcript abundance by directly counting each transcript 
as opposed to other techniques, such as microarray, that rely on relative counts or 
fluorescent based values. Another advantage of NanoString is the ease of sample 
preparation with minimal hands-on time that reduces the risk of technical errors 
compared to other gene expression platforms. The need to avoid purifying total RNA 
to get rid of gDNA is advantageous since RNA can be lost or degraded in the process 
of gDNA digestion. Potential errors in other techniques include the need to use multiple 
enzymes such as reverse transcriptase could introduce technical variation. The 
advantage of assessing many genes in a single reaction in an almost fully automated 
platform is that this reduces the chance of committing technical errors. The use of 
internal spiked positive and negative controls is a useful check on quality of the 
transcript count unlike other gene expression platforms. 
7.3  Limitations  
Potential limitations with the NanoString nCounter system were found during the 
course of these studies. It was not possible to design a fully species-specific probe 
since Nm shares many genes between species. Of the 47 genes selected for this 
study, 17 showed cross reactivity with other neisseria species. This is a major 
disadvantage when measuring gene expression from Nm in mixed samples where 
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other neisseria species may be present, for example, the detection of nadA in some 
samples where it was not present in the Nm genome.  
Although it is possible that more than one colony was selected for WGS, another 
limitation with the Nanostring technique seen in this study was the observation that 
specificity was reduced at low levels of gene expression, showing for example eight 
false positive results for frpC when this gene was absent on WGS. Threshold cut off 
levels may need refinement.  
It was only possible to analyse samples with bacterial density greater than 100 gene 
copies/ml.  Although most Nm carriage samples had bacterial density <100 gene 
copies per ml, these samples may be of less importance for transcriptomic study as 
high-density samples are probably more relevant to the risk of transmission.  
7.4  Implications and future work  
Despite the limitations of the NanoString platform, its strengths allow an important 
insight into the expression of current or potential vaccine antigens. Highly expressed 
genes in many individuals could be used to propose new vaccine candidate proteins. 
Consistently expressed specific genes in our panel would help to pinpoint the active 
genes in carriage and transmission. Correlation of those consistently expressed genes 
with levels of immunity produced could be assessed in future work.  The NanoString 
designed probes can be used to measure gene expression in disease isolates to 
compare with expression pattern in carriage isolates. The technique has the potential 
for study of gene expression in carriage and disease isolates of other pathogenic 
organisms carried in the human pharynx such as Streptococcus pneumoniae, 
Staphylococcus aureus, and Haemophilus influenzae. 
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7.5  Conclusion 
The methodologies established in this thesis could be very important for future 
transcriptomics related studies on Nm and other bacteria carried in the human 
pharynx. The potential of the NanoString nCounter technology to assess different 
genes from complex samples, such as pharyngeal samples even where bacterial 
density is relatively low, will give an insight into the biology of Nm transcriptomics. This 
is especially relevant to the assessment of actual and potential vaccine antigens. One 
of the current protein vaccine genes (nadA) even if it had been highly immunogenic, 
is not expressed in most Nm carriage strains, so that the effect of this protein in a 
vaccine to generate herd protection may be limited. Other proteins that are expressed 
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Appendix A Gene detection and expression profiling of 
Neisseria meningitidis using NanoString nCounter platform 
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Detection of bacterial gene transcripts in low density mucosal samples is challenging. We evaluated the 
NanoString nCounter system for transcript detection in Neisseria meningitidis (Nm) cultures. The method was 
sensitive, reproducible (R2 =0.99) and demonstrated changes in gene expression. Studying Nm transcripts from 
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Appendix B The 47 selected genes with their functions 
Vaccine antigens 
Gene/protein   Comment/ Function 
Components of Bexsero 4CMenB vaccine   
 In general, these vaccine antigens were identified through reverse vaccinology as conserved proteins that generate bactericidal 
antibodies 
fhbP/fHbp (also in Trumenba) 
Factor H binding protein. Surface exposed lipoprotein which binds to human factor 
H, an inhibitor of the alternative complement pathway.  
nadA / NadA G 
Neisseria adhesin A. Pathogenicity factor with a role in host cell adhesion and 
invasion.  
nhbA/NHBA  
Neisserial heparin-binding antigen. Lipoprotein which binds heparin in-vivo through 
an arginine rich region and protects against complement. 
porA /PorA Variable but important in immunity. Component of OMV NZ  
GNA2091 (Combined with fHbp) Induced protective immunity in some assays.  
GNA1030 (Combined with nhba) Induced protective immunity in some assays.  
Capsular polysaccharide vaccines  
cssA, cssB, cssC Capsule biosynthesis for genogroups B, C, W, Y.  
Potential vaccine antigens  
Proposed as vaccine candidates. In general, there is less certainty about ability of these antigens to generate bactericidal antibodies in 
humans and/or they are less well conserved. 
nspA/NspA  
Neisserial surface protein A. Binds to domain 6 and 7 of human fH and acts 
cooperatively with fHbp. Potential vaccine antigen. However, phase 1 trial showed 
no bactericidal antibodies.  
tbpA&tbpB/TbpA&TbpB  
Transferrin binding protein. Potential vaccine antigen. Uncertainty around 
bactericidal immunity.  





Major role in adhesion.  Binds to serum vitronectin to inhibit complement mediated 
killing. Potential vaccine antigen. Can generate bactericidal antibodies  
NMB 1567/ MIP 
Macrophage infectivity potentiator. Proteomics identified as potential vaccine 
antigen. Important for meningococcal survival in blood. Can elicit bactericidal 
antibodies in mice but not in all studies.  
NMB 1946 
Proteomics identified as potential vaccine antigen.  Can elicit bactericidal antibodies 
in mice.  
NMB 1468 
Uncharacterised protein. Proteomics identified as potential vaccine antigen.  Can 
elicit bactericidal antibodies in mice  
NMB 1612  
Metabolic amino acid ABC transporter. Proteomics identified as potential vaccine 
antigen but may not generate bactericidal antibodies.  
NMB 0088/ FadL like protein 
Proteomics identified as potential vaccine antigen.  Can elicit bactericidal antibodies 
in mice.  
pilP/PilP 
Proteomics identified as novel potential vaccine antigen. Tfp biosynthesis and 
motility via interaction with OMP secretion pilQ.  
pilE/PilE 
Proteomics identified as potential vaccine antigen. Main constituent of Type IV pili, 
but variability has prevented use in vaccines. 
NMB0294 /DsbA-2 
Proteomics identified as novel potential vaccine antigen. Important in disulphide 
bond formation. 
GNA33  
Lipoprotein, lytic transglycolase.  Genome derived neisserial antigen identified 
through reverse vaccinology. Highly conserved. Elicits bactericidal antibodies. 
Potential vaccine candidate.  
GNA992 
Adhesin. Genome derived neisserial antigen identified through reverse vaccinology.  
Conserved, elicits bactericidal antibodies. Potential vaccine antigen (26) 
 tspA/TspA 
T cell stimulating carrier protein A (51). It may enhance the effectiveness of 
vaccines by acting as protective immunogen (25)  
acp/ ACP 
Adhesin complex protein. Upregulated under iron-depleted conditions Vaccine 
potential  




Many potential genes. Selection on basis of importance, virulence, variation in expression during colonisation. Probably not considered 
as vaccine candidates. 
msf/Msf  
Meningococcal surface fibril. Previously called nhhA or hsf which binds 
preferentially to activated vitronectin (aVn).   
pilC/PilC1 Required for pilus-mediated adhesion. 
xseB 
Inducible repair system. Upregulates when interacts with host cells. Critical for 
adaptation to host  
NMA0797 
Two component system required for colonisation. Promotes adaptation of Nm to 
grow on host cells.  
narP/NarP 
Two-component system. Metabolism of nitrogen oxides: encoding the NarP 
regulator of the two-component system NarP/NarQ, involved in denitrification 
process. Identified using in-vitro colonisation model.  
nnrS/NnrS Encodes heme- and copper-containing membrane protein. 
NMB0552 Identified using in-vitro colonization model.  
estD/ esterase D  Putative esterase D. Identified using in-vitro colonisation model. 
fadD1 Long chain fatty acid-CoA ligase. Identified using in-vitro colonisation model.  
NMB1845 
Putative membrane associated thioredoxin. Identified using in-vitro colonisation 
model. 
cysW Permease. Induction following adhesion.   
cysT Permease. Induction following adhesion.  
cysA Sulphate ABC transporter.  Induction following adhesion.  
NMB0573 
Controls the response to nutrient availability, important role in colonisation, indicator 
of general amino acid abundance.  
pilN/PilN   
Adhesin.  Involved in assembly of Type IV pili. Virulence gene upregulated on 
colonisation. 
pilO/PilO  Adhesin.  Involved in assembly of Type IV pili. 
pilV/PilV  Adhesin.  Involved in assembly of Type IV pili. 
nhhA/NhhA  
Neisseria hia/hsf homologue A (also known as hsf).  Auto-transporter like NadA. 




app/App  Adhesion and penetration protein. Auto-transporter like NadA. 
nadR/NadR Transcriptional regulator. Binds nada promoter.  
hsp90/Hsp90 Heat shock protein. Interacts with NadA. 
iga/ IgA  Immunoglobulin IgA protease. Virulence gene upregulated on colonisation. 
fbpB/ FbpB  Involved in iron uptake. Virulence gene upregulated on colonisation. 
tonB/ TonB  Involved in iron uptake. Virulence gene upregulated on colonisation. 
lbpB/ LpbP  Involved in iron uptake. Virulence gene upregulated on colonisation.  
expB/ ExpB Iron uptake. Virulence gene upregulated on colonisation. 
opa/Opa  
Major role in adhesion and invasion. Integral outer membrane protein synthesized 
as a precursor, contains signal for inner membrane transport.  Virulence gene 
upregulated on colonisation. 
frpC/ FrpC  Potential toxin. Virulence gene upregulated on colonisation. 
hpuA /HpuA  
Iron acquisition. Lipoprotein, haemoglobin receptor. Shows phase variation in 
persistent meningococcal carriers.  
hmbR /HmbR 
Involved in the catabolism of Heme, hem. Shows phase variation in persistent 
meningococcal carriers. 
mspA /MspA Autotransporter.  Shows phase variation in persistent meningococcal carriers.  
nalP /NalP Autotransporter. Shows phase variation in persistent meningococcal carriers.  






Appendix C Scatter plot of Neisseria meningitidis 
transcript count (log) vs. bacterial density(log) showing 
expressed and unexpressed genes    
The x-axis is bacterial transcript count (log) and the y-axis is the transcript count in 








































































































   










Appendix D Protocol BrisMenNHC study 
Recruitment and follow up. 
Any participants who indicated, during consent to the cross-sectional Wellcome Trust 
funded study, that they would be happy to be approached about a further study will be 
asked to provide their contact details. Ethics-approved information about the study will 
be distributed to students at participating schools/colleges in collaboration with those 
institutions. Student and school staff engagement and participation in organisation of 
recruitment will be welcomed whenever offered. Consenting and swabbing sessions 
will be organised at the schools. 
Consent will be taken in writing from students by members of the study team at the 
time of enrolment (first follow-on swabbing visit). The majority of eligible students are 
expected to be between 16 and 18 years old; however, a few may be 15 or 19 years 
old. Participants aged 15 can give consent for themselves as long as they fully 
understand the proposed procedure (Gillick competent). In such cases there is a 
degree of clinical judgement, which would be exercised by the study team members 
involved in taking consent. 
Students will be asked to complete a brief questionnaire and have a throat swab taken 
at each visit. Communication with participants concerning follow up visits will be 
guided by the participating schools but, based on experience of previous studies, will 
most likely be conducted by SMS-text messaging and email.  
Collection of pharyngeal swabs 
After consent has been obtained, the oropharynx of each participant will be swabbed 




swab will be used to briefly touch the back of the throat, sweeping from one tonsil to 
the other across the back of the pharynx, behind the uvula.  Some people find this 
uncomfortable, and a small proportion will ‘gag’ when the swab is taken; this is a 
harmless reflex and is only momentary. 
One “head” of the double-headed swab will be introduced into a 2ml vial containing 
1.5 ml skimmed milk-tryptone-glycerol-glucose (STGG) broth, the shaft broken, and 
the swab tip left inside the vial. The other “head” of the swab will be placed into a 2ml 
vial containing 1.5 mL RNAlater solution. All samples will be kept at 2-8C and returned 
to the laboratory within 2-6 hours. There they will be vortexed, and the STGG vials 
frozen at minus 80C until analysis. These samples will be used for detection of 
meningococci by PCR. (Subject to further funding, they could also be used for 
detection of meningococci by culture.) The RNAlater samples will be incubated 
overnight at 4°C to allow thorough penetration of the swab tissue by the solution and 
will then be transferred to -80°C for long-term storage. All samples will be collected, 
used, stored and disposed of in accordance with the Human Tissue Act 2004. 
Meningococcal PCR. 
A sodC-based multiplex real-time PCR assay will be used for the detection of 
Neisseria meningitidis. Primer and probe sequences will be based on published 
literature. (177) PCR reaction volume will be 20µl using a 384-well optical plate. Each 
PCR reaction mixture will contain 5µl of sample DNA extract, 5µl of primer/probe mix 
(100µM concentration) and 10µl of TaqMan® Fast Universal PCR Master Mix (Applied 
Biosystems®, California, USA). The assay will be carried out using the Applied 
Biosystems® ViiA7™ Real-Time PCR system under the following conditions: 1 cycle 




annealing at 95°C for 3 seconds followed by elongation at 60°C for 60 seconds. T4 
bacteriophage will be used as an internal control to ensure adequate DNA extraction 
with 10µl added prior to the DNA extraction process. Negative controls will be included 
in every 24-sample batch. N. meningitidis ATCC 53417 reference strain will be used 
as positive controls and dilutions will be included in each RT-PCR run. 
Analysis will be performed using ViiA7™ Software version 1.1 (Applied Biosystems®, 
California, USA). Fluorescence measurements will be taken in real time and for each 
sample the cycle threshold (Ct) will be taken as fluorescence detectable above the 
baseline level. Ct values of ≤36 will be taken as positive.  
Conversion of cycle threshold (CT) numbers to colony forming units (CFUs). For the 
bacterial quantitative PCR assay, N. meningitidis ATCC 53417 reference strain is 
used. The organism is cultured in liquid medium (BHI agar supplemented with 10% 
defibrinated horse blood and 2% isovitalex enrichment) and retrieved in the 
exponential growth phase (assessed using spectrophotometry). The solution is serially 
ten-fold diluted in Skimmed milk-Tryptone-Glucose-Glycerol (STGG) broth and plated 
out for counting of colony forming units (CFUs). The same dilution series is used for 
real time bacterial PCR for conversion of cycle threshold (CT) values to CFU/ml.  For 
negative control, the PCR assays is run on blank STGG broth and a panel of non-
targeted bacterial species. DNA extractions from the target species are used as 
positive controls. The standard curve for N. meningitidis is based on an average of 
pooled data of two dilution series, each run three times, and this curve is used to create 





Appendix E Protocol SPIT study 
Recruitment, immunisation and follow up 
Information about the study will be distributed to students at participating 
schools/colleges in collaboration with those institutions. Student and school staff 
engagement and participation in organisation of recruitment will be critical to success 
and preliminary contact has already been established. Consenting, vaccination and 
sampling sessions will be organised at the schools. Students will indicate their 
interest/willingness to participate by attendance at these clinics and will have the 
opportunity to ask questions and discuss the study with a member of the research 
team before consent is taken. 
Consent will be taken in writing from students by suitably trained members of the study 
team at the time of enrolment. Participants will be asked for permission to inform their 
GP of their participation in the study, and to check GP and/or Child Health Database 
records for any other meningococcal vaccines they have received. Consent will also 
be sought for storage and future research on left-over samples after the study 
analyses have been completed; this will be optional, and students will be able to take 
part whether or not they agree to this aspect. The majority of eligible students are 
expected to be aged between 16 and 18 years, although some may be older.  
Following consent, participants will be asked to complete a brief questionnaire on risk 
factors for meningococcal carriage and to provide a saliva sample. Students will 
undergo a health check by a nurse at the start of the study to ensure they are fit to 





Vaccines will be administered by suitably trained and experienced nurses. Participants 
will be monitored immediately after receiving vaccine and asked to report any side 
effects they are concerned about. Equipment for the treatment of anaphylactic 
reactions will be available in the unlikely event that such a reaction occurred. Throat 
swabs will be taken before each vaccine dose and at the final study visit. At the second 
vaccination visit, participants will be asked to complete a brief questionnaire to 
evaluate acceptability of the study methods and to elicit comments and suggestions 
for future studies. They will be asked to provide weekly saliva samples (during term-
time) from enrolment, including at the first and second vaccinations, and again at the 
final study visit (3-5 months later). 
Communication with participants concerning follow up visits will be guided by the 
participating schools but, based on experience in previous studies, will most probably 
be conducted by primarily SMS-text messaging and email.  
Sample collection 
Pharyngeal swabs 
The oropharynx of each participant will be swabbed by a trained member of the 
research team.  A sterile oropharyngeal swab will be used to briefly touch the back of 
the throat, sweeping from one tonsil to the other across the back of the pharynx, behind 
the uvula.  Some people find this uncomfortable, and a small proportion will ‘gag’ when 
the swab is taken; this is a harmless reflex and is only momentary. 
One “head” of the double-headed swab will be introduced into a 2ml vial containing 
1.5 ml skimmed milk-tryptone-glycerol-glucose (STGG) broth, the shaft broken, and 
the swab tip left inside the vial. All samples will be kept at 2-8C and returned to the 




minus 80C until analysis. These samples will be used for detection of meningococci 
by PCR of DNA extracts (for density estimation) and/or DNA extracts of lawn cultures 
(for maximum sensitivity and optimal genogrouping). The other swab “head” will be 
stored in RNA preservation medium for future transcriptomics studies (to evaluate 
microbial and host gene expression profiles associated with carriage acquisition, 
density and clearance). The RNAlater samples will be incubated overnight at 4°C and 
will then be transferred to minus 80° C for long-term storage. 
All samples will be collected, used, stored and disposed of in accordance with the 
Human Tissue Act 2004 and no future studies will be undertaken on specific samples 
in the absence of appropriate and explicit consent. 
Saliva samples 
Participants will be provided with an empty 2ml vial, asked to pool saliva in their mouth, 
and then project it into the vial until this is at least half full. Saliva will either be stored 
neat or added to an equal volume of STGG broth prior to storage thus allowing culture 
amplication prior to PCR. 
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